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Abstract  
Heart failure due to cardiomyopathy or cardiac conduction disease is a major cause of 
mortality and morbidity in both developed and developing countries. Although defined as 
separate clinical entities, inherited forms of cardiomyopathies and cardiac conduction 
disorders have been identified that present with overlapping clinical features and/or have 
common molecular aetiologies.  
 
The objective of the present study was to identify the molecular cause of progressive familial 
heart block type II (PFHBII), an inherited cardiac conduction disorder that segregates in a 
South African Caucasian Afrikaner family (Brink and Torrington, 1977). The availability of 
family data tracing the segregation of PFHBII meant that linkage analysis could be employed 
to identify the chromosomal location of the disease-causative gene. Human Genome Project 
(HGP) databases have provided additional resources to facilitate the identification of 
positional candidate genes.  
 
Clinical examinations were performed on individuals of the PFHBII-affected family, and, 
where available, clinical records of subjects examined in a previous study by Brink and 
Torrington (1977) were re-assessed. Retrospective data suggested redefining the classification 
of PFHBII. Subsequently, linkage analysis was used to test described dilated cardiomyopathy 
(DCM), hypertrophic cardiomyopathy (HCM) and cardiac conduction-causative loci on 
chromosomes 1, 2, 3, 6, 7, 9, 11, 14, 15 and 19 for their involvement in the development of 
PFHBII. Once a locus was mapped, bioinformatics tools were applied to identify and 
prioritise positional candidate genes for mutation screening.  
 
The retrospective and prospective clinical study redefined PFHBII as a cardiac conduction 
and DCM-associated disorder and simultaneously allowed more family members to be traced. 
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Fortuitously, candidate loci linkage analysis mapped the PFHBII locus to chromosome 1q32, 
to a region that overlapped a previously described DCM-associated disorder (CMD1D), by 
the generation of a maximum pairwise lod score of 3.13 at D1S3753 (theta [θ]=0.0) and a 
maximum multipoint lod score of 3.7 between D1S3753 and D1S414. However, genetic fine 
mapping and haplotype analysis placed the PFHBII-causative locus distal to the CMD1D 
locus, within a 3.9 centimorgan (cM) interval on chromosome 1q32.2-q32.3, telomeric of 
D1S70 and centromeric of D1S505. Bioinformatics analyses prioritised seven candidate genes 
for mutation analysis, namely, a gene encoding a potassium channel (KCNH1), an 
extracellular matrix protein (LAMB3), a protein phosphatase (PPP2R5A), an adapter protein 
that interacts with a cytoskeletal protein (T3JAM), a putative acyltransferase (KIAA0205) and 
two genes encoding proteins possibly involved in energy homeostasis (RAMP and VWS59). 
The PFHBII-causative mutation was not identified, although single sequence variations were 
identified in four of the seven candidate genes that were screened. 
 
Although the molecular aetiology was not established, the present study defined the 
underlying involvement of DCM in the pathogenesis of PFHBII. The new clinical 
classification of PFHBII has been published (Fernandez et al., 2004) and should lead to 
tracing more affected individuals in South Africa or elsewhere. The identification of a novel 
disease-causative locus may point toward the future identification of a new DCM-associated 
aetiology, which, in turn, might provide insights towards understanding the associated 
molecular pathophysiologies of heart failure.  
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Opsomming 
Hartversaking as gevolg van kardiomiopatie of kardiale geleidingsiekte is ‘n hoof-oorsaak 
van mortaliteit and morbiditeit in beide ontwikkelde en ontwikkelende lande. Alhoewel 
gedefinieer as verskillende kliniese entiteite is oorerflike vorms van kardiomiopatie en 
kardiale geleidingsstoornisse geïdentifiseer met oorvleuelende kliniese eienskappe en/of 
molukulêre oorsake.  
 
Die doelwit van hierdie studie was om die molukulêre oorsaak van progressiewe familiële 
hartblok tipe II (PFHBII), ‘n oorerflike kardiale geleidingsstoornis, wat in ‘n Suid-Afrikaanse 
Kaukasiër familie segregeer (Brink en Torrington, 1977), te identifiseer. Die beskikbaarheid 
van familie data, beteken dat koppelingsanalise gebruik kan word om die chromosomale 
posisie van die siekte-veroorsakende geen te identifiseer. Menslike Genoom Projek (MGP) 
databanke het addisionele hulpbronne beskikbaar gestel om die identifikasie van posisionele 
kandidaat gene te vergemaklik. 
 
Kliniese ondersoeke is uitgevoer op PFHBII-geaffekteerde familielede, en waar beskikbaar is 
kliniese rekords van persone, wat in ‘n vorige studie deur Brink en Torrington (1977) 
geassesseer was, herontleed. Retrospektiewe data-analise het die kliniese herdefinisie van 
PFHBII voorgestel. Daarna is koppelingsanalise gebruik om dilateerde kardiomiopatie 
(DKM), hipertrofiese kardiomiopatie (HKM) en kardiale geleidingssiekte-veroorsakende loki 
op chromosoom 1, 2, 3, 6, 7, 9, 11, 14, 15 en 19 te ondersoek vir hul moontlike bydrae tot die 
ontwikkeling van PFHBII. Toe die lokus gekarteer was, is bioinformatiese ondersoeke 
gebruik om posisionele kandidaat gene te identifiseer en prioritiseer vir mutasie analise. 
 
Die retrospektiewe en prospektiewe kliniese ondersoek het PFHBII herdefinieer as ‘n 
geleidingsstoornis en DKM-verbonde siekte, en terselfde tyd het dit gelei tot die opsporing 
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van nog familielede. Toevallig het kandidaat loki-analise die PFHBII lokus op chromosoom 
1q32 gekarteer, na ‘n gebied wat met ‘n voorheen-beskyfde DKM-verbonde stoornis 
(CMD1D) oorvleuel, met die opwekking van ‘n makisimum paargewyse lod-getal van 3.13 
by D1S3753 (theta [θ] = 0.0) en ‘n maksimum multipunt lod-getal van 3.7 tussen D1S3753 en 
D1S414. Genetiese fynkartering en haplotipe-analise het die PFHBII-veroorsakende lokus 
afwaards van die CMD1D lokus geplaas, in ‘n 3.9 centimorgan (cM) gebied op chromosoom 
1q32.2-q32.3, telomeries van D1S70 en sentromeries van D1S505. Bioinformatiese analise 
het daarnatoe gelei dat sewe kandidaat gene vir mutasie analise geprioritiseerd is, naamlik, 
gene wat onderskeidelik ‘n kalium kanaal (KCNH1), ‘n ekstrasellulêre matriksproteïen 
(LAMB3), ‘n proteïen fosfatase (PPP2R5A), ‘n aansluiter proteïen wat met ‘n sitoskilet 
proteïen bind (T3JAM), ‘n asieltansferase (KIAA0205) en twee gene moontlik betrokke in 
energie homeostase (RAMP en VWS59) enkodeer. Die PFHBII-veroorsakende geen is nie 
geïdentifiseer nie, alhoewel enkele volgorde-wisselings geïdentifiseer is in vier van die sewe 
geanaliseerde kandidaat gene.  
 
Alhowel die molekulêre oorsaak van die siekte nie vasgestel is nie, het die huidige studie die 
onderliggende betrokkenheid van DKM in die pathogenese van PFHBII gedefinieer. Die 
nuwe kliniese klassifikasie van PFHBII is gepubiliseer (Fernandez et al., 2004) en sal lei tot 
die identifisering van nog geaffekteerde persone in Suid Afrika of in ander lande. Die 
identifikasie van ‘n nuwe siekte-verbonde lokus mag lei tot die toekomstige identifikasie van 
‘n nuwe DKM-verbonde genetiese oorsaak wat, opsig self, dalk insig kan gee in die 
molekulêre patofisiologie van hartversaking. 
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Abbreviations and Acronyms 
 
AV   atrioventricular 
 
bpm   beats per minute 
 
BrS   Brugada syndrome 
 
BTHS   Barth syndrome 
 
CCD   cardiac conduction defect 
 
CHB   complete heart block 
 
cM   centimorgan 
 
°C   degrees celsius 
 
DCM   dilated cardiomyopathy 
 
EBV   Epstein-Barr Virus 
 
ECG   electrocardiograph/electrocardiogram 
 
EF   ejection fraction 
 
HCM   hypertrophic cardiomyopathy 
 
HGP   Human Genome Project 
 
ICCD   isolated cardiac conduction disorder 
 
IVF   idiopathic ventricular fibrillation 
 
LAHB   left anterior hemiblock 
 
LBBB   left bundle branch block 
 
Lod   log of the odds ratio 
 
LPHB   left posterior hemiblock 
 
LQTS   long QT syndrome 
 
LVEDD   left ventricular end diastolic diameter 
 
MIM   Mendelian Inheritance in Man 
 
PCCD   progressive cardiac conduction disease 
 
PCR   polymerase Chain Reaction 
 
 x
PFHBI   progressive familial heart block type I 
 
PFHBII   progressive familial heart block type II 
 
RBBB   right bundle branch block 
 
rpm   revolutions per minute 
 
SB   sinus bradycardia 
 
SSCP   single stranded conformation polymorphism 
 
STACK   Sequence Tag Alignment and Consensus Knowledgebase 
 
UTR   untranslated region 
 
α    alpha 
 
β    beta 
 
δ    delta 
 
γ    gamma 
 
θ    theta 
 
Ca2+   calcium ion 
 
K+   potassium ion 
 
M   molar 
 
mg   milligram 
 
ml   millilitre 
 
mM   millimolar 
 
Na+   sodium ion 
 
ng   nanogram 
 
ρmol   picomole 
 
μg   microgram 
 
μl   microlitre 
 
μM   micromolar 
 
nm   nanometre 
 xi
Glossary 
ab initio - software that attempts to predict genes from sequence data without using prior 
knowledge about similarities to other genes. 
 
Allele - alternative form of a genetic locus; a single allele for each locus is inherited from 
each parent (one or two more forms of a particular gene or marker). 
 
Autosomal dominant - a gene (or disease allele) on one of the non-sex chromosomes that is 
expressed, even if only one copy is present. The chance of passing the gene (or disease allele) 
to offspring is 50% for each pregnancy. 
 
Autosomal recessive - a trait (or a disease) that is produced only when two copies of a gene 
(or disease allele) are present. 
 
Bioinformatics - the science of managing and analysing biological data using advanced 
computing techniques. 
 
Blast (Basic Local Alignment Search Tool) - a fast heuristic search tool developed by 
Altschul, Gish, Miller, Myers and Lipman at the National Centre for Biotechnology 
Information (NCBI) that allows sequence search queries against the Genbank® database via 
the worldwide web (WWW). BLAST is able to detect relationships among sequences that 
share only isolated regions of similarity. 
 
BLOCKS - an online database of multiply aligned ungapped segments corresponding to the 
most highly conserved regions of proteins documented in the PROSITE and Interpro 
database. 
 
Centimorgan (cM) - a unit of genetic distance equivalent to a 1% recombination during 
meiosis. One centimorgan is equivalent to a physical distance of approximately one megabase 
(Mb) in a genome. 
 
cDNA - complementary DNA- a piece of DNA copied in vitro from messenger ribonucleic 
acid (mRNA) by a reverse transcriptase enzyme. 
 
 xii
Codon – the basic unit of the genetic code, comprising three-nucleotide sequences of mRNA, 
which specifies an amino acid or translational stop signal. 
 
Contiguous - the result of joining overlapping collections of sequences or clones. 
 
Domain - a discrete portion of a protein with its own function. The combination of domains 
in a single protein determines its overall function.  
 
Draft sequence - the sequence produced by combining the information from the individual 
sequenced clones and positioning the sequence along the physical map of chromosomes. 
 
E-value (expectation value) - the number of different alignments with scores equivalent to or 
better than a score expected to occur in a database search by chance. The lower the E-value, 
the more significant the score. 
 
Expressed sequence tag (EST) – an expressed sequence tag is obtained by performing a 
single raw sequence read from the 3’ or 5’ end of a cDNA clone. 
 
Finished sequence - high-quality, low error, gap-free DNA sequence of the human genome.  
 
Freeze dates - snapshot of the most recent accession for each sequenced clone and ancillary 
data taken at a particular date. 
 
Genetic map - a genome map in which polymorphic loci are positioned relative to one 
another on the basis of the frequency with which they recombine during meiosis. The unit of 
distance is a cM, where 1cM denotes a 1% chance of recombination. 
 
Genotype - the set of genes that an individual carries; refers to the particular pair of alleles 
(alternative forms of a gene) that a person has at a given locus. 
 
Haploinsufficiency - an individual who is heterozygous for a certain gene mutation or 
hemizygous at a particular locus, often due to a deletion of the corresponding allele, is 
clinically affected because a single copy of the normal gene is incapable of providing 
sufficient protein production as to assure normal function. 
 
 xiii
Haplotype - a particular combination of alleles or sequence variations that are closely linked 
or likely to be inherited together on chromosomes. 
 
In silico - the term "in silico" has been introduced into life sciences and is similar to the terms 
"in vivo" (in the living system) and "in vitro" (in the test tube). It implies the gain of insights 
by theoretical considerations, simulations and experiments conducted in the silicon-based 
technology of a computer. 
 
Linkage - the tendancy of genes or other DNA sequences at specific loci to be inherited 
together as a consequence of their physical proximity on a single chromosome. 
 
Lod score - a measure of the likelihood of genetic linkage between loci. A lod score greater 
than +3 is often taken as evidence of linkage; a score less than –2 is often taken as evidence 
against linkage, or exclusion.  
 
Megabase (Mb) - unit of length for DNA fragments equal to 1 million nucleotides and 
roughly equal to 1 cM.  
 
Motif - a region within a group of related protein or DNA sequences that is evolutionarily 
conserved, presumably due to its functional importance. 
 
mRNA (messenger RNA) - RNA molecules synthesised from a DNA template (transcribed) 
which then serves as a template for the synthesis of a protein (translation). 
 
NCBI (National Centre for Biotechnology Information) - the National Centre for 
Biotechnology Information (NCBI) is part of the National Library of Medicine (NLM). Its 
mission is to develop new information technologies to aid in the understanding of 
fundamental molecular and genetic processes that control health and disease. NCBI developed 
and maintains the Entrez Search System and PubMed database. 
 
Pfam - an online database of protein families and multiple sequence alignments covering 
many common protein domains, created by ELL Sonnhammer, SR Eddy, E Birney, A 
Bateman and R Durbin. 
 
 xiv
Phenotype - the physical characteristics of a cell or organism as determined by the genetic 
constitution; also the specific physical characteristics of a disorder. 
 
Physical map - a map of the locations of identifiable landmarks on DNA (e.g., restriction-
enzyme cutting sites, genes). Distance is measured in base pairs. For the human genome, the 
lowest-resolution physical map is the banding patterns on the 24 different chromosomes; the 
highest-resolution map is the complete nucleotide sequence of the chromosomes. 
 
PROSITE - an authoritative database of protein families and domains. It consists of 
biologically significant protein sites, patterns and profiles. 
 
Single nucleotide polymorphism (SNP) – alternative alleles (a single base pair substitution, 
an insertion or deletion) present at a frequency of at least 1% in a population. 
 
STACK - the Sequence Tag Alignment and Consensus Knowledgebase (STACK) is 
generated by processing EST and mRNA sequences obtained from Genbank through a 
pipeline consisting of masking, clustering, alignment and variation analysis steps. STACK 
database is organised into 15 tissue-based categories and one disease category. 
 
Recombination - the process by which DNA is exchanged between homologous 
chromosome pairs during egg or sperm formation. Recombination has the effect of making 
the chromosomes of the offspring distinct from those of the parent. 
 
Transcript map - a map of locations of gene (mRNA, cDNA or EST) sequences that code 
for a protein. 
 
Transition - a type of nucleotide-pair substitution involving the replacement of a purine with 
another purine, or of a pyrimidine with another pyrimidine for example GC with AT. 
 
Transversion - a type of nucleotide-pair substitution involving the replacement of a purine 
with a pyrimidine, or vice versa, for example GC with TA. 
 
UniGene - an online database of non-redundant clustered Genbank and EST sequences for 
human, mouse, rat, cow, clawed frog and zebrafish. Each cluster contains sequences that 
 xv
represent a unique gene, as well as related information such as tissue types in which the gene 
has been expressed and map location. 
 
X-linked – a mutation in a gene on the X chromosome passed through a family, resulting in a 
specific trait or disease to be seen more commonly in males than females. 
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Introduction 
I have long felt that biology ought to seem as exciting as a mystery story, for a mystery story is 
exactly what biology is. 
- Richard Dawkins, "The Selfish Gene" 
 
1.1 Preface 
In 1950, Paul Wood stated, “Heart failure is a state in which the heart fails to maintain an 
adequate circulation for the needs of the body despite a satisfactory filling pressure”. More than 
50 years later, this condition is still recognised as the inability of the heart to function efficiently 
and is considered to be a major cause of morbidity and mortality (Braunwald, 1980; Eriksson, 
1995; Giles, 1997; Towbin and Bowles, 2002). Estimates from the United States of America 
(USA) indicate that heart failure affects more than 60 million individuals in that country and, per 
annum, accounts for more than U$200 million in associated hospitalisation costs (Manolio et al., 
1992; Schönberger and Seidman, 2001; Seidman and Seidman, 2001; Towbin and Bowles, 
2002). In Europe, it is estimated that more than 50 million individuals are affected by heart 
failure (Franz et al., 2001). However, in developing countries, the societal and economic cost of 
heart failure have not been estimated, although it has been proposed that changing lifestyles may 
cause similar patterns of incidence to that observed in the USA and Europe (Garros et al., 1980; 
World Health Organisation (WHO) website, http://www.who.org).  
 
Heart failure results when the heart is no longer able to pump efficiently because of abnormal 
cardiac remodelling, usually in the form of hypertrophy of the myocardial wall or dilatation of 
the cardiac ventricles (Braunwald, 1980). Normally, the heart undergoes compensatory cardiac 
remodelling in response to coronary artery disease (myocardial infarction and ischaemia), 
valvular heart disease, alcohol and certain drugs, toxins, arrhythmias or cardiomyopathies 
(Braunwald, 1980). Occasionally the remodelling may become maladaptive and trigger events 
 5 
that lead to complete cardiac malfunction (Towbin and Bowles, 2004). In the past, the primary 
focus of medical research was to identify effective means to prevent heart failure that had 
developed as a secondary consequence to pathological insults such as inflammation, infection, 
drugs, alcohol or toxins (Braunwald, 1980). However, in the 1990s, it was realised that the 
progression to heart failure was mostly associated with large families in which many members 
presented with primary forms of cardiomyopathy (Maron et al., 1995). Furthermore, inter- and 
intra-familial clinical variability was often demonstrated, which led to the suggestion that heart 
failure itself was a primary condition and that the phenotypic variation was a consequence of 
genetic heterogeneity (Maron et al., 1984; Graber et al., 1986; Solomon et al., 1990; Michels et 
al., 1992; Grünig et al., 1998).  
 
The relevance of heart failure to the present study 
The present study will demonstrate that progressive familial heart block type II (PFHBII) 
(Mendelian Inheritance in Man [MIM] accession number 140400) is a primary form of 
cardiomyopathy that is complicated by cardiac conduction defects that shows progression to 
heart failure. The cause of PFHBII is unknown, but it is hypothesised that the clinical and 
pathophysiological characteristics of other diseases that are associated with heart failure may 
provide clues to the likely molecular aetiology of the disorder. Accordingly, this literature review 
aims to give a clinical overview and to describe the molecular aetiologies that have been 
identified for two types of primary cardiomyopathy, namely, dilated cardiomyopthy (DCM) and 
hypertrophic cardiomyopathy (HCM), in addition to providing insight into the clinical and 
genetic characteristics of inherited cardiac conduction disorders. Common clinical features and 
molecular aetiologies between different clinical conditions will be reviewed, thereby providing 
further clues to the possible cause of PFHBII. As initiatives such as the Human Genome Project 
(HGP) have provided resources that have accelerated the identification of numerous disease-
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causative aetiologies, the application of these resources will also be reviewed. 
 
1.2 PFHBII 
1.2.1 History and genealogy 
In 1977, Brink and Torrington described PFHBII as an adult-onset cardiac conduction disorder of 
unknown aetiology displaying an autosomal dominant pattern of inheritance, which segregates in 
a South African Caucasian Afrikaner family. Genealogical studies performed by Brink and 
Torrington in 1977 (Fig. 1.1) had traced the segregation of the disorder in a family descended 
from a Dutch immigrant who arrived in South Africa in 1713 and who had settled in a region in 
the Eastern Cape Province seven years later.  
 
For the present study, P. Brink and A. Goosen (personal communication) traced the siblings and 
progeny of subjects that had previously been assessed, or were interviewed by Brink and 
Torrington (1977) and Torrington (PhD thesis, 1979), some 25 years ago. These investigations 
could only identify the disease in the family described by Brink and Torrington (1977), and for 
this reason, the present study has focused on the same kindred, even though previous studies have 
supported the notion that the occurrence of PFHBII may be more widespread than merely in one 
kindred (see section 4.5). 
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Fig. 1.1  
The four-generation pedigree described by Brink and Torrington (1977) showing the autosomal 
dominant transmission of PFHBII.  
The study by Brink and Torrington (1977) had identified 144 members of a family in which PFHBII 
segregates. Twenty-four of the family members were clinically assessed, of which 13 were identified with 
cardiac conduction defects.  
 
1.2.2 Clinical characteristics 
In their publication, Brink and Torrington (1977) defined the clinical features of PFHBII on 
electrocardiograph (ECG) analysis as isolated sinus bradycardia (SB), isolated left posterior 
hemiblock (LPHB) associated with syncopal episodes, Stokes-Adams seizures (light-headedness) 
or complete heart block (CHB) with narrow QRS complexes. Almost 10 years thereafter, A. 
Brink suggested that PFHBII was possibly associated with an inherited cardiomyopathy (Van der 
Merwe et al., 1986), although no data was supplied to substantiate this claim. Later, P. Brink 
(personal communication) indicated that he had identified individuals in the PFHBII-affected 
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family that demonstrated progression from conduction defects to DCM. This data promoted the 
possibility that cardiomyopathy was a primary feature of the disorder.  
 
Presently, the molecular cause of PFHBII has not been established, although the availability of a 
number of affected individuals in a family has allowed the application of linkage analysis and 
positional cloning or positional candidate gene strategies to search for the disease-causative gene. 
Since inherited cardiac diseases with clinical features similar to PFHBII have been described 
globally and in South Africa, it is possible that this disorder has been described elsewhere, 
although by a different clinical designation. Therefore, the following sections will give an 
overview of the clinical features and molecular aetiologies of conditions akin to PFHBII, which 
may be associated with progression to heart failure.  
 
1.3 Familial cardiomyopathies  
1.3.1 Familial DCM: history and clinical classification 
In 1961, Whitfield documented a family that presented with a “cardiomyopathy” that was, at the 
time, defined as a disease of the heart muscle for which the cause was unknown. Subsequently, 
Kariv et al., (1966) identified another family with a cardiomyopathy that was accompanied by 
Stokes-Adams seizures, while, four years later, Goodwin (1970) identified families that either 
presented with a congestive type of cardiomyopathy or a clinical form that was associated with 
hypertrophy (see section 1.3.5). The congestive form of cardiomyopathy that Goodwin (1970) 
had described was characterised by ventricular dilatation and contractile dysfunction, hence its 
subsequent classification as DCM (Gardner et al., 1987). Currently, numerous studies have 
described families with autosomal dominant, autosomal recessive and X-linked inherited forms of 
DCM that may occur in isolation or in conjunction with conduction defects, arrhythmias or 
skeletal myopathies (Table 1.1).  
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Table 1.1 
Timeline of familial DCM-associated disorders  
Authors Clinical features Country where 
described 
#Mode of 
inheritance 
Emanuel (1972) Isolated DCM England Recessive 
Waxman et al., (1974) Ventricular dilatation, conduction 
defects, ventricular tachycardia, atrial 
fibrillation and mitral insufficiency  
Canada Dominant 
Brink et al., (1976) Restrictive DCM and dysrhythmias South Africa Dominant 
Ross et al., (1978) DCM and arrhythmias North America Dominant 
Sekiguchi et al., (1978) DCM and conduction defects Japan Recessive 
Moller et al., (1979) DCM, septal hypertrophy, arrhythmias 
and conduction defects 
Germany Dominant 
Marcus et al., (1982) Right ventricular dysplasia, ventricular 
tachycardias, right-heart failure or 
asymptomatic cardiomegaly 
France Unknown 
Barth et al., (1983) DCM, neutropenia and mild skeletal 
myopathy 
Netherlands X-linked 
Ibsen et al., (1985) Right ventricular dilatation, ventricular 
arrhythmias and conduction defects 
Netherlands Unknown 
Krasnow et al., (1985) DCM, cataracts and hip-spine disease North America Recessive 
Protonotarios et al., (1986) Naxos syndrome characterised by right 
ventricular dysplasia, woolly hair and 
keratinosis 
Greece Recessive 
Berko and Swift (1987) DCM and mild skeletal myopathy, late 
progression to heart failure in females 
North America X-linked 
Schmidt et al., (1988) DCM, dysrhythmias, dyspnoea and 
exercise-induced sinus tachycardia. 
North America X-linked 
Graber et al., (1986) DCM and conduction defects North America Dominant 
Kass et al., (1994) DCM and conductions defects North America Dominant 
Durand et al., (1995b) DCM and conduction defects North America Dominant 
Krajinovic et al., (1995) Isolated DCM Italy Dominant 
Rampazzo et al., (1995) Exercised-induced ventricular 
tachycardias, right ventricular 
degeneration 
Italy Dominant 
Olson and Keating (1996) DCM, sinus node dysfunction, 
superventricular tachyarrhythmia, 
conduction defects and stroke 
North America Dominant 
Messina et al., (1997) DCM, skeletal myopathy and 
conduction defects 
North America Dominant 
Olson et al., (1998) Isolated DCM North America Dominant 
Li et al., (1999) Isolated DCM North America Dominant 
Kamisago et al., (2000) Early onset DCM North America Dominant 
Schönberger et al., (2000) DCM and sensorineural hearing loss North America Dominant 
Norgett et al., (2000) DCM, woolly hair and keratoderma  Ecuador Recessive 
Olson et al., (2001) Isolated DCM North America Dominant 
Daehmlow et al., (2002) Isolated DCM Germany Dominant 
Hanson et al., (2002) DCM and conduction defects North America Dominant 
Murphy et al., (2004) Isolated DCM England Recessive 
# = autosomal inheritance pattern, except for X-linked disorders; DCM = dilated cardiomyopathy 
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1.3.2 Molecular genetics of DCM 
At the onset of the 1970s, numerous families with DCM-associated disorders that progressed to 
heart failure had already been described (Table 1.1), although the prevalence of the condition in 
those lineages had not been determined. However, in 1978, Sekiguchi and colleagues reported 
that 31% of patients with DCM in the Japanese population had a family history of heart failure. 
The subsequent decade-and-a-half produced a number of reports describing families that 
presented with DCM either in isolation or with accompanying features (Table 1.1). Prior to the 
report by Sekiguchi et al., (1978), DCM-associated disorders had mainly been portrayed as 
conditions that occurred as a result of environmental factors or lifestyle, as described by 
Braunwald in “A Textbook of Cardiovascular Medicine” (Braunwald, 1980). Later, Michels and 
colleagues (1992) initiated a study to establish whether familial forms of DCM were as frequent 
as conditions caused by environmental factors. The study demonstrated that at least 20% of the 
individuals with DCM-associated defects had a familial form of the disease (Michels et al., 
1992). As numerous reports accumulated describing families with DCM in which the disease-
associated loci had been identified (see sections hereafter), Grünig et al., (1998) re-evaluated the 
previous data on the prevalence of inherited DCM. These authors subsequently suggested that as 
many as 35% of patients with DCM had a familial form of the disease, of which autosomal 
dominant inheritance was the most common pattern. 
 
1.3.2.1 Molecular aetiologies of autosomal dominant DCM 
1.3.2.1.1 Disease loci and causative genes associated with isolated DCM 
Currently, causative mutations associated with isolated forms of DCM have been described in 11 
genes, namely, the gene encoding cardiac troponin T (TNNT2) mapped on chromosome 1q32 
(Durand et al., 1995b; Kamisago et al., 2000; Li et al., 2001) (MIM 601494), titin (TTN) on 
chromosome 2q31 (Siu et al., 1999; Gerull et al., 2002) (MIM 604145), desmin (DES) on 
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chromosome 2q35 (Li et al., 1999) (MIM 604765), delta (δ)-sarcoglycan (SGCD) on 
chromosome 5q33 (Tsubata et al., 2000) (MIM 606685), phospholamban (PLB) on chromosome 
6q22 (Schmitt et al., 2003) (MIM 172405), metavinculin (VCL) on chromosome 10q22-q23 
(Bowles et al., 1996; Olson et al., 2002) (MIM 193065), cardiac myosin-binding protein C 
(MYBPC3) on chromosome 11p11 (Daehmlow et al., 2002) (MIM 115197), cardiac muscle LIM 
protein (CSRP3) on chromosome 11p15 (Knöll et al., 2002) (MIM 607482), beta (β)-myosin 
heavy chain (MYH7) on chromosome 14q12 (Kamisago et al., 2000) (MIM 115200), cardiac 
actin (ACTC) on chromosome 15q14 (Olson et al., 1998) (MIM 115200) and alpha (α)-
tropomyosin (TPM1) on chromosome 15q22 (Olson et al., 2001) (MIM 115196) (Fig. 1.2). 
Additionally, two isolated DCM disorders have been mapped to loci on chromosome 6q12-q16 
(CMD1K) (Sylvius et al., 2001) (MIM 605582) and chromosome 9q12-q13 (CMD1B) 
(Krajinovic et al., 1995) (MIM 600884) (Fig. 1.2), although their associated molecular 
pathophysiology has yet to be identified. 
 
1.3.2.1.2 Disease loci and causative genes associated with DCM and conduction defects 
Various studies have described families in which cardiac conduction abnormalities accompany 
DCM (Sekiguchi et al., 1978; Graber et al., 1986; Kass et al., 1994; Durand et al., 1995b; Hanson 
et al., 2002) (Table 1.1). Presently, causative mutations associated with disorders that present 
with DCM and cardiac conduction defects have been identified in two genes, namely the gene 
encoding lamin A and C (LMNA) on chromosome 1p1-1q21 (Kass et al., 1994; Fatkin et al., 
1999) (MIM 115200) and TNNT2 (Hanson et al., 2002) (Fig. 1.2). Two additional loci have been 
described, for which the molecular aetiology has not been identified. These loci map to 
chromosome 2q14-q22 (CMD1H) (Jung et al., 1999) (MIM 604288) and chromosome 3p21-p25 
(CMD1E) (Olson and Keating, 1996) (MIM 601154) (Fig. 1.2). 
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Fig. 1.2 
Human cytogenetic map indicating mapped DCM-causative loci and genes. 
ACTC = cardiac actin; ARVC = arrhythmogenic right ventricular cardiomyopathy; BTHS = Barth syndrome; CMD = dilated cardiomyopathy locus; CMH = 
hypertrophic cardiomyopathy locus; CSRP3 = muscle LIM protein; DES = desmin; DMD = dystrophin; DSP = desmoplakin; G4.5 = tafazzin; JUP = 
plakoglobin; LMNA = lamin A and C; MYBPC3 = cardiac myosin-binding protein C; MYH7 = β-myosin heavy chain; PLB = phospholamban; RYR2 = 
ryanodine receptor type 2; SGCD = δ-sarcoglycan; TNNT2 = cardiac troponin T; TPM1 = α-tropomyosin; TTN = titin; VCL = metavinculin; XLCM = X-linked 
DCM. Disease-causative genes are shown in blue. 
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1.3.2.1.3 Disease loci and causative mutations associated with DCM, skeletal myopathies 
and conduction defects 
Syndromes that are associated with skeletal myopathies and DCM are fairly common, although 
these have been mainly associated with X-linked conditions (see section 1.3.2.3). Conversely, 
autosomal dominantly inherited DCM-associated disorders that present with skeletal myopathies 
are less prevalent. In 1997, Messina et al., described mapping a DCM-causative locus that is 
associated with skeletal myopathies accompanied by conduction defects to chromosome 6q23 
(CMD1F) (MIM 602067) (Fig. 1.2). Currently, there are no other reports of families with 
autosomal dominantly inherited primary DCM that present with skeletal myopathies and 
conduction defects. However, families with Kearns-Sayre syndrome (Kearns, 1965; Drachman, 
1975) (MIM 530000), a neuromuscular disease caused by deletion mutations in muscle 
mitochondria, which may result in chronic, progressive or external ophthalmoplegia (eye muscle 
paralysis), hearing loss, pigment degeneration of the retina, conduction defects and DCM, have 
been reported.  
 
1.3.2.1.4 Disease loci and causative genes associated with DCM and sensorineural hearing 
loss 
Schönberger et al., (2000) characterised a family with a rare form of DCM that was accompanied 
by sensorineural hearing loss, for which they mapped the causative locus to a region on 
chromosome 6q23-q24 (CMD1J) (MIM 605362) (Fig. 1.2). The causative gene for this disorder 
remains unknown and no additional autosomal dominant DCM-associated disorders with 
abnormal auditory function have been described, although, sensorineural deafness may be a 
clinical feature that is associated with Kearns-Sayre syndrome (Kearns, 1965) (see previous 
section).  
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1.3.2.1.5 Disease loci associated with cardiac arrhythmias 
Arrhythmogenic right ventricular dysplasia (ARVD) (MIM 107970) (reclassified as 
arrhythmogenic right ventricular cardiomyopathy [ARVC] in 1996 by the WHO) is a disorder 
characterised by supraventricular or ventricular arrhythmias, conduction defects, right ventricular 
dysplasia or dilatation leading to ventricular degeneration brought about by fibro-fatty deposits in 
the ventricular free wall (Marcus et al., 1982). By 1985, a number of families and sporadic cases 
of individuals with ARVC had been described (Marcus et al., 1982; Ibsen et al., 1985) (Table 
1.1), even though no family studies had been undertaken at the time, to elucidate the genetic 
cause of the condition. About 10 years later, Rampazzo et al., (1995) described a family that 
presented with an ARVC-like disorder (termed ARVC2) (MIM 600996) that was characterised 
by exercise-induced polymorphic ventricular tachycardias and fatty-fibrous replacement of the 
right ventricle, without notable structural changes to the heart. The same authors also reported 
mapping the causative gene for ARVC2 to a locus on chromosome 1q42-q43 (Rampazzo et al., 
1995) (Fig. 1.2). Subsequently, Tiso et al., (2001) described a positional candidate gene analysis 
that resulted in the identification of four ARVC2-causative mutations in four unrelated families 
in the gene that encodes the cardiac ryanodine receptor type 2 (RYR2) (Fig. 1.2). 
 
1.3.2.2 Molecular aetiologies of autosomal recessive DCM 
Autosomal recessive inheritance has been reported in 16% of all described families that present 
with DCM (Towbin and Bowles, 2001). One of the earliest reports of autosomal recessive 
isolated DCM was by Emannuel (1972). Thereafter, families were identified in which autosomal 
recessive DCM occurred in isolation (Krasnow et al., 1985) or was accompanied by features such 
as cataracts, joint disease, woolly hair, keratinosis or keratoderma (Protonotarios et al., 1986). 
The availability of families with recessive forms of DCM, has allowed the application of linkage 
analyses to identify the causative genes for these disorders.  
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To this end, Coonar and colleagues (1998) described the results of a linkage study in 
consanguinous Greek families with Naxos syndrome (Protonotarios et al., 1986) (MIM 601214) 
(Table 1.1), which placed the causative gene at a locus on chromosome 17q21 (Fig. 1.2). Two 
years later, McKoy et al., (2000) reported that they had performed positional candidate gene 
analyses at the Naxos syndrome locus and had identified a homozygous deletion mutation in the 
plakoglobin protein-encoding gene (JUP) (Fig. 1.2). Soon thereafter, Norgett et al., (2000) 
reported that they had identified a mutation in the gene that encodes desmoplakin (DSP) (MIM 
605676) (Fig. 1.2), which caused DCM, woolly hair and keratoderma in three families of 
Ecuadorian descent.  
 
More recently, Murphy et al., (2004) reported that they had identified an autosomal recessive 
DCM-causative mutation in the gene that encodes cardiac troponin I (TNNI3) (MIM 115210). 
Although only two subjects were identified with the mutation in troponin I, these authors 
suggested that other recessive disease genes might be identified using techniques specifically 
designed to identify homozygous sequence variations (Murphy et al., 2004).  
 
1.3.2.3 Molecular aetiologies of X-linked DCM 
X-linked cardiomyopathies are common conditions that affect approximately one in 3500 males 
(Fatkin and Graham, 2002). Barth et al., (1983) described a family with a syndromic form of 
cardiomyopathy that presented with DCM and mild skeletal myopathy (Table 1.1). Four years 
later, Berko and Swift (1987) described another family in which teenage male subjects presented 
with DCM and mild skeletal myopathy and older female subjects presented with late-onset 
atypical chest pain and progression to heart failure. This condition was subsequently termed X-
linked DCM (XLCM) (MIM 302045). The following year, Schmidt et al., (1988) described a 
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third family with an X-linked form of DCM that presented with DCM, dysrhythmias, dyspnoea 
and exercise-induced sinus tachycardia. Genetic studies in these families with the syndromic 
form of DCM and X-linked type resulted in mapping the associated disease loci, as well as 
identifying the molecular aetiologies of these conditions (see below). 
 
1.3.2.3.1 Barth syndrome 
Bolhuis and colleagues (1991) had mapped a condition, which was termed Barth syndrome 
(BTHS) (MIM 302060) because Barth et al., (1983) had first described the disease, to a locus on 
chromosome Xq28 (Fig. 1.2). Later, Bione et al., (1996) reported that they had performed a 
positional candidate gene analysis at the locus on chromosome Xq28 and had identified two 
BTHS-causative mutations in one family in the tafazzin protein-encoding gene (G4.5). Presently, 
this is the only report of cardiomyopathy-associated mutations in G4.5. 
 
1.3.2.3.2 XLCM  
Towbin and colleagues (1993) described a linkage study that had been performed in the North 
American family previously described by Berko and Swift (1987), which resulted in mapping 
XLCM to a locus on chromosome Xp21.1 (Fig. 1.2). Five years prior to the study by Towbin and 
colleagues (1993), deletion mutations that cause two forms of muscular dystrophy, namely 
Duchenne (Hoffman et al., 1987) and Becker muscular dystrophy (Koenig et al., 1988) were 
identified in the dystrophin protein-encoding gene (DMD). Because cardiomyopathy was a 
presenting feature of Duchenne’s and Becker’s muscular dystrophy, Muntoni and colleagues 
(1993) screened DMD in an Italian family with XLCM, which resulted in these authors 
describing a disease-causative deletion mutation in the promoter region of the gene. Later, in 
1998, Ferlini and colleagues reported that they had identified another mutation in DMD that 
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activated a cryptic splice site in intron 11 and was associated with XLCM in another Italian 
family. 
 
1.3.3 Mechanisms of familial DCM 
The identification of the molecular aetiologies of various DCM-related disorders have provided 
clues that aided in elucidating the pathophysiological mechanisms of the disease. Moreover, 
DCM-causing mutations were identified in genes that encode, among others, structural protein 
constituents of cardiomyocytes (cardiac muscle cells), hence the formulation of hypotheses that 
explain the pathological pathways associated with heart failure. 
 
1.3.3.1 Alterations in cardiomyocyte structural proteins 
1.3.3.1.1 Structure of the cardiomyocyte 
In order to illustrate the mechanisms of DCM that occur as a consequence of alterations in 
cardiomyocyte structure, the architecture of the muscle cell first has to be understood. 
Cardiomyocytes consist of cytoskeletal and filamentous proteins that maintain the structural 
integrity of the cell, and sarcomeric proteins, which constitute the functional unit of muscle 
contraction (Jaenicke et al., 1990) (Fig. 1.3). A sarcolemmal membrane consisting of anchoring 
and channel proteins, which allow cell-to-cell contact and the influx/efflux of nutrients and ions, 
encloses the cardiomyocyte (Fig. 1.3). The nucleus of the cardiomyocyte is embedded within the 
cytosol of the cell and is surrounded by a nuclear envelope that consists of structural and channel 
proteins (Fig. 1.3). It is important to remember that this is a rudimentary description of the 
structure of the cardiomyocyte, as there are a myriad of other proteins that interact with the 
constituents described above. The present study will focus on the cardiomyocytic components in 
which mutations have been identified that cause familial forms of cardiomyopathy.  
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1.3.3.1.2 Structural alterations and defective force transmission  
Physiological functioning of the heart requires that the contractile force that is generated by the 
sarcomere be transmitted via the cytoskeleton to the sarcolemmal membrane and to adjacent 
myocytes (Fung et al., 1995). In 1993, Muntoni et al., described an XLCM-causative deletion 
mutation in dystrophin, a cytoskeletal protein that is attached to the sarcolemma (Fig. 1.3). 
Fortuitously, this finding was later to provide clues to the potential pathological mechanisms of 
DCM. Thus, when Olson et al., (1998) identified two DCM-causative mutations in cardiac actin 
that were located in amino acid residues involved in actin-cytoskeletal interactions, correlations 
were drawn between these defects and that described in dystrophin, which led to the suggestion 
that DCM occurred as a consequence of alterations in cytoskeletal integrity and reduced force 
transmission. For this reason, in 1998, Towbin suggested that DCM be classified as a 
“cytoskeletalopathy”. Subsequent studies describing DCM-causing mutations in the cytoskeletal 
proteins desmin (Li et al., 1999), metavinculin (Olson et al., 2002) and cardiac muscle LIM 
protein (Knöll et al., 2002) provided further evidence to support Towbin’s (1998) description of 
DCM as a cytoskeletalopathy. 
 
At about the same time, four other studies had described DCM-associated mutations in genes that 
encode the membrane-associated proteins lamin A and C (Fatkin et al., 1999), desmoplakin 
(Norgett et al., 2000), δ-sarcoglycan (Tsubata et al., 2000) and plakoglobin (McKoy et al., 2001). 
The lamin A and C proteins stabilise the nuclear envelope (Lin and Worman, 1993, Hutchison, 
2002), while desmoplakin, δ-sarcoglycan and plakoglobin are attached to the sarcolemma and 
form cell-to-cell junctions (Norgett et al., 2000; Tsubata et al., 2000). Although the lamin A and 
C, desmoplakin, δ-sarcoglycan and plakoglobin proteins are membrane bound, they are attached 
to other cytoskeletal proteins that, in turn, are linked to the sarcomere (Fig. 1.3). Therefore, it was 
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suggested that the DCM-causing mutations in these proteins also reduce cardiac force 
transmission (Fatkin et al., 1999; Tsubata et al., 2000).  
 
 
Reproduced and adapted from Moolman-Smook et al., (2003) 
Fig. 1.3 
The cellular localisation and interaction of the proteins constituents of the cardiomyocyte.  
Schematic representation of a cross-section through a cardiomyocyte indicating the cellular location and 
interactions of proteins in which mutations have been identified that cause DCM and HCM (see text). 
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1.3.3.1.3 Structural alterations and defective force generation 
The identification of DCM-causing defects in proteins involved in contractile force transmission 
set a precedent for screening genes encoding cytoskeletal proteins, although most of these studies 
were unsuccessful. However, in 2000, Kamisago and colleagues reported mapping a DCM-
causative locus to chromosome 14q12.2-q11.2 and concomitantly described mutations in the 
sarcomeric β-myosin heavy chain protein, which, had previously been implicated in the 
pathogenesis of HCM (Geisterfer-Lowrance at al., 1990). The same group then performed 
candidate gene analyses of other sarcomeric protein-encoding genes in which mutations had been 
shown to cause HCM and subsequently described a DCM-associated mutation in cardiac troponin 
T (Kamisago et al., 2000) 
 
The finding by Kamisago et al., (2000) was important because mutations in β-myosin heavy 
chain and troponin T had been shown to cause HCM by altering the stoichiometry of the 
sarcomeric proteins, thereby causing a reduction in cardiac contractile force (Thierfelder et al., 
1994; Watkins et al., 1996). Thus, based on the functional domains in which the particular DCM-
causing mutations were identified, Kamisago and colleagues (2000) suggested that defects in β-
myosin heavy chain and troponin T altered stereospecific myosin-actin interactions and actin-
myosin ATPase activity, respectively, which in both instances, resulted in DCM by reducing the 
overall generation of contractile force. 
 
Additionally, in the same study, Kamisago et al., (2000) proposed that at least 10% of all cases of 
familial DCM were likely to be attributed to defects in genes that encode sarcomeric proteins. 
Consequently, other studies described DCM-associated mutations in the genes encoding the 
sarcomeric proteins α-tropomyosin (Olson et al., 2001), cardiac myosin-binding protein C 
 21 
(Daehmlow et al., 2002) and titin (Gerull et al., 2002). Incidentally, separate mutations in these 
sarcomeric proteins had also been implicated as cause of HCM (Thierfelder et al., 1994, Watkins 
et al., 1995; Moolman-Smook et al., 1998; Satoh et al., 1999). Therefore, it was suggested that 
reduced contractile force was also a primary cause of DCM (Schönberger and Seidman, 2001; 
Seidman and Seidman, 2001). 
 
1.3.3.2 Alterations in cardiomyocyte calcium (Ca2+) homeostasis 
Given the multitude of proteins that participate in cardiac contractile force generation and force 
transmission, it would be expected that more DCM-causative mutations would have been 
identified in genes whose protein products are components of the sarcomere or cytoskeleton. 
However, to date, no defects have been described in other sarcomeric or cytoskeletal proteins, 
despite many extensive investigations. The lack of success suggested that additional 
pathophysiological mechanisms might be involved in the pathogenesis of DCM. 
 
The first indication of other DCM-associated disease mechanisms developed as a consequence of 
the identification of ARVC2-causative defects in the cardiac ryanodine receptor 2 (Tiso et al., 
2001). The precise pathological mechanism that causes ARVC has remained inconclusive, 
although the identification of mutations in this receptor, as well as the recognition that right 
cardiac ventricular degeneration was a defining characteristic of ARVC, provided possible clues. 
 
The ryanodine receptor regulates the release of Ca2+ from the sarcoplasmic reticulum (SR) (Fig. 
1.4) and it has been suggested that mutations in this receptor may increase the release of Ca2+ 
from the SR (Fatkin and Graham, 2002). The consequent elevated cytosolic Ca2+ levels are 
thought to disrupt excitation-contraction coupling and thereby trigger arrhythmias or promote cell 
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death, the latter being suggested as a feasible explanation for the degeneration of the right 
ventricle that is frequently observed in ARVC (Fatkin and Graham, 2002). 
 
 
 
 
Reproduced and adapted from Chien (2000) 
Fig. 1.4 
Protein components of the sarcoplasmic reticulum (SR) involved in regulating Ca2+concentrations. 
During cardiac contractile force generation, Ca2+ enters into the cardiomyocyte via L-type Ca2+ channels 
and Na+/Ca2+ exchangers and triggers the ryanodine receptors to release Ca2+ into the cytosol, where it 
binds to the sarcomeric proteins that are involved in contractile force generation. During cardiac 
relaxation, the Ca2+-ATPase (SERCA2) pump, which are modulated by the phosphoprotein 
phospholamban (PLB), remove Ca2+ from the cytosol and restores sarcoplasmic reticulum basal levels. 
An asterisk denotes a protein in which mutations have been shown to cause DCM. 
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In addition, a missense mutation that causes DCM and rapid progression to heart failure was 
recently described in phospholamban (Schmitt et al., 2003), a transmembrane protein that 
regulates the activity of a cardiac Ca2+-ATPase (also called SERCA2), which, in turn, is 
responsible for the re-uptake of Ca2+ from the cytosol (McTiernan et al., 1999) (Fig. 1.4). 
Interestingly, decreased SERCA2 activity has been associated with progression to heart failure 
(Struder et al., 1994), although no causative mutations have yet been described in this protein. 
Therefore, Schmitt et al., (2003) proposed that a mutation in phospholamban caused DCM and 
acute heart failure because of a disturbance in Ca2+ homeostasis, which was a direct result of the 
constitutive inhibition of SERCA2.  
 
1.3.3.3 Alterations in energy homeostasis 
The molecular aetiologies and underlying pathophysiologies of autosomal dominant, recessive 
and X-linked inherited disorders, in which DCM is a primary feature, have, in fact, only been 
established in the last decade. However, Ozawa et al., (1990) had previously demonstrated that 
mitochondrial defects caused sporadic forms of HCM and DCM. In the same year, Tanaka et al., 
(1990) identified a mutation in a mitochondrial protein-encoding gene (tRNA-ILE) that causes 
fatal infantile cardiomyopathy. The mutation was thought to affect cellular energy generation and 
metabolism, given the role of mitochondria in the electron transport system and its production, 
via oxidative phosphorylation, of the energy substrate adenosine triphosphate (ATP) (Tanaka et 
al., 1990). The five years that followed produced two studies that described mutations in tRNA-
ILE that encodes a mitochondrial protein (Silvestri et al., 1994; Casali et al., 1995) and which 
were associated with cardiomyopathy and skeletal myopathy. However, none of the studies 
implicating mitochondrial defects had established whether the mutations were the cause or the 
consequence of the cardiomyopathy, given the fact that the mitochondrial genome is prone to 
spontaneous mutations related to physiological ageing (Melov et al., 1995).  
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The identification of BTHS-causative mutations in the enzyme tafazzin (Bione et al., 1996) re-
established the hypothesis that deficits in energy homeostasis caused DCM-associated disorders. 
Defects in tafazzin, which belongs to a protein family known as acyltransferases, are thought to 
cause cardiomyopathy because of the enzyme’s inability to catalyse the production of specific 
glycerophospholipids (Bissler et al., 2002). The glycerophospholipids form part of the inner 
mitochondrial membrane and play a role in respiratory-chain transport and oxidative 
phosphorylation required to produce ATP (Neuwald, 1997). The data indicated that mutations in 
tafazzin cause BTHS as a result of a reduction in the production of energy (Bissler et al., 2002).  
 
1.3.4 A synopsis of familial DCM 
Familial DCM is a clinically variable and genetically heterogeneous condition, which may 
account for up to 35% of seemingly idiopathic forms of DCM. The causative genes for a number 
of familial DCM disorders have been identified, although, for some, the associated molecular 
aetiologies have yet to be elucidated. However, the identification of common genetic defects has 
suggested that the underlying causes of DCM are alterations in cardiomyocyte structure or Ca2+ 
and/or energy homeostasis. In addition, DCM shares common molecular aetiologies with other 
cardiomyopathies that are associated with progression to heart failure, notably ARVC and HCM 
(also see sections hereafter). Consequently, the accumulation of knowledge might provide clues 
for the elucidation of the molecular aetiologies of disorders for which, presently, only disease 
causative loci have been identified.  
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1.3.5 Familial HCM: history and clinical classification 
The first description of a familial form of a cardiomyopathy was by Teare (1958), who described 
six families in which young adults presented with asymmetric thickening (hypertrophy) of the 
myocardial wall. At the time, the cardiac hypertrophy was not considered a disease, but rather a 
physiological adaptation of the heart toward mechanical stress and reduced cardiac output (Teare, 
1958). Subsequently, Nasser et al., (1967) and Maron et al., (1974) identified additional families 
that presented with asymmetric or obstructive forms of cardiac hypertrophy. Then, in a landmark 
study by Maron and Epstein (1979), the term “hypertrophic cardiomyopathy” was suggested as 
the preferential nomenclature of families with asymmetric septal hypertrophy (ASH) – this study 
pioneered the present classification of different forms of the cardiac condition under one clinical 
term known as HCM.  
 
Histological and morphological studies have further defined HCM as a complex disease of the 
myocardium that is characterised by myofibrillar disarray, interstitial fibrosis, left ventricular 
hypertrophy and/or asymmetric interventricular septal hypertrophy (Maron, 1984; Maron et al., 
1995). The underlying clinical feature of HCM, in the absence of hypertension or aortic stenosis, 
was demonstrated to be an impairment of cardiac relaxation (diastole) (Maron et al., 1995; 
Maron, 1997). The condition exhibits a variety of associated clinical features that range from 
mild symptoms such as shortness of breath (dyspnoea) and chest pains (angina), to more severe 
features, such as atrial or ventricular arrhythmias and sudden death, which may occur with or 
without the presence of left ventricular or interventricular septal hypertrophy (Maron, 1995; 
Maron, 1997). Furthermore, a number of studies had mapped disease loci and had identified 
HCM-causative mutations in sarcomeric proteins (Jarcho et al., 1989; Geisterfer-Lowrance et al., 
1990; Tanigawa et al., 1990; Carrier et al., 1993; Watkins et al., 1993; Thierfelder et al., 1994; 
Watkins et al., 1995). Consequently, the molecular genetic data demonstrated that the clinical 
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variability of HCM was due to genetic locus heterogeneity (Maron, 1997; Marian and Roberts, 
2001). 
 
1.3.6 Molecular genetics of familial HCM 
1.3.6.1 Molecular aetiologies of autosomal dominant HCM 
Dominant inheritance patterns occur in approximately 50% of familial HCM (Maron et al., 
1984). Presently, HCM-causative mutations have been described in 13 genes, namely TNNT2 on 
chromosomes 1q32 (Watkins et al., 1993; Thierfelder et al., 1994; Moolman et al., 1997) (MIM 
191045), TTN on chromosomes 2q31 (Satoh et al., 1999) (MIM 188840), the regulatory myosin 
light chain (MYL3) gene on chromosome 3p21 (Poetter et al., 1996) (MIM 160790), the troponin 
C (TNNC1) gene on chromosome 3p14-p21 (Hoffmann et al., 2001) (MIM 191040), the gene 
encoding the alpha subunit of adenosine monophosphate (AMP)-activated protein kinase 
(PRKAG2) on chromosome 7q36 (MacRae et al., 1995; Blair et al., 2001; Arad et al., 2002) 
(MIM 194200), MYBPC3 on chromosome 11p11 (Carrier et al., 1993; Watkins et al., 1995; 
Niimura et al., 1998; Moolman-Smook et al., 1998) (MIM 115197), CSRP3 on chromosome 
11p15 (Geier et al., 2003) (MIM 600824), the essential myosin light chain (MYL2) gene on 
chromosome 12q23-q24 (Poetter et al., 1996) (MIM 160781), the α-myosin heavy chain (MYH6) 
gene on chromosome 14q12 (Tanigawa et al., 1990; Niimura et al., 2002) (MIM 192600), MYH7 
on chromosome 14q12 (Jarcho et al., 1989; Geisterfer-Lowrance et al., 1990; Moolman et al., 
1995) (MIM 192600), ACTC on chromosome 15q14 (Mogensen et al., 1999; Olson et al., 2000) 
(MIM 192600), TPM1 on chromosome 15q22 (Thierfelder et al., 1993; Thierfelder et al., 1994) 
(MIM 115196) and TNNI3 (Kimura et al., 1997) (MIM 191044) (Fig. 1.5).  
 
 
 27 
 
 
 
 1                     2                   3                   4                5                6                7               8               9                10              11              12             13 
 14                  15                  16                 17              18             19               20            21                22              X               Y 
Fig. 1.5 
Human cytogenetic map indicating mapped HCM-causative loci and genes. 
ACTC = cardiac actin; CMH = hypertrophic cardiomyopathy (HCM) locus; CSRP3 = muscle LIM protein; MYBPC3 = cardiac myosin-binding protein C; 
MYL2 = essential myosin light chain; MYL3 = regulatory myosin light chain; MYH6 = α-myosin heavy chain; MYH7 = β-myosin heavy chain; PLB = 
phospholamban; PRKAG2 = adenosine monophosphate (AMP)-activated protein kinase; TNNC1 = cardiac troponin C; TNNI3 = cardiac troponin I; TNNT2 
= cardiac troponin T; TPM1 = α-tropomyosin. Disease-causative genes are shown in blue. 
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 28
1.3.6.2 Molecular mechanisms of familial HCM 
By 2002, HCM-associated mutations had been identified in 11 genes whose protein products are 
components of the sarcomere, specifically β-myosin heavy chain (Geisterfer-Lowrance et al., 
1990), α-myosin heavy chain (Tanigawa et al., 1990), cardiac troponin T and α-tropomyosin 
(Thierfelder et al., 1994), cardiac myosin-binding protein C (Watkins et al., 1995; Niimura et al., 
1998; Moolman-Smook et al., 1998); the essential and regulatory myosin light chains (Poetter et 
al., 1996), troponin I (Kimura et al., 1997), cardiac actin (Mogensen et al., 1999; Olson et al., 
2000), titin (Satoh et al., 1999) and troponin C (Hoffmann et al., 2001) (Fig. 1.3). Defects in 
these proteins indicated that HCM was primarily a disease of the sarcomere, hence the term 
“sarcomeropathy” was coined by Thierfelder et al., in 1994, and, more importantly, it pointed to 
the common underlying disease mechanism. 
 
1.3.6.2.1 Alterations in force generation  
Animal model studies have been performed to determine the physiological effect of HCM-
associated mutations and, in most cases, it demonstrated that the mutant proteins are effectively 
incorporated into the cardiac myofilament, but become “poison peptides” that impaired the 
normal functioning of the sarcomere (Watkins et al., 1996; Rust et al., 1999). Mutations that alter 
proteins and cause HCM in humans have been genetically engineered into the genomes of 
various animal models in order to gain a better understanding of their associated 
pathophysiologies. However, the conclusions drawn from these studies have been inconsistent 
(Maass and Leinwand, 2000), as will be discussed below.  
 
Tardiff et al., (1998) demonstrated that mutations in troponin T altered α-tropomyosin-actin 
activity and caused the cardiac myofibres to be in a hypercontractile state; thus increasing force 
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generation. However, the animal model study by Yang and colleagues (1998) that was designed 
to determine the effects of truncation mutations in cardiac myosin-binding protein C 
demonstrated that the altered protein resulted in a leftward shift in the pCa2+-force curve, thereby 
reducing the power stroke because the myofibres were in a hypocontractile state. An analogous 
study undertaken thereafter demonstrated that different truncation mutations in cardiac myosin-
binding protein C caused a hypercontractile state of the myofibres (Witt et al., 2001), thereby 
contradicting the previous study by Yang et al., (1998). Additionally, Spindler et al., (1998) 
demonstrated that the myofibres in mice with the α-myosin heavy chain-403 (αMHC403/+) 
heterozygous mutation, which was analogous to the arginine-403 glutamine HCM-causative 
mutation in humans, demonstrated hypocontractility and a reduction in overall contractile work.  
  
However, there was a turning point in 1999, when Redwood and colleagues noted that different 
HCM-causative mutations each resulted in abnormal Ca2+ sensitivities and thus proposed that 
defective proteins increased contractile velocity and created a hypercontractile state. Redwood et 
al., (1999) suggested that the same mutant proteins could also reduce the maximum contractile 
force that was generated, thereby creating an opposing hypocontractile state. A more important 
theme of this review was the hypothesis that altered cardiac energetics gave rise to the 
hypertrophy associated with some forms of HCM (Redwood et al., 1999). This statement 
challenged the dogma at the time, but by design, it encouraged other investigations into the role 
of cellular energy in HCM.  
 
1.3.6.2.2 Alterations in cellular energy homeostasis: a “Pandora’s box” 
The cell energetics hypothesis proposed by Redwood et al., (1999) was most likely based on the 
research by Spindler et al., (1998) and Sweeney et al., (1998), who had demonstrated in animal 
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model studies that HCM-causative mutations in the β-myosin heavy chain placed a greater 
energy demand on cardiac myfibrils. However, Blair et al., (2001) provided the first evidence in a 
human model of the role of cellular energy homeostasis when they described genetic defects, 
which were associated with HCM accompanied by Wolff-Parkinson-White (WPW) syndrome, in 
PRKAG2, the gene that encodes the gamma (γ)-2 subunit of AMP-activated protein kinase 
(AMPK).  
 
The enzyme AMPK serves as a cellular “fuel gauge” by activating glycolysis and fatty acid (FA) 
uptake when the cellular ATP level falls below threshold concentrations (Hardie and Carling, 
1997; Blair et al., 2001). Prior to Blair and colleagues’ (2001) findings, Milan et al., (2000) had 
demonstrated that mutations in a gene that encodes the γ-3 subunit of AMPK caused a glycogen 
storage disorder that was associated with skeletal muscle abnormalities in pigs. Although the 
Milan et al., (2000) report did not describe any cardiac abnormalities, it was important because it 
demonstrated severe porcine skeletal muscle hypertrophy. Thus, Blair et al., (2001) suggested 
that the underlying mechanism of cardiac hypertrophy was an inability by the cardiomyocytes to 
maintain an adequate cellular energy supply, given that cardiac hypertrophy could be a primary 
feature associated with certain HCM-causative mutations.  
 
The identification of mutations in AMPK contradicted previous findings that solely implicated 
sarcomeric proteins in the pathogenesis of HCM. Nonetheless, it offered an explanation as to 
how hyper- or hypo-contractile states of the myofibres resulting from sarcomeric protein 
mutations could both cause HCM. 
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The energy homeostasis hypothesis  
It has been proposed that, for HCM, a decreased supply of ATP (energy) might inhibit Ca2+ re-
uptake by SERCA2 (Ashrafian et al., 2003; reviewed by Moolman-Smook et al., 2003). The 
reduced SERCA2 activity causes an increased availability of cytosolic Ca2+ that could trigger 
hypertrophic pathways (Spindler et al., 1998), or, in extreme cases, provide substrates for 
arrhythmogenic events resulting in sudden cardiac death (Somura et al., 2001). The hypothesis 
that alterations in energy homeostasis and changes in Ca2+ handling are involved in the 
pathogenesis of DCM has additionally been suggested (Seidman and Seidman, 2001; Watkins, 
2003) (also refer to section 1.3.3.2 and 1.3.3.3). Consequently, unlocking the “Pandora’s box” 
has unravelled some of the mysteries of the cardiomyopathies, which lead to the suggestion of “a 
unifying hypothesis” to describe the common pathophysiologies in DCM and HCM (Fatkin and 
Graham, 2002). This paradigm shift has provided impetus towards the search for other proteins 
that may play a role in Ca2+ or cellular energy homeostasis (Seidman and Seidman, 2002; 
Watkins, 2003). Additionally, this data is important for the present study, as it opens a new vista 
of likely candidate genes in which to search for the PFHBII-causative mutation. 
 
1.3.7 A synopsis of familial HCM  
Presently, familial HCM-causative mutations have been described in 11 genes encoding protein 
components of the sarcomere, one gene encoding a cytoskeletal protein (CSRP3) and a gene 
encoding a regulatory enzyme (PRKAG2). Functional studies to determine the physiological 
effects of HCM-causative mutations have indicated that deficits in force generation are an 
underlying mechanism in the pathogenesis of the condition. In addition, the identification of 
HCM-associated defects in an enzyme (AMPK) that is involved in maintaining cellular ATP 
levels has suggested that improper cellular energy homeostasis may be an additional cause of 
HCM. This hypothesis of improper energy homeostasis ties in with other speculations supporting 
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the role of Ca2+ and provides plausible evidence that common processes might be involved in the 
pathogenesis of all forms of cardiomyopathy. 
 
1.4 Familial cardiac conduction disorders 
The previous sections aimed to draw a clinical and aetiological comparison between PFHBII and 
diseases associated with cardiomyopathies. Pathologically, isolated (“pure”) cardiac conduction 
abnormalities are usually the first clinical manifestation of PFHBII, so much so that Brink and 
Torrington (1977) classified the disorder as a cardiac conduction disease. Based on later 
investigations by P. Brink (personal communication), as well as the present study, it is evident 
that PFHBII is a primary cardiomyopathy. However, it is possible that the cause of other pure 
forms of cardiac conduction disease might well provide insight to the identity of the PFHBII-
causative gene. Thus, a review of these forms of cardiac disorders is provided hereafter. 
 
1.4.1 History and clinical features of isolated cardiac conduction diseases 
At the beginning of the 20th century, Morquio (1901) provided the first contemporary 
documentation of a familial cardiac conduction disorder, by describing a family that presented 
with clinical features of syncope (loss of consciousness) and SB. Almost three decades later, both 
Aylward (1928) and Aitken (1932) described individuals in two different families who presented 
with characteristics that suggested congenital forms of cardiac conduction disease. The study by 
Aitken et al., (1932) was particularly significant because it demonstrated the first use of ECG 
analysis to diagnose cardiac conduction defects. In the decades that followed, a multitude of 
studies described individuals in families with clinical features that may be associated with cardiac 
conduction disease – a summary of the clinical features and mode of inheritance is provided in 
Table 1.2. The leading characteristics that were identified by ECG analysis were bi-fascicular 
block (BFB), complete atrioventricular (AV) block (also defined as CHB), left anterior 
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hemiblock (LAHB), left axis deviation (LAD), left bundle branch block (LBBB) occurring in 
conjunction with broad QRS complexes, PR interval prolongation (first-degree heart block), right 
bundle branch block (RBBB), syncope and/or sudden death (Table 1.2).  
 
In the context of the present study, it has to be noted that numerous inherited cardiac conduction 
disorders have been described in South African families (Combrink et al., 1962; Myburgh and 
Steenkamp, 1973; Brink and Torrington, 1977; Torrington et al., 1986; Van der Merwe et al., 
1986; Brink et al., 1995). Later sections will illustrate the relevance of these investigations and 
their impact on the global understanding of cardiac conduction diseases. 
 
1.4.2 The cardiac conduction system: structural complexity and disease manifestation  
The cardiac conduction system is comprised of specialised connective tissue and structures that 
resemble undeveloped myofibrils (James and Sherf, 1971; Virágh and Challice 1982; James, 
2002). A number of studies have demonstrated that different proteins are expressed in the 
different regions of the atrial and ventricular conduction systems (Anderson and Ho, 1998; 
Schram et al., 2001; Pennisi et al., 2002; Myers and Fishman, 2003). Generally, disorders of the 
cardiac conduction system have a common pathological feature of causing a delay or complete 
block of the electrical impulse that is generated at the SA node and progresses via connective 
fibres through the AV node, Bundle of His and the cardiac bundle branches toward the Purkinje 
fibres of the heart (Fig. 1.6). The particular location of the conduction abnormality has been 
shown to be significant because it accounts for the clinical and electrophysiological features of 
that disorder (Waxman et al., 1974). Thus, by identifying the location of the conduction 
abnormality, insights can be gained to the likely cause of the defect. 
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Table 1.2 
Timeline of familial isolated cardiac conduction disorders 
Authors Clinical features Country where 
described 
#Mode of 
inheritance 
Morquio (1901) Syncope, SB France Unknown 
Aylward (1928) Congenital heart block England Unknown 
Aitken (1932) Congenital heart block England Unknown 
Conner et al., (1959) CHB North America Unknown 
Combrink et al., (1962) CHB, RBBB South Africa Dominant 
Lenègre (1964) RBBB, LBBB with broad QRS 
complexes, CHB, syncope and 
sudden death 
France Dominant 
Gazes et al., (1965) Congenital heart block North America Dominant 
Wagner and Hall (1967) CHB North America Dominant 
Lev (1970) RBBB, LBBB with broad QRS 
complexes, CHB, syncope and 
sudden death 
France Dominant 
Sarachek and Leonard 
(1972) 
SB, congenital heart block, 
adult-onset first-degree heart 
block and second-degree heart 
block 
North America Dominant 
Myburgh and 
Steenkamp (1973)  
Congenital AV block South Africa Unknown 
Schaal et al., (1973) RBBB, LAD and CHB North America Dominant 
Lynch et al., (1975) SB and arrhythmias North America Dominant 
Brink and Torrington 
(1977) 
Type I – RBBB, LAHB, CHB 
with broad QRS complexes; 
Type II – SB, LPHB, CHB with 
narrow QRS complexes 
South Africa Dominant 
Stephan (1978) RBBB and CHB Lebanon Dominant 
Barak et al., (1987) First, second or complete AV 
block, Adam-Stokes attacks and 
sinus node dysfunction 
Israel Dominant 
Schott et al., (1999) Type I - Adult onset progressive 
RBBB and AV block; Type II – 
non-progressive 
Netherlands and 
France 
Dominant 
Tan et al., (2001) broad P waves, first-degree heart 
block, broad QRS complexes 
and severe SB 
Netherlands Dominant 
# = autosomal inheritance pattern, except where the type of inheritance is unknown; AV = atrioventricular; CHB = 
complete heart block; LAD = left axis deviation; LAHB = left anterior hemiblock; RBBB = right bundle branch 
block; SB = sinus bradycardia 
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Fig. 1.6 
Anatomy of the cardiac conduction system. 
AV = atrioventricular; SA = sinoatrial 
 
1.4.3 Molecular genetics of familial isolated cardiac conduction disorders 
1.4.3.1 Mapping disease loci for progressive familial heart block type I (PFHBI) and 
isolated cardiac conduction disease (ICCD) 
PFHBI 
In 1962, Combrink and colleagues first documented a familial cardiac conduction disease in 
South Africa when they described a Caucasian family that presented with RBBB and CHB. 
Fifteen years thereafter, Brink and Torrington (1977) described another Caucasian South African 
family that presented with RBBB, LAHB, BFB or CHB with broad QRS complexes, a disorder 
they classified as progressive familial heart block type I (PFHBI) (MIM 113900). In addition, 
Brink and Torrington (1977) noted that the clinical features of PFHBI were similar to the features 
that Combrink et al., (1962) had previously described in a South African family, and thus 
suggested that the two families belonged to the same kindred (Brink and Torrington, 1977). 
Later, in 1986, Torrington and colleagues traced nine additional PFHBI-affected families, 
although, to date, it is not apparent whether any of these families were related to the family 
described by Combrink et al., (1962). In the mid-990s, Brink and colleagues (1995) reported the 
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results of genome-wide linkage analysis, which positioned the PFHBI-causative gene on 
chromosome 19q13.3 (Fig. 1.7). Subsequent haplotype analysis refined the location of the 
PFHBI-causative gene to within a 2.4 megabase (Mb) interval flanked by markers D19S902 and 
D19S866 (Box 1) (Z. Arieff, personal communication).  
 
ICCD 
In the same year that Brink and colleagues had described mapping the PFHBI locus, de Meeus et 
al., (1995) reported mapping the conduction disorder that was previously described by Stephan in 
1978 in a Lebanese family, a condition termed isolated cardiac conduction disease (ICCD), to a 
region on chromosome 19q13.3 (Fig. 1. 7). The ICCD-causative locus spans a 2.7Mb region 
flanked by markers D19S606 and D19S866, a region that overlaps with the PFHBI locus (Box. 1) 
(Z. Arieff, personal communication). Although identified in different countries and in families of 
different ethnicity, because the two diseases map to within a common chromosomal interval, it 
has been suggested that PFHBI and ICCD are the same disease even though classified by 
different names (P. Brink, personal communication).  
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Fig. 1.7 
Human cytogenetic map indicating mapped cardiac conduction disease loci and genes. 
BrS = Brugada syndrome; CCD = cardiac conduction defect; ICCD = isolated cardiac conduction disease; LQTS3 = long QT syndrome type 3; PCCD = 
progressive cardiac conduction disease; PFHBI = progressive familial heart block type I; SCN5A = cardiac Na+ channel. Disease-causative genes are shown 
in blue. 
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1.4.4 Molecular aetiologies of isolated cardiac conduction disorders 
1.4.4.1 Progressive cardiac conduction defect  
Lenègre (1964) and Lev et al., (1970) described a number of French families that presented with 
cardiac conduction disturbances that were characterised by RBBB, LBBB with broad QRS 
complexes, CHB, syncope and progression to sudden death (Table 1.2). Later, the term Lenègre-
Lev disease was used to describe the clinical entities described by Lenègre (1964) and Lev et al., 
(1970), while, more recently, progressive cardiac conduction defects (PCCD) (Schott et al., 1999) 
(MIM 600163) is increasingly being used to describe conditions with these conduction 
abnormalities. 
 
Although PCCD is the most common form of isolated cardiac conduction anomaly, little was 
known about its underlying molecular aetiology, until 1999, when Schott and colleagues reported 
that they had performed a linkage study in a French and a Dutch kindred with PCCD and had 
mapped the causative gene to a locus on chromosome 3p21 (Fig. 1.7). Their subsequent 
candidate gene mutation analyses at the locus identified a PCCD-causative splice site mutation, 
which segregated in the French, but not the Dutch, family in a gene encoding a cardiac-expressed 
sodium (Na+) channel (SCN5A). Further mutation analyses of SCN5A identified a unique deletion 
mutation that segregated exclusively in the affected Dutch family (Schott et al., 1999). The 
findings by Schott et al., (1999) were interesting because mutations had previously been 
described in SCN5A that caused three types of inherited cardiac arrhythmias known as long QT 
syndrome (LQTS) type 3 (LQT3) (Wang et al., 1995) (MIM 603830), Brugada syndrome (BrS) 
(Brugada and Brugada, 1992; Chen et al., 1998; Bezzina et al., 1999; Rook et al., 1999) (MIM 
601144) and idiopathic ventricular fibrillation (IVF) (Chen et al., 1998) (MIM 600163). 
Although LQT3, BrS and IVF are associated with rapid heart rhythms, while PCCD is associated 
with a slowing of the heart rate, the identification of cardiac conduction- and arrhythmia-
 39 
causative mutations in SCN5A was significant because it provided clues to the underlying 
mechanism of diseases of the cardiac conduction system. This will be discussed in section 1.4.5. 
 
1.4.4.2 Cardiac conduction defect (CCD) 
Tan et al., (2001) described a family that presented with broad P waves, first-degree heart block, 
broad QRS complexes and severe SB, a disorder designated cardiac conduction defect (CCD) 
(MIM 115080). The previous identification of mutations in a cardiac Na+ channel by Schott et al., 
(1999) as cause of PCCD (see previous section) suggested that other cardiac conduction 
abnormalities might have similar molecular aetiologies. Using this rationale, Tan et al., (2001) 
performed a positional independent candidate gene analysis, which resulted in the identification 
of a CCD-causative mutation in SCN5A (Tan et al., 2001) (Fig. 1.7). These results aided in 
identifying the pathological mechanisms of different cardiac conduction system disorders (Tan et 
al., 2001). 
 
1.4.5 Mechanisms of cardiac conduction disorders 
1.4.5.1 Alterations in ion channel electrophysiology  
Prior to the reports by Schott et al., (1999) and Tan et al., (2001), the underlying disease 
mechanisms of familial cardiac conduction disorders had not been established. However, the 
pathophysiologies of the arrhythmic disorders LQTS types 1-6 (MIM 192500, 152427, 600919, 
176261, 603830 and 603796) and BrS (Brugada and Brugada, 1992), which could also be 
accompanied by cardiac conduction defects such as LAD and RBBB, were well established and 
served as a model that helped to elucidate the mechanisms that lead to cardiac conduction 
defects.  
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It had been demonstrated that genetic defects in various genes that encode two potassium (K+) 
channels and their associated subunits (Wang et al., 1996; Curran et al., 1995; Splawski et al., 
1997; Tyson et al., 1997; Abbott et al., 1999) and a Na+ channel (Wang et al., 1995) were the 
underlying causes of LQTS, while BrS was also caused by mutations in a gene encoding a 
cardiac Na+ channel (Chen et al., 1998; Bezzina et al., 1999; Rook et al., 1999). Interestingly, the 
LQT3- (Wang et al., 1995), BrS- (Chen et al., 1998; Bezzina et al., 1999; Rook et al., 1999) and 
IVF-causative mutations (Chen et al., 1998) have been identified in SCN5A, the same cardiac Na+ 
channel in which mutations were shown to cause PCCD and CCD. These common molecular 
aetiologies suggested that cardiac conduction disorders and arrhythmias shared similar 
pathophysiologies. 
 
Pathophysiology of CCD 
Functional eletrophysiological studies indicated that LQTS-causative mutations in SCN5A altered 
cardiac electrical conductance by delaying channel repolarisation, which, in turn, causes a 
slowing of the overall heart rhythm and eventually results in the prolongation of the QT interval 
(Wang et al., 1995). Alternately, BrS-causative mutations in SCN5A were shown to increase 
cardiac Na+ channel repolarisation, causing the heart’s electrical activity to become disordered, 
thus triggering unsynchronised atrial and ventricular contractions (Chen et al., 1998). 
Consequently, Tan et al., (2001) performed similar functional studies to determine the effect of 
the CCD-causative mutation on Na+ channel electrophysiology and demonstrated that it caused a 
delay in channel repolarisation, but did not alter the overall rhythm of the heart. Consequently, 
the delayed channel repolarisation caused a slowing of the conduction impulse between the atrial 
and the ventricular conduction fibres without triggering the arrhythmic events associated with 
LQTS and BrS (Tan et al., 2001). 
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Pathophysiology of PCCD 
In 2003, Probst et al., described the results of an in vitro cell-transfection study to determine the 
functional consequences of a splice site mutation in SCN5A (IVS.22+2 T→C) that had previously 
been described by Schott et al., (1999) as cause of PCCD. Three fundamental outcomes were 
derived from this study. Firstly, the study predicted that the mutation caused an in-frame skipping 
of exon 22, which resulted in a Na+ channel in which the voltage-sensitive DIIIS4 domain was 
absent. Secondly, the study showed that PCCD was caused by haploinsufficiency, because the 
mutated copy of the protein was processed correctly within the cardiac cell membrane, but the 
defective protein did not generate an inward current, which resulted in a reduction in the velocity 
of the conduction impulse (Probst et al., 2003). Lastly, Lenègre (1963) and Lev et al., (1964) had 
suggested that natural fibrosis of the cardiac conduction system caused progressive AV block, 
although fibrosis was observed in elderly individuals who did not have AV block (Davies et al., 
1967). Taking this into consideration, Probst et al., (2003) suggested that, for PCCD, the 
progression to CHB spanning a number of years occurred as a result of normal age-dependent 
fibrosis of the conduction system, which exacerbated the alteration in the conduction velocity that 
was caused by the genetic defect in the cardiac Na+ channel. 
 
1.4.6 A synopsis of familial isolated cardiac conduction disorders 
Cardiac conduction system disorders are clinically variable, although the location of the 
abnormality has provided insight into the probable causes of these defects. The causative gene(s) 
for two familial cardiac conductions disorders (PFHBI and ICCD) have been mapped to the same 
locus on chromosome 19q13.3, while the underlying cause of two other forms of cardiac 
conduction disorders (PCCD and CCD) have been shown to be genetic defects in a cardiac Na+ 
channel. These genetic defects were shown to cause alterations in channel electrophysiology by 
slowing the conduction impulse. Genetic defects in SCN5A have additionally been associated 
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with the development of the cardiac arrhythmic disorders, LQTS and BrS, which indicates that 
common molecular aetiologies may exist for different clinical entities that affect cardiac 
electrophysiology. 
 
1.4.7 Familial cardiomyopathies and cardiac conduction diseases in South Africa: 
contributions to global knowledge  
1.4.7.1 Diseases of the myocardium 
In the USA, DCM is estimated to affect nearly 40 in 100 000 individuals (Durand et al., 1995a), 
and, furthermore, is considered to be the foremost indication of heart transplantations in older 
individuals (Seidman and Seidman, 2001; Towbin and Bowles, 2004). However, in South Africa, 
current statistics on the prevalence of DCM have been difficult to obtain, which probably reflects 
a lack of data because of the complex nature of the condition, rather than the low prevalence of 
the disease (Moolman-Smook et al., 2003). One genetic study has been performed in South 
African populations in which the prevalence of DCM-associated mutations in cardiac and skeletal 
actin was determined (Mayosi et al., 1999). These authors suggested that the global prevalence of 
DCM-causative mutations in cardiac and skeletal actin was low in comparison to mutations in 
other DCM-associated genes. Later, Takai et al., (1999) and Karkkainen et al., (2002) provided 
more evidence that supported Mayosi and colleagues’ original proposal. 
 
On the other hand, HCM has an estimated prevalence of 0.2% (or one in 500) in populations in 
the USA and Europe and has been shown to be a leading cause of death in young adults in those 
countries (Maron et al., 1995). As with DCM, the prevalence of HCM has not been established in 
South Africa, although numerous important HCM-associated findings have been reported from 
this country (Moolman et al., 1995; Moolman et al., 1997; Moolman-Smook et al., 1998; 
Moolman-Smook et al., 1999; Moolman-Smook et al., 2002). 
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Although DCM and HCM are separate clinical entities, myocyte hypertrophy is often observed in 
patients with DCM, while individuals with HCM have been shown to progress to DCM (Seidman 
and Seidman, 2000). The novel arginine-92 tryptophan (Arg92Trp) mutation in cardiac troponin 
T, which was shown to segregate in two South African families (Moolman et al., 1997), is an 
example of the latter. The mutation causes mild or undetectable hypertrophy, although numerous 
individuals with this defect have been identified that demonstrate rapid progression to a DCM-
like phenotype that is associated with a high incidence of sudden cardiac death (J. Moolman-
Smook, personal communication).  
 
Other studies in South African families have also contributed significantly to the overall 
understanding of the molecular mechanisms of cardiomyopathies. The study by Moolman-Smook 
et al., (1998) described the first missense mutation in the C5 domain of cardiac myosin-binding 
protein C that causes adult-onset HCM. Subsequent investigations have demonstrated that HCM-
causative missense mutations modulate the interactions between three myosin-binding protein C 
domains (Moolman-Smook et al., 2002). Significantly, Moolman-Smook et al., (2002) proposed 
a new model for the arrangement of cardiac myosin-binding C in the sarcomere, thereby 
repealing previous tenets and, in so doing, provided novel insights into the causes of HCM.  
 
1.4.7.1.2 Diseases of the cardiac conduction system 
In South Africa, the prevalence of cardiac conduction disease has not been established, barring 
the study by Torrington et al., (1986), which suggested that PFHBI had a prevalence of one in 
500 South Africans of European descent. Because of the availability of large families in which 
PFHBI segregated, Brink et al., (1995) undertook a study that described mapping the first locus 
(in South Africa and internationally) linked to an isolated cardiac conduction disorder. Although 
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the PFHBI-causative gene has not been identified, the identification of the causative locus may 
have provided a starting point for subsequent linkage studies by other investigators. It has been 
reported in the publication by Schott et al., (1999) that the authors had performed a candidate 
locus linkage analysis that initially analysed and excluded the PFHBI locus prior to the eventual 
identification of PCCD-causative mutations in SCN5A. Therefore, studies considered to be 
unique to South Africa could facilitate investigations in other countries. 
 
1.4.8 The implication of establishing common clinical and genetic links between diseases 
It is not unreasonable to posit that PFHBII, which has some clinical features that are similar to 
the familial cardiomyopathies and cardiac conduction disorders described in this review, might 
well have been described in other families but under a different clinical designation. Therefore, it 
is essential to establish whether clinical entities with similar features may represent a disease 
caused by a defect in the same gene. In order to address this possibility, analyses of candidate 
loci that are associated with diseases that present with clinical features similar to PFHBII can be 
undertaken. However, once a locus has been mapped, identifying the disease-causing gene is by 
no means an effortless task, although resources provided by HGP databases have provided an 
adjunct to molecular genetic analyses. It has been suggested that HGP resources will accelerate 
the identification of the underlying cause of familial cardiac diseases (Roberts, 2000; Komajda 
and Charron, 2001). Consequently, this review will shift a gear by providing an overview of the 
HGP and, in particular, underline the advantages and the drawbacks of using these technologies 
to identify disease-causative genes. 
 
1.5 The HGP: background  
The “Human Genome Project” was initiated in 1988 and one of its primary aims was to construct 
physical, genetic and transcript maps of the human genome (Ikawa, 1991; Roberts 2000; Yaffe et 
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al., 2001; National Human Genome Research Institute [NHGRI] website, 
http://www.nhgri.nih.gov). A second objective of the HGP was the development of computer-
based biological tools that collectively became known as bioinformatics (the application of 
information technology and in silico molecular biology to store and analyse one dimensional 
data) (Sansom and Smith, 2000; Chieurel, 2002). By 2002, molecular genetic approaches had 
linked approximately 25% of the estimated 4000 Mendelian genetically inherited diseases to 
chromosomal regions in the human genome (Perez-Iratxeta et al., 2002). However, about 450 of 
the linked diseases described then had no associated disease-causative gene (Perez-Iratxeta et al., 
2002), although it had been widely suggested that the application of HGP data would accelerate 
the identification of those molecular aetiologies (Guttmacher and Collins, 2002; Perez-Iratxeta et 
al., 2002). A few of these successes will be illustrated in sections hereafter.  
 
1.5.1 Identifying disease-causative genes and the HGP  
1.5.1.1 The pre-HGP era: 1970-1988 
For at least two decades, linkage analysis has successfully been used to map disease-causative 
loci (Lathrop and Lalouel, 1984; Ott, 1999). Once a chromosomal locus was mapped, positional 
cloning techniques such as cDNA selection and exon trapping were executed to identify genes 
and differentiate expression profiles within contiguous genomic clones at the locus (Duyk et al., 
1990, Parimoo et al., 1991). Positional cloning techniques have been successful in identifying 
disease genes that are associated with cardiac disorders. The LQTS types 1, 2 and 3-causative 
genes, the former two encoding cardiac K+ channels, and the latter encoding a Na+ channel, were 
identified using “wet-bench” positional cloning strategies (Curran et al., 1995; Wang et al., 1995; 
Wang et al., 1996). Additionally, three sarcomeric protein-encoding genes in which mutations 
have been described that cause HCM (MYH7, TNNT2 and TPM1) were identified by positional 
cloning by Geisterfer-Lowrance et al., (1990) and Thierfelder et al., (1994). The initial successes 
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of positional cloning studies paved the way for position-dependent and even position-
independent candidate gene analyses, once common molecular aetiologies had been identified for 
LQTS and HCM (Watkins et al., 1995; Keating and Sanguinetti, 2001). Some examples of 
LQTS-associated genes identified by position-dependent or positional independent analyses are 
the K+ channel genes, KCNE1 (Splawski et al., 1997; Tyson et al., 1997) and KCNE2 (Abbott et 
al., 1999), and examples of HCM-associated genes are TTN (Satoh et al., 1999), MYL2 (Poetter et 
al., 1996) and TNNI3 (Kimura et al., 1997). 
 
1.5.1.2 Successful applications of HGP resources 
Initially, HGP databases provided the sequences of genetic markers at loci spanning the human 
genome (Weissenbach et al., 1992). These genetic marker maps facilitated linkage studies and 
resulted in the identification of numerous disease-causative loci (Sullivan et al., 1999). Positional 
cloning techniques were then used to identify genes at a locus that was linked to a particular 
disease. However, positional cloning strategies were expensive and time-consuming, and, thus, 
towards the end of the 1990s, bioinformatics analyses were increasingly applied to identify novel 
genes at a given locus (Sullivan et al., 1999). The use of bioinformatics technologies resulted in 
the identification of novel genes, and, more often than not, assisted in the subsequent 
identification of disease-causing mutations in those genes. Examples of in silico analyses that 
have resulted in the identification of novel genes implicated as cause of cardiac disorders, ion 
channel defects or skeletal myopathies are listed in Table 1.3. Bioinformatics analyses have more 
recently been used to create transcriptional profiles of the human heart (Bortoluzzi et al., 2000), 
which in turn, have provided information for subsequent studies that have identified the 
differences in expression profiles that are associated with DCM and HCM (Dos Remedios et al., 
2003; Yung et al., 2004).  
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Despite numerous successful applications of the HGP data and bioinformatics, there are caveats 
that need to be applied when utilising in silico disease-causing gene identification approaches 
instead of conventional wet-bench laboratory procedures. 
 
Table 1.3 
A representative list of disease-causative genes associated with cardiac disorders, channelopathies or 
skeletal myopathies that were identified using bioinformatics analysis  
Gene Protein product (associated disease in brackets) Reference 
PDS Sulphur channel (Pendred syndrome) Everett et al., 1997 
DTNB Dystrobrevin beta (Limb-girdle muscular 
dystrophy) 
Puca et al., (1998) 
SCN1A Sodium channel (Epilepsy and febrile seizure 
type 2) 
Escayg et al., (2000) 
LGMD2G Dystrophin (Limb-girdle muscular dystrophy 
type 2) 
Moriera et al., (2000) 
NDRG1 Oxygen regulated protein (Charcot-Marie-
Tooth disease) 
Kalaydjieva et al., (2000) 
SCA10 Ataxin-10 (Spinocerebellar ataxia type 10)  Matsuura et al., (2000) 
GAN Gigaxonin (Giant axonal neuropathy and 
cytoskeletal disorganisation) 
Bomont et al., (2000) 
SRF Serum response factor (DCM in mice) Wang et al., (2001), 
Zhang et al., (2003) 
TNNI3K Cardiac-specific kinase (possible 
cardiomyopathy similar to an autosomal 
recessive form of DCM)  
Zhao et al., (2003) 
 
1.5.2 Limitations of the HGP: caveat emptor 
1.5.2.1 Sequence errors 
By the year 1999, it was estimated that at least 10Mb of sequence data were deposited per week 
into HGP databases (Felsenfeld et al., 1999). The large amounts of data that were submitted to 
HGP databases have made these resources susceptible to an accumulation of sequencing and 
annotation errors (Felsenfeld et al., 1999). Unfortunately, the enormity of the HGP makes it 
impossible to have error-free databases. Therefore, a number of acceptable error rates per 
sequence read have been set, which then, by analysing the number of errors in every 10 sequence 
reads of the same genomic segment, is used to categorise data into finished or draft sequence 
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(Sansom and Smith, 2000). As a general rule, an error rate of less than one error per 10 000 bases 
is set as a standard for categorising a sequenced portion of a genome as finished sequence 
(Sansom and Smith, 2000). Consequently, any sequence obtained from an HGP database, even 
so-called finished sequence, will contain errors. Therefore, in order to minimise the effects of 
these errors, it has been suggested that at least two separate analytical algorithms or databases 
should be used when performing bioinformatics analyses (Attwood, 1999) (refer to section 2.11), 
since sequence quality varies between databases. 
 
1.5.2.2 Gene annotation and prediction accuracy: “real” versus “virtual” genes 
The sheer volume of sequence errors and the limited capabilities of gene prediction programs 
have hampered the accurate determination of the total number of genes in the human genome 
(Istrail et al., 2004). Furthermore, the accuracy of HGP gene prediction algorithms has been 
questioned (Burge and Karlin, 1997; Felsenfeld et al., 1999; Bork, 2000), although Katsanis and 
colleagues (2001) demonstrated that gene prediction quality improved in direct proportion to an 
improvement in sequence quality. Certain databases, such as the Ensembl database 
(http://www.ensembl.org), have circumvented the limitations of gene prediction programs by 
using ab initio gene prediction in conjunction with nucleotide and protein similarity searches 
from i) different regions of the human genome and ii) other model organisms such as the mouse, 
rat, pufferfish, zebrafish and chimpanzee, to obtain a 95% gene prediction accuracy (Stein, 2001). 
Although there are sequence and annotation limitations, the gradual completion of the genome 
sequencing projects of model organisms is yielding important data that minimises these 
shortcomings (Chieurel, 2002; Ouyang et al., 2003). 
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1.5.3 Current sequence and annotation status of the HGP 
1.5.3.1 The status of the complete human genome  
Initially, the HGP had set out to complete a ten times (10x) sequence coverage of the 
approximately three billion bases comprising the human genome (NHGRI website). By the year 
2002, a four times draft sequence coverage of the human genome was completed (Initial Human 
Genome Sequencing Consortium, 2001) and the following year in April 2003, a cumulative total 
of 93% of the human genome was completely sequenced with at least an eight to ten times 
sequence coverage (Ensembl website). Previously, the total number of genes in the human 
genome had been estimated to range between 29 000-150 000 genes (Attwood, 2000; Harrison et 
al., 2002; Collins et al., 2003). There have been conflicting estimates regarding the total number 
of human genes, although, recently, consensus was reached which hinted at a figure of 
approximately 27 000 genes that constitute the human genome (Pennisi, 2003). However, this 
data is constantly changing and more recent analyses of the Ensembl website have indicated that 
there are now considered to be approximately 65 000 genes in the human genome (as of June 
2004). The rapid changes in the predicted number of genes highlight the problems associated 
with gene prediction (a discussion on these problems and their possible influence on the 
outcomes of the present study is provided in section 4.8.2). The basis of the present study is a 
description of mapping the PFHBII-causative gene to a locus on chromosome 1 and, hence, the 
current annotation status of that chromosome will also be reviewed. 
 
1.5.3.2 The status of human chromosome 1  
The estimated size of human chromosome 1 is approximately 246Mb (Ensembl website). As of 
14 April 2004, the sequencing status of chromosome 1 was indicated to be approximately 95% 
complete, which corresponds to about 233Mb of finished nucleotide sequence (The Sanger 
Centre website, http://www.sanger.ac.uk). In addition, 1995 genes that have been identified by 
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experimental means, or by gene prediction programmes, and 119 pseudogenes have been 
assigned to chromosome 1 (Ensembl website). Based on these data, human chromosome 1 has an 
average gene density of one gene every 116 kilobases (kb). The chromosomal region described in 
this study, to which the PFHBII gene is mapped, has an approximate gene density of one gene 
every 110kb. The relevance of the sequence and annotation status of chromosome 1, relative to 
the present study, is further elaborated on in section 4.8.2. 
 
1.6 The present study 
A previous report by Van der Merwe et al., (1986) suggested that PFHBII was possibly a cardiac 
conduction disorder that was accompanied by a congestive form of cardiomyopathy. If this held 
true, then clues to the underlying molecular aetiology of PFHBII could be obtained by analysing 
the molecular pathophysiologies of both cardiac conduction disorders and cardiomyopathies.  
 
Although cardiac conduction defects, cardiac arrhythmias and cardiomyopathies generally occur 
in isolation, various familial disorders have been identified in which the clinical features of the 
one condition may accompany features that are associated with the other. Additionally, numerous 
studies have identified DCM- and HCM-causative mutations in different domains of the same 
gene (Geisterfer-Lowrance at al., 1990; Thierfelder et al., 1994, Watkins et al., 1995; Moolman-
Smook et al., 1998; Satoh et al., 1999; Kamisago et al., 2000; Olson et al., 2001; Daehmlow et 
al., 2002; Gerull et al., 2002). Mutations have also been identified in different domains of a 
cardiac ion channel (SCN5A) that cause the cardiac conduction defects, PCCD and CCD, as well 
as the arrhythmic disorders LQT3, BrS and IVF (Brugada and Brugada, 1992; Wang et al., 1995; 
Chen et al., 1998; Bezzina et al., 1999; Rook et al., 1999; Schott et al., 1999; Tan et al., 2001). 
 
Thus, the first step in identifying the PFHBII-causative gene was to establish whether DCM, 
 51 
and/or other cardiac-associated features, is part of the clinical spectrum of the disorder. This 
investigation was important in order to establish whether PFHBII demonstrated a clinical overlap 
with other cardiac disorders; thereby also providing a basis for subsequent molecular genetic 
analyses. To this end, retrospective and prospective studies were performed to obtain all available 
clinical data and medical histories of subjects from the PFHBII-affected family. This 
investigation indicated that DCM is an additional a feature of PFHBII (Fernandez et al., 2004) 
(see section 3.1 and 4.1 for more detail).  
 
Overlapping clinical features and common molecular aetiologies have been identified for 
numerous cardiomyopathies and cardiac conduction disorders. Therefore, it was hypothesised 
that PFHBII may share a common aetiology with a previously mapped cardiac disorder. Thus, 
genetic linkage analyses of candidate loci (chromosomal regions linked to previously described 
disorders that were associated with conduction defects and/or DCM or HCM) were performed. 
Fortuitously, linkage was established to a locus on chromosome 1q32.2-q32.3, a region that 
overlapped a previously described DCM-associated disorder (CMD1D). Genetic fine mapping 
and haplotype analysis placed the PFHBII-causative locus distal to the CMD1D locus, thus 
supporting the identification of a novel locus associated with DCM and cardiac conduction 
defects. Bioinformatics analyses were employed to identify positional candidate genes, which 
resulted in the selection of seven plausible genes that were screened for the PFHBII-associated 
mutation. 
 
In summary, the present study mapped the PFHBII-causative gene to a novel locus on 
chromosome 1 and redefined the clinical classification of PFHBII; the latter might result in the 
identification of additional affected individuals in South Africa, or in other countries. It is 
possible that PFHBII, although classified by a different clinical name, may have been identified 
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in other families in South Africa, or in other countries. Therefore, mapping the PFHBII locus 
might lead to other groups mapping the same disease to the locus described in the present study. 
In so doing, the new mapping data could be used to further refine the PFHBII locus, thus 
reducing the interval in which to search for the disease-causative gene. Even though the PFHBII-
associated mutation was not identified in this study, the future identification of the causative gene 
may provide insight to understanding the pathophysiology of heart failure.  
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Materials and methods 
No amount of experimentation can ever prove me right; a single experiment can prove me wrong. 
- Albert Einstein 
 
2.1 General 
The University of Stellenbosch (US) Faculty of Health Sciences Ethics Committee reviewed and 
granted permission for the study (project number 99/067), according to guidelines set by the 
WHO/International Society and Federation of Cardiology Task Force (Richardson et al., 1996). Prior 
to commencement of the investigation, informed oral or written consent was obtained from each of the 
study participants. Parental or guardian consent was obtained for minors under the age of 18 years. 
Blood samples were drawn and clinical evaluations were performed on members of the family in 
which PFHBII segregates. Blood procurement and clinical evaluations were performed by Prof. P. A. 
Brink (Senior Specialist Internist, Tygerberg Hospital, Cape Town,RSA) or by a medical practitioner 
chosen by the individual. All acquired clinical data was stored at the Department of Internal Medicine, 
Tygerberg Hospital (Cape Town, RSA). Extracted deoxyribonucleic acid (DNA) (see section 2.5) was 
stored at the US/Medical Research Council (MRC) Centre for Molecular and Cellular Biology (Cape 
Town, RSA). 
 
2.2 Selection of subjects 
2.2.1 Members of a family in which PFHBII segregates  
Individuals entered into the study were members of a family previously described by Brink and 
Torrington (1977). Twenty-six Caucasian South African Afrikaner subjects from the PFHBII-affected 
family were entered into the study (Fig. 2.1), of whom 13 individuals had been clinically examined in 
the original investigation by Brink and Torrington (1977).  
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Fig. 2.1 
The South African PFHBII-affected kindred. 
The mutigeneration pedigree shows the PFHBII-affected family of Caucasian South African Afrikaner 
descent. An asterisk (*) indicates subjects that were entered into the present study and filled symbols 
indicate individuals that have been diagnosed with or have a clinical history of PFHBII. Individuals 
II:5, II:7, II:9, II:11, III:9, III:15, III:16, III:18, III:19 III:20, III:22, III:24 and III:25 were clinically 
assessed in the original study by Brink and Torrington (1977). The clinical status of all subjects from 
the PFHBII-affected family is provided in section 3.1. 
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2.2.2 Unrelated subjects from the Caucasian South African Afrikaner subpopulation 
To establish genetic marker allele frequencies, a panel of 30 anonymous Caucasian South African 
Afrikaner individuals with no clinical history of PFHBII was entered into the study. The same panel of 
unrelated subjects was used to estimate the frequencies of identified sequence variations (see section 
2.12) in the South African Caucasian Afrikaner subpopulation. 
 
2.3 Clinical evaluation 
General assessments 
Subjects were evaluated using previous clinical history, physical examination, 12-lead ECG, M-mode 
and 2-dimensional echocardiography. Diagnosis was based on evidence of cardiac conduction disease 
and/or the presence of DCM (Brink and Torrington, 1977; Fernandez et al., 2004). ECG diagnosis of 
affected individuals was defined by the presence of SB (a heart rate of less than 50 beats per minute 
[bpm]), LAHB/LPHB, first-degree heart block or CHB with narrow QRS complexes (Brink and 
Torrington, 1977; Fernandez et al., 2004). Minimum criteria for an echocardiograph diagnosis of DCM 
were an ejection fraction of less than 45% and a left ventricular end-diastolic diameter of greater than 
5.6 centimetres (cm) in the absence of hypertension, ischaemic or valvular heart disease. All 
echocardiographic measurements were made according to the American Society of Echocardiography 
guidelines (Sahn et al., 1978). In some cases, family members were re-examined because their 
previous clinical assessment had been incomplete or had been performed more than five years prior to 
the start of the present study. All assessments of clinical records were performed by Prof. P Brink. 
 
Clinical data used to establish a clinical profile of PFHBII 
Clinical records of family members who opted not to give blood for the genetic linkage study were 
obtained, with the patients’ permission, from their personal physician, or, alternately, the subject 
provided his/her own clinical details (A Goosen, personal communication). The clinical histories of 
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deceased members of the PFHBII-affected family were obtained by interviewing living first- or 
second-degree relatives in person or telephonically. Clinical histories of spouses of clinically affected 
family members were obtained in order to exclude the possibility that these subjects were clinically 
affected (with PFHBII), or possibly, that they presented with another familial cardiac-associated defect 
that could have a pathological effect on their progeny. In general, individuals with a clinical history of 
a pacemaker implantation or an indication of heart transplantation were assigned a clinically affected 
status. Clinical data for the 26 subjects that were genotyped for the linkage study were obtained by the 
method described in section 2.1.  
 
Clinical designations for linkage analysis 
A conservative phenotypic classification approach was used for linkage analysis, to avoid 
misclassifying subjects from the family in which PFHBII segregates. Progressive slowing of the heart 
rate may be an indication of underlying atrioventricular disease (Talajic et al., 1991). Therefore, 
individuals with a heart rate between 50-55 bpm were assigned a clinically uncertain status. Individuals 
with a previous clinical history of the disease, but for whom the clinical data could not be obtained, or 
for whom a second clinical examination indicated that they did not meet the criteria for classification 
as clinically affected, were designated clinically uncertain. These criteria were included because of 
concerns of setting a clinical diagnosis based on a single ECG examination. Due to the late onset of the 
disorder, individuals younger than 20 years were not clinically investigated and were assigned a 
clinically uncertain status. All clinical assignments were made prior to genotype allocation.  
 
2.4 Procurement of blood  
Blood was collected from family members through venous puncture of the ante cubital fossa of the 
forearm. Nine millilitres (ml) and 4.5ml of blood were respectively collected in a heparin tube 
(Vacutainer, UK) and an ethylenediamine tetraacetic acid (EDTA) tube (Vacutainer, UK).  
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2.5 DNA extraction from peripheral blood 
DNA was extracted from EDTA-treated peripheral blood (see previous section) using the method 
previously described by Corfield et al., (1993) – a list of the solutions used to treat blood and for DNA 
extractions is provided in Appendix A. The DNA was then resuspended in 200μl of distilled water 
(dH2O) in a 1.5ml eppendorf tube (Whitehead Scientific, RSA) and mixed at 4°C for 16 hours in a 
Voss rotor (Malden, UK). Ten microlitres of the resuspended DNA was aliquoted into a clean 
eppendorf tube, diluted with 490μl of dH2O and dispensed into a quartz curvette (Laboratory and 
Scientific Equipment Company [Lasec], RSA). The curvette containing the diluted DNA was placed 
into a Spectronic 1201 spectrophotometer (Milton Roy, UK) that was set at a wavelength of 260 
nanometers (nm) and the absorbance reading was recorded. The concentration of the extracted DNA in 
micrograms per microlitre (μg/μl) was determined by multiplying the absorbance reading by 2.5.  
 
Establishing cell lines from blood 
Approximately 5ml of heparin treated blood (section 2.4) was used to establish lymphoblastoid cell 
lines using the method described by Neitzel (1986) – a list of the solutions used to establish cell lines is 
provided in Appendix A. On completion of the growth phase, the cells were transferred to 2ml Nunc 
tissue culture tube (Sterilab, RSA) and kept in a polystyrene container lined with cotton wool, which 
was placed at -70°C overnight in an ultra low temperature refrigerator (Revco, USA). After 16-20 
hours, the tubes were taken out of refrigerator and were placed in a liquid nitrogen Union Carbide 
model Bx186 freezer (Washington, USA) and stored until required.  
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2.6 Data capture 
All blood samples that were included for DNA extractions were indexed in the computer database 
programme, Lab Management (Microsoft Access, LABdata.mdb, Soft Craft Systems 1996-8). The 
programme stored names, dates of birth, sample numbers, project names and dates of entry. Cell lines 
were given the same accession number as blood samples, but were stored in a separate file in the 
database. Only authorised personnel were permitted to access the data and all information was 
confidential. No commercial gain was derived from the study and all data was used solely for research 
purposes. 
 
2.7 Construction of a family pedigree  
Genealogical data and clinical information of members from the family in which PFHBII segregates 
were entered into the Cyrillic 2.10 programme (Cherwell Scientific, UK) and used to construct a 
multigeneration family pedigree (Fig. 2.1). 
 
2.8 Genetic analysis  
2.8.1 Selection of candidate loci 
Disorders associated with DCM and cardiac conduction defects, isolated DCM, HCM, isolated cardiac 
conduction defects and a cardiac arrhythmia, which map to chromosome 1p1-1q21, 1q32, 2q14-q22, 
3p22-p25, 6q23, 7q35-q36, 9q12-q13, 11p11, 14q12, 15q11-q14, 15q22 or 19q13.3 (Table 2.1) (refer 
to Fig. 1.2, 1.5 and 1.7), were selected for a candidate loci genetic linkage study. For the linkage study, 
short tandem repeat (STR) markers at the selected candidate loci were used in polymerase chain 
reaction (PCR)-based genotype analyses (section 2.8.7).   
 
2.8.2 Genetic marker information at selected candidate loci  
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Information for the genetic map locations of STR markers at candidate loci (Table 2.1) was obtained 
from the Marshfield Genetic Map Marker information database 
(http://research.marshfieldclinic.org/genetics/Map_Markers/maps/IndexMapFrames.html) and the 
Genome Database (http://www.gdb.org).  
 
Table 2.1 
Primer sequences and annealing temperatures of selected STR markers used in a candidate loci linkage analysis 
of members of the PFHBII-affected family    
  
Candidate locus 
Maker  Forward primer sequence (5'-3')  Reverse primer sequence (5’-3’)  Tm (°C) 
Chromosome 1p1-1q21 
D1S305   CCAGNCTCGGTATGTTTTTACTA CTGAAACCTCTCTGTCCAAGCC 55 
D1S2702  CCCCTTGGCATAGGGTTCAAGA AGCCAGGCATCTGCACCTTC  55 
D1S176   CCATAATTGTGTGTACAACT  AGTTCTTCAGAGAAACAGGA  55 
Chromosome 1q32.2-q32.3 
D1S456  CTTCAGGATCAGGGACAAACT GCCACATACCTCCTTACCTTG  55 
D1S491   ATCTCCCTGGCAATGATTTT  TGTCAGCAAGAANTGTGAAAGT 55 
D1S70  TCTCGTTCCCTCCCCTGTCT  TCACGCTGAGCTCTGTTTTA  55 
D1S3753 CATGTAATTCAGGTTAGCATGA GAGCGATGATAGTGCCACTAC 55 
D1S205   CTGAGCACAGCAGTGGTCTC  AAGGCTTATCAAGAGCGAGG  55 
D1S414   GCACAGTTCAACATCCATT  TCTCTGTCATTTTAGGTCTATTTCT 55  
D1S2810 TCAGTTCCTGGTTACCGTTA  CCGTTCTTATGAGCCTTACA  55 
D1S2780 TCTGTGTTCCTAAGTATTAAAAACC ATCCAACCCTGACAACTG  55 
D1S425  CTAAAACAAAACACTCAGAACCACA ACCTAGCACAAGGCTTCACA  55 
D1S505   GGAAGGCTTGCTCTTG  CCTCACCCATGACACTG  55 
D1S217  TTATAACCAACCCTGTCACAG  GCACATTTCCGGTAAAAGAA  55 
Chromosome 2q14-q22 
D2S2224  AACTCCATCCCGGTGC  ATGTGTGCCTGTGGGTTTAG  55 
D2S2339  TGCCTTGAGGACCACT  TGCAATGTAACTAATTTTGTACTAA 55 
D2S2215  ACCTGGGACTCAGAAAAGTT  TGCTGTGCCTAAAAGTATGC  55 
D2S112   GAGTGGCGGTGAGAAGGTAT  AGCCATTGCTATCTTTGAGG  55 
Chromosome 3p22-p25 
D3S1263  CTGTTGACCCATTGATACCC  TAAAATCACAGCAGGGGTTC  55 
D3S2303  TTTCTGCCCTGCCTACATG  TCAGAATCACCCACAAGGG  55 
D3S1211  CAGGGCTTGTGGGATTAGAA  ATTTCAGATTTCAGGACAAGGG 55  
Chromosome 6q23 
D6S262   ATTCTTACTGCTGGAAAACCAT GGAGCATAGTTACCCTTAAAATC 55 
Chromosome 7q35-q36 
D7S505   ACTGGCCTGGCAGAGTCT   CAGCCATTCGAGAGGTGT  55 
Chromosome 9q12-q13 
D9S152   CCAGTTTTTTACTCTCTTCTCTCTC GTTATGTTAGCTTTCTAAATGGCTG 55 
Chromosome 11p11 
D11S1344  CCCTGAACTTCTGCATTCAC  GCGCCTGGCTTGTACATATA  55 
Chromosome 14q12 
*MYH7int24  CATCCTCTAACCCTACCCCC  TTGAGTTGTGGGGCCTAG  55 
Chromosome 15q14 
ACTC   TCAGAGACAAATGGTGACAGC GACATTGTTGGCATACAGG  55 
D15S108  AGGAGAGCTAGAGCTTCTAT  GTTTCAACATGAGTTTCAGA  55 
Chromosome 19q13.3 
D19S412  GAATGAGACTCTGTGTCTCAAAACA ACCTCATGTGTCTCCTCCTT  52 
D19S902  CCATCCTAATGAGGGCAA  GCACCAGTGACTGCCTGT  50 
D19S596  GAATCCGAGAGGTGGG  GCCAGAGCCACTGTGT  50 
D19S246  AGAGTGAGATTCCACCTTTC  GAAACACATCATTTACCCAC  52  
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* = genetic marker supplied by Dr. J. Moolman-Smook (University of Stellenbosch, RSA); °C = degrees Celsius; Tm = 
annealing temperature. Underlined markers were used in genetic fine mapping analysis (see text, section 2.9.2). 
 
2.8.3 STR allele frequencies in the Caucasian Afrikaner subpopulation 
The Centre pour l’Étude du Polymorphisme Humain (CEPH) (now known as Centre Jean Dausset) 
maintains a database containing information on population STR marker allele frequencies that have 
been obtained by genotype analyses in reference families of Northern European descent 
(http://www.cephb.fr/cephdb). However, for the present study, it was speculated that the STR allele 
distributions and allele frequencies in Caucasian South African subpopulations may be different from 
the Northern European reference families. Therefore, STR allele frequencies were determined by 
genotype analysis of 30 unrelated ethnically matched South African Caucasian Afrikaner individuals 
(section 2.2.2). The observed allele frequencies were then used to calculate the heterozygosity values 
of the STR markers at chromosome 1q32.2-q32.3 (Table 2.1). 
.  
2.8.4 Calculating STR marker heterozygosity values 
The allele frequencies for each STR marker were used to calculate the marker heterzygosity value 
using the equation H = 1 - ∑frs2, where H is the observed heterozygosity value and ∑frs is the sum of 
the allele frequencies at that marker (Ott J, 1999). Heterozygosity values were then used as a criterion 
to select the STR markers that would be used in linkage analysis study in the PFHBII-affected family 
(see section 2.9.1). 
 
2.8.5 Selection of STR markers at candidate loci 
Genetic markers with little variation in frequency of distribution of the individual alleles (determined 
in the panel of 30 Caucasian Afrikaner subjects) (see section 2.8.3) and with an observed 
heterozygosity value of equal to or greater than 0.60, were selected for genotype analysis of subjects 
from the PFHBII-affected family (Table 2.1). Allele frequencies (see Appendix and heterozygosity 
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values for the STR markers at chromosome 1q32.2-q32.3 are available in at the website of the 
US/MRC Centre for Molecular and Cellular Biology and the Department of Medical Biochemistry 
(Cape Town, RSA), 
http://www.sun.ac.za/Internet/Academic/Health/schools/Basic_appl_health/med_physbio/med_bioche
m/dept/Research.html#pfhb2. For the present study, population allele frequencies were only 
determined at chromosome 1q32.2-q32.3 (see Appendix E), because using CEPH allele data, or setting 
the population allele frequencies to equal, did not change the strongly negative lod scores that had been 
generated at the other investigated candidate loci (data not shown). 
 
2.8.6 Synthesis of STR oligonucleotide primers  
Oligonucleotide primer sequences of the STR markers selected for linkage analysis (Table 2.1) were 
obtained from published material and the National Centre for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov), Sanger Centre (http://www.sanger.ac.uk), Lawrence Livermore 
(http://www.bio.llnl.org) or the Genome Database (http://www.gdb.org) web sites. The primers used in 
the PCR-based genotype analysis (Table 2.1) were synthesised at the DNA synthesis laboratory 
(Department of Biochemistry, University of Cape Town, Cape Town, RSA) or Research Genetics 
(Huntsville, Alabama, USA). 
 
2.8.7 Genotype analysis 
2.8.7.1 PCR-based amplification of STR alleles  
The selected STR markers (Table 2.1) were used in a PCR-based amplification reaction to identify the 
segregation of tandem repeat alleles in members of a family in which PFHBII segregates. Genomic 
DNA obtained from 26 members of the PFHBII-affected family (section 2.2.1) and the Caucasian 
Afrikaner control panel of 30 subjects (section 2.2.2) was used as a template for separate PCR 
amplification reactions with the STR markers listed in Table 2.1. The amplification was performed in 
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10μl reactions containing 200 nanograms (ng) genomic DNA, 50ng each of the forward and reverse 
primers, 1 microcurie (μCi) [α-32P]-dCTP (Amersham International, UK), 25 micromolar (μM) 
unlabelled dCTP, 200μM of each dATP, dGTP and dTTP, 1.5mM MgCl2, 1μl 10x Taq DNA 
polymerase buffer (Promega, USA) and 0.5 units (U) Taq DNA polymerase (Promega, USA). Standard 
parameters in a Techne GeneE thermal cycler (Cambridge, UK) for 30 cycles were as follows: 
denaturing at 94°C for 30 seconds, annealing at 55°C for 30 seconds, except D19S412 and D19S246 
(52°C) and D19S902 and D19S596 (50°C), and extension at 72oC for 30 seconds (Table 2.1).  
 
2.8.7.2 Gel electrophoresis of PCR-amplified repeat alleles 
The PCR amplification products (see previous section) were mixed with 6μl of loading dye (Appendix 
A) and heat-denatured at 80°C for 2 minutes in a heating block (Techne Dri-block, UK), after which 
3μl of the denatured sample was loaded onto a 6% denaturing polyacrylamide gel (Appendix A). Gel 
electrophoresis was performed for 2-3 hours at 1800 volts (V) (Merck, GmbH) (Appendix A). The 
electrophoresis apparatus was then dismantled and the gel carefully lifted from the plate using 3MM 
Whatmann paper (Merck, GmbH) that was cut to the same size as the glass plate (see Appendix A for 
glass dimensions). The gel was covered with cling wrap (GLAD™), dried on a gel drier (Drygel 
Slabgel Sr model se1160, Scientific Associates, RSA) for 1 hour and exposed to an X-Ray film (Protea 
Medical, RSA) in an autoradiograph cassette. Once exposed, the film was developed in a dark room in 
developer solution for 2 minutes, stop solution for 30 seconds and fixer solution for 1 minute 
(Appendix A).  
 
2.8.7.3 Assigning repeat allele genotype scores  
PCP amplification analysis and gel electrophoresis provides a means to identify the differences in 
paternally and maternally inherited repeat allele lengths at a given locus (Weber, 1990). Based on the 
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principle of size separation, larger sized repeat lengths will migrate more slowly through a gel matrix, 
whereas shorter repeat lengths migrate faster and will be positioned further from the wells into which 
they were loaded. The PCR-amplified repeat alleles analysed by gel electrophoresis (section 2.8.7.1 
and 2.8.7.2) generated radioisotope signals at different positions on an autoradiograph. The 
radioisotope signals closest to the well (representing the largest repeat allele length) was assigned a 
value of 1 and all consecutive signals were assigned an increasing numerical value. The numerical 
values were then used to allocate genotype scores for each individual. The numerical values 
corresponding to two radioisotope signals with the strongest intensities were used as the genotype 
score for an individual. However, final genotype scores were assigned only after consensus was 
reached between two independent investigators who were blinded to the clinical status of the 
individual.  
 
A sample that did not produce a radioisotope signal and, therefore, could not be assigned a genotype 
score was re-amplified and re-assessed by gel electrophoresis and autoradiography analysis. For the 
subsequent analysis, an amplification product that had previously been assigned a final genotype score 
served as a standard against which successive sample analyses were scored.  
 
2.9 Linkage analysis 
2.9.1 Statistical parameters used for log of the odds (lod) score calculations 
Linkage computations 
Pairwise (or two-point) and multipoint linkage analysis was performed using the personal computer 
versions of the MLINK and LINKMAP options of the LINKAGE package (version 5.2) (Lathrop and 
Lalouel, 1984). All lod score calculations were performed using a computer workstation with a 
Pentium III processor (Intel®, USA). 
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Setting population allele frequencies 
Allele frequencies at each STR marker on chromosome 1q32.2-q32.3 were determined in a Caucasian 
South African Afrikaner panel, as described in section 2.8.7. The allele frequency in the Caucasian 
Afrikaner population was then calculated using the equation n divided by N, where n is the number of 
times a specific allele was observed and N is the total number of chromosomes that were analysed.  
 
Setting disease allele frequency 
The present study assumed that the disease allele was rare, since PFHBII has only been identified in 
one South African family (P. Brink, personal communication). Therefore, lod score calculations were 
performed with the frequency of the normal and disease allele assumed to be 0.9999 and 0.0001, 
respectively (P.A. Brink, unpublished data). 
 
Age-dependent penetrance 
The manifestation of PFHBII-associated clinical features is presumed to be age-dependent (Fernandez 
et al., 2004 and the present study). Therefore, clinical data obtained from members of the PFHBII-
affected family were analysed to determine the percentage of individuals that presented with disease 
symptoms within specific ranges in age (10 year age-ranges were selected for the present study). This 
data was then used to calculate a disease penetrance for clinically unaffected individuals who were 
within a specific age-range and who carried the disease-associated haplotype. For this study, the sole 
unaffected individual with the disease-associated haplotype, who was included in the lod score 
calculation (individual IV:3), was assigned a liability (penetrance) class of 40%. 
  
Multipoint analysis 
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By testing a disease-marker relationship, pairwise lod score calculations provide an indication that a 
disease maps near a particular marker (Ott, 1999). However, limited marker informativeness may 
reduce the statistical power of a pairwise linkage study (Lathrop and Lalouel, 1984; Ott, 1999). By 
testing the relationships between a disease and a series of markers that map close to each other, 
multipoint analysis minimises the influence of limited marker informativeness (Lathrop and Lalouel, 
1984). For the present study, multipoint analyses were performed using genotype data from the 
PFHBII-affected family and intermarker distances between sets of successive markers. The 
information was entered into the LINKMAP programme, which generated locations scores between the 
disease and a marker-set. Multipoint scores for a specific marker set were then calculated by dividing 
the location scores by 4.6 (the divisor factor is derived from the equation 2ln [10] = 4.6) (Lathrop and 
Lalouel, 1984). The calculated multipoint scores for each marker set were plotted against the genetic 
distances (in centimorgan [cM]) between markers at the locus. Thereafter, the maximum obtained lod 
score minus one unit (“1-lod-down”) analysis provided a 90% estimate of the genetic interval in which 
causative gene was likely to be located (Ott, 1999). 
 
2.9.2 Fine mapping analysis 
For a single linkage test, a lod score of +3 or more (1000:1 odds) indicates a disease is linked to a 
locus, whereas a score of -2 or less excludes a locus as cause of a disease (Ott, 1999). Pairwise linkage 
analysis was initially performed with selected markers at candidate loci (Table 2.1). If a marker was 
identified where a maximum lod score of greater than 1.5 was generated (in the present study it was 
markers at chromosome 1q32.2-q32.3), then genotype analysis proceeded with additional informative 
markers at that locus (fine mapping) (Table 2.1). Pairwise and multipoint lod score calculations were 
then assessed using the new set of markers.  
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The markers used for fine mapping analysis were also selected because they flanked identified 
recombination events, which were identified after haplotype construction with the STR marker data 
from the initial lod score calculations (see section 2.9.3). 
 
In order to test the stability of the obtained lod values, the allele frequencies were reset to equal or the 
disease penetrance was varied (Hodge and Greenberg, 1992). Additionally, as linkage is dependent on 
robust clinical specifications, the obtained lod scores were re-calculated by changing the clinical status 
of one affected family member (individual III:11, Fig. 2.1). The reasons for selecting this particular 
subject are provided in section 3.2.2. 
 
2.9.3 Haplotype analysis at a PFHBII-linked locus   
Fine mapping analysis creates a landscape of markers that are closely linked and have well-defined 
chromosomal positions. For the present study, haplotypes were constructed manually taking into 
account the parental distribution and phase of each marker allele. It was opted not to use the Cyrillic 
2.10 programme (Cherwell Scientific, UK) to construct the haplotypes because of the computational 
limitations of the software, namely, the inability of the software to compute phase when one of the 
parental alleles was absent (due to technical difficulties). 
  
Initially, haplotypes were constructed at a locus on chromosome 1q32.2-q32.3 where preliminary 
analysis generated a lod score of greater than 1.5. Fine mapping analysis was then performed (see 
previous section), after which haplotypes were re-constructed by including the additional STR marker 
genotype scores.  
  
2.10 Construction of a genetic, physical and transcript map 
2.10.1 Selection of genomic clones spanning the PFHBII locus 
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Agar stabs of Bacterial Artificial Chromosome (BAC), P1 Artificial Chromosome (PAC) and Yeast 
Artificial Chromosome (YAC) vectors, containing fragments of genomic sequence derived from the 
locus on chromosome 1q32.2-q32.3, were obtained from the Wellcome Trust Sanger Centre (Hinxton, 
UK) and Research Genetics. Based on information obtained from the Sanger Centre chromosome 1 
database (http://www.sanger.ac.uk/HGP/Chr1), ten genomic clones that spanned the PFHBII locus 
were selected for genetic, physical and transcript mapping analysis (Table 2.2) (Fig. 2.2).  
 
Table 2.2 
Genomic clones used in the construction of a genetic, physical and transcript map of the PFHBII locus 
Clone       Size (base pairs) 
CTA-55I10             90 429 
RP1-272L16           157 875 
RP1-28O10             97 700 
RP3-434O14           135 928 
CTA-447D17             26 524 
CTA-321I20             19 974 
RP4-782D21             84 464 
CTA-11C7           109 302 
RP5-879K22           137 678 
YAC 937D4      ~2 000 000   
 
2.10.2 Isolation of BAC and PAC genomic DNA  
An inoculating loop (Sterilab, RSA) was inserted once into the agar stab and streaked across a Luria 
broth agar (LA) plate (Appendix A) containing chloramphenicol (Roche, GmbH) at a final 
concentration of 12.5 μg/ml. The LA plate was then incubated at 37°C for 12-16 hours in a Sanyo 
Incubator (Vacutec, RSA). Thereafter, isolations of large clone inserts using alkaline lysis were 
performed (Sambrook et al., 1989). To this end, a single colony was picked from the streaked LA plate 
using a toothpick and inoculated into 500ml of LB broth (Appendix A) in an Erlenmeyer flask 
containing chloramphenicol (12.5µg/ml). The culture was incubated for 16 hours at 37°C with shaking 
in an orbital shaker/incubator model LM530 (YIH DER, RSA), after which it was transferred to 
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Sorvall centrifuge bottles and centrifuged at 4000rpm at 4°C for 15 minutes in a Sorvall HB4 rotor to 
harvest the cells.  
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Fig. 2.2
Genetic markers and genomic clones that span the PFHBII locus on chromosome 1q32.2-q32.3. 
Genetic markers and intermarker distances in centimorgans (cM) were obtained from genomic databases (see text). The BAC, PAC and YAC 
clones that were selected for genetic, physical and transcript mapping at the PFHBII locus are numbered: 1 = CTA-55I10; 2 = RP1- 272L16; 3 = 
RP1-28O10; 4 = RP3-434O14; 5 = CTA-447D17; 6 = CTA-321I20; 7 = RP4-782D21; 8 = CTA-11C7; 9 = RP5-879K22; 10 = YAC 937D4. 
The relative clone positions are based on draft Sanger Centre sequence data that was available at the time (June 2000).  
0.5cM
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The supernatant was then decanted and the cells were resuspended in 10ml of Solution I (Appendix A) 
and 20ml of Solution II (Appendix A), by inverting the centrifuge bottle several times, which was then 
allowed to stand at room temperature for 10 minutes. Thereafter, 15ml of ice-cold Solution III 
(Appendix A) was added to the cell suspension, the bottle was inverted several times, allowed to stand 
for 10 minutes on ice and then centrifuged at 4000rpm in a Sorvall HB4 rotor for 15 minutes at 4°C, 
which resulted in the cellular debris being pelleted at the bottom of the centrifuge bottle. The 
supernatant was transferred from the centrifuge bottle to a clean 50ml Evergreen tube (Lasec, RSA), to 
which 0.5 volumes of isopropanol (Merck, GmbH) was added to precipitate the genomic DNA. The 
suspension containing the precipitated DNA was centrifuged for 6 minutes at full speed at room 
temperature in a Beckman bucket centrifuge model TJ-6 (rotor diameter of 35cm) (Beckman, USA). 
The supernatant was discarded and 500µl of 70% EtOH was added to the pelleted DNA in the 
Evergreen tube, which was then resuspended by inverting the tube several times. The resuspended 
DNA was centrifuged at 4000rpm at room temperature for 5 minutes, after which the EtOH was 
discarded and the DNA pellet was allowed to dry at room temperature. The dried DNA pellet was 
resuspended in 100µl TE (Appendix A), transferred to a clean 1.5ml eppendorf tube and stored at 4°C. 
 
2.10.3 Isolation of YAC DNA  
An inoculating loop was inserted once into the agar stab containing copies of a YAC genomic clone, 
then streaked onto a YPD plate (Appendix A) and incubated at 30°C for 1-2 days. One colony was 
picked with an inoculating loop, re-streaked on another YPD plate and incubated at 30°C for a further 
1-2 days. A single colony was then picked and inoculated into 10ml of YPD medium and incubated 
overnight at 30°C in an orbital shaker/incubator. The solution containing the cells was then poured into 
a centrifuge bottle, after which the cells were pelleted by centrifugation at 1000 rpm for 10 minutes in 
a Sorvall centrifuge and washed twice in 10ml of 40 millimolar (mM) EDTA/90mM 2-
mercaptoethanol (Appendix A).  
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Thereafter, the supernatant was decanted and approximately 700µl of lysis buffer (Appendix A) was 
added to the lysed cells, which were then incubated at 68°C for 15 minutes. The lysate was 
resuspended by vortexing and then split into equal volumes in two eppendorf tubes. Six hundred 
microlitres of phenol:chloroform:isoamyl alcohol (PCI) (Sigma, USA) was added to each tube 
containing the resuspended lysate, which was then centrifuged at 12 000rpm for 10 minutes. The 
aqueous phase of both suspensions was pooled in a clean eppendorf tube to which 700µl of 
isopropanol was added. The solution was incubated at room temperature for 15 minutes and 
centrifuged at 12 000rpm for 15 minutes, after which the supernatant was discarded and the pellet was 
resuspended by vortexing and then washed with 500µl of 70% EtOH, as previously described in 
section 2.10.2. The DNA pellet was air-dried, resuspended in 300µl of TE and 30µg RNase (0.05 
U/mg) (Roche, GmbH) and incubated at 37°C for 2 hours with intermittent vortexing to dissolve the 
pellet.  
 
Seven hundred microlitres of isopropanol was then added and the mixture was incubated at room 
temperature for 15 minutes. The DNA, which had now precipitated in the isopropanol, was centrifuged 
at 12 000rpm for 15 minutes in a Beckman Microfuge® Lite bench top centrifuge (Beckman, USA) 
and subsequently washed twice with 500µl of 70% EtOH as previously described. The washed pellet 
was air-dried and resuspended in 300µl of TE and 750µl EtOH, stored on ice for 10 minutes and then 
centrifuged at 12 000rpm for 15 minutes. An additional 70% EtOH wash was performed as previously 
described after which the pellet was allowed to air-dry. The DNA pellet was resuspended in 200µl TE 
and stored at 4°C.  
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2.10.4 PCR-based mapping of genetic markers onto genomic clone-insert DNA sequence  
Short tandem repeat markers were mapped onto genomic clones (Table 2.2) using a PCR-based assay, 
to determine whether the selected clones contained sequence that 1) spanned the PFHBII-linked locus 
and 2) were contiguous (overlapping) across the described disease interval. The 11 genetic markers at 
chromosome 1q32.2-q32.3 (Table 2.1) were used in an amplification assay that was similar to the 
method described in section 2.8.7.1, except that the PCR reaction mix contained 0.5µl of BAC, PAC or 
YAC DNA as genomic template, no radioactive isotope was added and 200µM of each 
deoxynucleotide (dATP, dCTP, dGTP and dTTP) was added.  
 
Once the PCR amplification reaction was complete, a 1.5% gel was prepared that consisted of 0.75 
milligrams (mg) agarose (Whitehead Scientific, RSA) mixed in 50ml of 1xTBE in a glass beaker 
(Schott, GmbH) (Appendix A) and placed in a microwave oven for 2 minutes to dissolve the agarose. 
Thereafter, 10mg/ml of ethidium bromide (EtBr) (Sigma, USA) was added and the solution was then 
poured into a Scigen casting tray (Whitehead Scientific, RSA). At one end of the casting tray, a well-
forming comb was positioned into the gel. Once the gel was set, the comb was removed and the gel 
was placed in a Scigen electrophoresis tank (Whitehead Scientific, RSA) into which 150ml of 1xTBE 
was added. Thereafter, 5μl of the PCR amplification product (see previous paragraph) was mixed with 
2μl of loading buffer (Appendix A) and loaded into a well. Electrophoresis then proceeded at 100 volt 
(v) for 20 minutes, after which the gel containing the amplified product was analysed using a 3UV™ 
transilluminator model LMS-26E ultra violet light source (Upland, USA) set at a wavelength of 
302nm. A permanent photographic record of the gel analysis was obtained using a Sony Graphic 
System UP-860CE system (Sony, RSA).  
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2.11 Bioinformatics analyses 
2.11.1 Mapping genetic markers onto in silico genomic clone sequences 
Electronic versions of genomic clone-insert sequences (Table 2.2) and the selected STR markers 
(Table 2.1) at the PFHBII locus were obtained from the Sanger Centre chromosome 1 and the NCBI 
databases. In silico (computer-based) mapping analyses were then performed via the Internet (US 
internet service provider). 
 
The electronic versions of the selected genomic clone-insert sequences and STR markers at the 
PFHBII locus were aligned to each other using the “Blast 2 sequences” option of the BLAST algorithm, 
which is available at the NCBI web address, http://www.ncbi.nlm.nih.gov/BLAST. The procedure for 
the alignment analysis is as follows: the Blast 2 sequences web page has two sequence input windows. 
The sequence of a genomic clone-insert was retrieved, using the “copy” option, from a database and 
inserted, using the “paste” option, into the “subject” window in the Blast 2 sequences web page. The 
sequence of the STR markers at chromosome 1q32.2-q32.3 (Table 2.1) was inserted into the “query” 
window using the “copy and paste” options described previously. The information was then submitted 
and the alignment results were returned in a separate web page. 
 
2.11.2 Identifying candidate genes at the PFHBII locus 
Using similarity searches to identify new genes 
After mapping the PFHBII-causative gene to within a locus on chromosome 1q32.2-q32.3, the search 
for candidate genes proceeded in June 2001. In 2000, Schutte et al. reported that they had generated an 
extensive physical and transcript map of the Van der Woude syndrome (VWS) (MIM 119300) locus on 
chromosome 1q32-q41. However, later analyses of HGP databases indicated that their map did not 
extend beyond chromosomal band 1q32.2 (Ensembl database, Jan 2001). Initially, the present study set 
out to incorporate Schutte and colleagues’ mapping data of chromosome 1q32, in addition to 
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generating additional mapping and annotation data at the locus. However, because in silico sequence 
and annotation data of the region were available at the time (Sanger Centre chromosome 1 database, 
June 2001), it was opted to use HGP-generated transcript maps and similarity analyses (bioinformatics) 
to identify and select genes at the PFHBII locus.  
 
The similarity analyses were performed using the “nucleotide” option of the BLAST programme. 
Electronic versions of genomic clone-insert sequences (see section 2.11.1) were placed into the 
“query” window (“copy and paste” option, see section 2.11.1) and the BLASTN search option was 
selected. This option queries a nucleotide sequence against a nucleotide database. The influence of low 
complexity or sequence repeat regions was minimised by selecting the “low complexity filter” option 
(also known as “masking”) (see BLAST webpage). This option was included because low complexity 
regions are sequences that code for transmembrane helices or coiled-coiled domains, which are so 
abundant in eukaryotic genomes that they can cause false-positive alignments (Huynen et al., 1998). 
The query sequence was then submitted and the results were returned in a separate web page.  
  
Using databases to identify the positions and functions of annotated genes at the PFHBII locus 
The Ensembl, the University of California Santa Cruz (UCSC) (http://genome.ucsc.edu) and NCBI 
databases provided an in silico catalogue of the genomic position, structure(s) and the function(s) of 
known genes and their protein products. Known genes are defined as transcripts identified by 
experimental analysis, which are expressed in vivo (Stein, 2001). By comparison, computer predicted 
genes are in silico-identified sequences that meet criteria for classification as a gene, but for which 
there is no experimental data to support that it has an in vivo biological function. These in silico genes 
are also catalogued in the HGP databases (Burge and Karlin, 1997) and were included in the 
bioinformatics analysis in the present study. For the present study, all gene annotation data was 
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obtained from NCBI builds 28 and 31 (24 December 2001 and 5 November 2002 freeze dates), 
respectively (Appendix B).  
 
The similarity analyses identified genes that encode proteins with homology or similarity to protein 
signatures in which mutations have been described that cause cardiomyopathies and/or cardiac 
conduction disorders (see sections 1.3.2.1, 1.3.6.1 and 1.4.4). However, because this approach could 
result in the identification of a large number of plausible candidate genes, additional bioinformatics 
alignment analyses was used to shorten the list of possible causative genes.  
 
Comparing levels of functional similarity  
Functional similarity analyses use scoring matrices to assess whether an alignment is functionally 
significant and not purely significant because the sequences are identical (Dayhoff et al., 1978; 
Henikoff and Henikoff et al., 1992). The BLAST (the “protein-protein” [BLASTP] option), BLAT 
(http://genome.ucsc.edu/cgi-bin/hgBlat), Pfam (http://www.sanger.ac.uk/Software/Pfam), BLOCKS 
(http://www.blocks.fhcrc.org) and PROSITE (http://www.expasy.org/prosite) algorithms (Appendix C) 
were used to perform pairwise functional alignment analyses. If the result obtained from two or more 
of the algorithms differed, then the candidate gene was not included in further analyses. The cut and 
paste options (described in previous sections) were used to submit protein sequences to the BLAS, 
BLAT, Pfam and BLOCKS algorithms. 
 
Tissue expression profiling to further prioritise candidate genes 
Cardiac tissue expression was a prerequisite in the selection of candidate genes for mutation analysis. 
The expression profiles of genes were determined by inserting electronic versions of the nucleotide 
sequence of a candidate gene into the query window of the Sequence Tag Alignment and Consensus 
Knowledgebase (STACK) (http://www.sanbi.ac.za/Dbases.html) algorithm and then submitting it to the 
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“stack_heart” expressed sequence tag (EST) database (Appendix D). The expression data of possible 
candidate genes were additionally queried against the Unigene (http://www.ncbi.nlm.nih.gov/Unigene) 
database (Appendix D). This analysis differed from the previous bioinformatics procedure because the 
Unigene database uses a word or phrase-based input. The gene name or gene accession number was 
inserted into the “search for” box and then submitted to the Unigene EST database. For both the 
STACK and Unigene database submissions, the results were returned on the same webpage. 
It might be relevant to mention that, although cardiac tissue expression was a requirement for selection 
of candidate genes, genes that were not expressed in cardiac tissue but that fulfilled all other selection 
criteria, were also considered for mutation analysis. The selection of these genes will be discussed in 
section 4.9. 
 
2.11.3 Selecting candidate genes for mutation analysis 
Threshold alignment significance levels 
The algorithms used in the present study produced alignment probability (P) or Expect values (E-
values), which indicate the difference between alignment matches that have a mathematical 
significance and matches that have a biological significance (Altschul et al., 1997; Attwood and Parry-
Smith., 1999). A significance threshold level of 95% or greater, for a sequence of 40 nucleotides or 
more, was applied in this study (Altschul et al., 1997). Although 40 nucleotides represent a short 
sequence, masking of low complexity regions increased the probability of obtaining a match that had 
biological significance (Altschul et al., 1997). Generally, a protein alignment P-value closer to 1.0 
(one) or an E-value closer to 0.0 (zero) represents a significant score. For the protein alignment 
analyses, P-values greater than 0.9 or E-values less than 0.01 were set as a significant threshold level 
for a gene to be considered for mutation screening (Altschul et al., 1997). For STACK expression 
analyses, a default E-value of 0.999 was set as a cut-off level.  
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2.12 Mutation analysis 
2.12.1 Designing oligonucleotide primers  
Non-radioactive PCR-single stranded conformation polymorphism (PCR-SSCP) analysis was 
performed on all the coding exons of prioritised candidate genes, according to a modified method from 
Orita et al. (1989). In this study, unique oligonucleotide primers were designed using data from the 
genomic sequence flanking individual exons and splice junctions of the selected candidate genes 
(Appendix F). The oligonucleotide primer sequences for the novel gene termed VWS59 (see section 
3.5.1) were obtained from Dr. B. Schutte (University of Iowa, USA) (Appendix F). Each primer’s 
sequence consisted of 18-30 nucleotides, for which the last nucleotide of the primer at the 5’ and the 3’ 
end of the exon was positioned at least 10 nucleotides from the start of the exon. For large exons, 
primers were designed to analyse the exon in a series of overlapping amplification products (Appendix 
F). The annealing temperature of each primer was calculated using the programme DNAMAN version 
4.0 (E. Rybicki, University of Cape Town, RSA). For each primer set, the lesser of the two calculated 
annealing temperatures minus 2ºC was used as the final PCR amplification annealing temperature 
(Appendix F).  
 
2.12.2 PCR-SSCP amplification conditions 
For each exon, genomic DNA of three clinically affected subjects (individuals II:7, III:1 and III:9), two 
unaffected first-degree relatives (individuals III:4 and III:6) and an unaffected spouse of a member of a 
PFHBII-affected family (individual III:8) (see Table 3.1 and Fig. 3.1) was analysed by PCR-SSCP 
analysis (see below). Genomic DNA of 30 Caucasian Afrikaner individuals were also used in 
subsequent PCR amplification reactions to determine the frequency of the identified sequence 
variations using PCR-SSCP analysis (section 2.12.3). 
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The amplification of each coding region of the prioritised candidate genes was performed in a 50μl 
reaction containing 200 nanograms (ng) genomic DNA, 120ng of each of the forward and reverse 
primers, 200μM of each dATP, dCTP, dGTP and dTTP, 1.5mM MgCl2, 1μl 10x Taq DNA polymerase 
buffer and 0.5 units (U) Taq DNA polymerase. Standard PCR-amplification parameters in a Techne 
GeneE thermal cycler for 30 cycles were as follows: denaturing at 94°C for 30 seconds, annealing for 
30 seconds at the calculated Tm for each primer set (Appendix F) and extension at 72oC for 30 
seconds. The amplification product lengths are described in Appendix F.  
 
2.12.3 PCR-SSCP gel electrophoresis 
For PCR-SSCP gel electrophoresis analysis, 8% and 10% mildly-denaturing polyacrylamide gel 
solutions (Merck, GmbH), each containing 5% glycerol and 15% urea, were prepared by the method 
described in Appendix A.  
 
A 5μl aliquot of the PCR-amplified product was placed into a 1.5ml eppendorf tube containing an 
equal volume of SSCP loading dye (Appendix A) and heat-denatured in a heating block for 3 minutes 
at 95°C. The denatured samples were loaded into the wells of the PCR-SSCP gel and electrophoresis 
proceeded at a constant power of 25W for 16 hours at 4ºC. The gel apparatus was then dismantled, the 
gel was silver stained (Appendix A) and air-dried for a minimum of 2 hours to avoid the gel cracking 
or fading. The gels were analysed and all PCR products showing electrophoresis mobility variations 
were re-amplified and re-assessed by electrophoresis as previously described. Samples with confirmed 
mobility variations were purified (see section 2.12.4) and sequenced manually using the fmol® cycle 
sequencing system (Promega, USA) or by using an ABI-377 automated sequencer (PE Biosystems, 
USA) (section 2.12.5). 
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Variant gel-banding patterns were assumed to represent a sequence variation at a specific nucleotide 
position in the coding or non-coding region of the candidate gene. Subsequent sequence analysis of the 
samples showing variant gel-banding patterns (section 2.12.5) determined the different nucleotide 
combinations (or alleles) at a specific position in the sequence. The frequency of a specific allele was 
then determined by comparing PCR-SSCP electrophoresis patterns of members of the family in which 
PFHBII segregates against 30 unrelated, unaffected South African Caucasian Afrikaner control 
individuals. Family members and individuals from the Caucasian Afrikaner panel with the same gel 
banding patterns were assumed to have the same allele combinations. Allele frequencies were 
calculated as described in section 2.8.3.  
 
2.12.4 Gel purification of PCR products for sequencing analysis 
The GFX™ DNA and gel band purification kit (Amersham Pharmacia Biotech, NJ, USA) was used to 
purify all samples in which gel mobility variants were identified. Thirty microlitres of the PCR 
amplification product was loaded into a well on a 1.5% agarose gel and electrophoresis proceeded for 1 
hour. The gel was viewed using an ultraviolet light source at 302nm.Thereafter, using a clean scalpel 
blade, a slice of agarose containing the DNA band was excised and transferred to a clean pre-weighed 
1.5ml eppendorf tube and the new weight recorded. Ten microlitres of GFX™ Capture buffer 
(Amersham Pharmacia Biotech, NJ, USA) was added for each 10mg gel slice (limited to a maximum 
amount of 300μl). The purification of the PCR-amplified product using the GFX™ DNA and gel band 
purification kit proceeded according to the manufacturer’s instructions. 
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2.12.5 Characterisation of sequence variants  
2.12.5.1 Cycle sequencing 
Variant gel-banding patterns for the candidate gene VWS59 were characterised by direct PCR cycle 
sequencing of using the fmol® sequencing kit. For each variant, the sequencing reaction mix contained 
2μl of gel purified amplification product as template DNA, 5μl 5x sequencing buffer, 5% 
dimethylsulfoxide (Sigma Fine Chemicals, St. Louis, USA), 1 picomole (ρmol) of the PCR 
amplification product oligonucleotide primer and 1μl α-32P [dCTP] (Amersham, UK). Four microlitres 
of the above cocktail were added to four separate pre-chilled 0.5ml eppendorf tubes, each containing 
2μl aliquots comprised of all four deoxynucleotides (2.5μM concentration stocks of dATP, dCTP, 
dGTP or dTTP) and a specific dideoxynucleotide (ddATP, ddCTP, ddGTP and ddTTP). The samples 
were then placed in a pre-heated GeneE Thermal Cycler (Techne Cambridge, UK) at 95°C for 2 
minutes, after which, the cycling profile at the original PCR amplification conditions was performed 
(Appendix F). Four microlitres of sequencing stop solution (Promega, USA) was added to each tube 
when the PCR reaction was completed.  
 
2.12.5.2 Gel electrophoresis of cycle sequencing products 
A 6% denaturing polyacrylamide gel was prepared as described in Appendix A. The PCR-amplified 
samples (see previous section) were heat-denatured at 95°C for 2 minutes in a heating block, then 4μl 
aliquots of each sample were loaded into four separate wells and electrophoresis was performed for 2 
hours at 1800V. The apparatus was switched off after 2 hours and 4μl aliquots of the same heat-
denatured samples were loaded into four separate lanes and electrophoresis proceeded for a further 2 
hours. After the electrophoresis had proceeded for a combined time of 4 hours, the gel apparatus was 
dismantled and prepared for autoradiography as described in Appendix A. The nucleotide sequence 
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corresponding to the radioisotope signal in each dideoxynucleotide sample lane was read from the 
bottom end of the autoradiograph towards the top. 
   
2.12.5.3 Automated sequence analysis 
The PCR amplification products in which gel mobility variations were identified by PCR-SSCP 
analysis were sequenced at the US Core Sequencing Facility (Stellenbosch, RSA). Five microlitres of 
the gel purified amplification product (described in section 2.12.4), which was diluted to a minimum 
concentration of 3.3ng/μl, was supplied with both forward and reverse PCR primers that were diluted 
to a concentration of 6.6ρmol. Even though the PCR-SSCP technique used in the present study was 
proposed to have an optimum detection sensitivy equal to and greater than 95% (W de Lange, PhD 
thesis), a PCR-SSCP quality control test was performed in the present study. To this end, 29 exons that 
were previously analysed by PCR-SSCP, were subsequently re-screened by direct automated 
sequencing. For this analysis, a minimum of two PCR amplification products (exon and flanking splice 
junctions) of each of the seven prioritised candidate genes (a total of 14), which did not demonstrate 
PCR-SSCP gel mobility variations, was directly sequenced. The remaining 15 of the 29 sequenced 
exons were PCR-amplified products with lengths of less than 150bp or more than 300bp. These 
samples were selected because PCR-SSCP analysis has optimal detection sensitivities within the 
product size range of 150-250bp (Orita et al., 1989).  
 
2.12.5.4 Automated sequence interpretation 
Sequence text files (file extension: *.seq) were viewed and edited using DNAMAN version 4.0. The 
programme Chromas version 2.22 (Technelysium (Pty) Ltd, Australia) was used to view and edit 
sequence chromatograms (file extension: *.ab1). The “translate DNA to protein” analysis tool 
(http://www.expasy.ch) was used for six-frame translations of the nucleotide sequence, which was 
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obtained from automated sequence analysis as described in section 2.12.5.3, into protein sequence. The 
BLAST alignment algorithm was used to match automated sequence text files against matching 
database sequence entries (see section 2.11.1) and the ClustalW programme (http://www.ebi.ac.uk) 
was used to generate a graphical alignment of protein sequences. These analyses were performed using 
the same copy and paste options described in sections 2.11.1 and 2.11.2. All validated sequence 
variations were submitted to the single nucleotide polymorphism (SNP) database 
(http://www.ncbi.nlm.nih.gov/SNP).  
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Results 
Ode to LINKAGE 
Therefore, it can fairly be concluded 
For PFHBII, on which we work secluded, 
Twelve loci have so far been excluded 
If by computation we have not been deluded 
Anonymous (modified) 
 
3.1 Clinical evaluation 
Establishing a clinical profile of PFHBII 
All available clinical data (clinical histories or clinical examination records) obtained from 
members of the PFHBII-affected family (Table 3.1) was analysed to identify patterns of cardiac 
abnormalities that are associated with the disorder. Of the 43 individuals for which clinical data 
were obtained, 14 were identified that presented with cardiac conduction defects that ranged from 
SB and first-degree AV block to CHB (Table 3.1). Four of these 14 clinically affected subjects 
developed DCM (Table 3.1) (individuals II:11, III:2, III:9 and III:25). A possible 
“cardiomyopathy” was suspected in one subject (Table 3.1) (individual II:1), although the clinical 
evidence to support this speculation could not be obtained. Another subject (Table 3.1) (individual 
III:26) developed DCM without prior or accompanying conduction abnormalities, possibly 
indicating that DCM may be an underlying cause of PFHBII. Generally, subjects with PFHBII 
displayed cardiac conduction defects and accompanying DCM or demonstrated progression to 
DCM between 5-22 years after an initial diagnosis of conduction abnormalities. This clinical 
information was then used to formulate a clinical profile of PFHBII, the results of which have been 
published in the Cardiovascular Journal of South Africa (Fernandez et al., 2004). The three 
significant outcomes of this clinical study were, PFHBII is a conduction disease associated with 
DCM, progression from SB to CHB or DCM was observed and, the PFHBII-associated cardiac 
conduction defects were located in the proximity of the AV node or Bundle of His, because none of 
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the clinically affected subjects presented with defects in the bundle branches of the cardiac 
conduction system (see Fig. 1.6). A detailed discussion of these results is presented in section 4.1. 
 
Table 3.1 
Clinical characteristics of subjects from the core PFHBII-affected family studied retrospectively 
Individual Age# 
(years) 
Sex P-R interval 
(msec) 
EF 
(%) 
LVEDD 
(cm) 
Comments / clinical features 
I:1 61 M nd nd nd CHB, deceased at age 61 yrs  
I:2 nd F nd nd nd Clinically unaffected  
II:1 40 M nd nd nd SB (HR = 26 bpm), CHB (pacemaker 
at age 41 yrs), deceased at age 41 yrs  
II:2 nd F nd nd nd Clinically unaffected 
II:3 45 M nd nd  nd CHB (pacemaker at age 45 yrs), failed 
PM, deceased at age 45 yrs  
II:4 nd F nd nd nd Clinically unaffected 
II:5* 68 M 200 76 4.8 Clinical history of SB, HR = 53 bpm on 
re-evaluation, clinically uncertain 
II:6 nd F nd nd nd Clinically unaffected 
II:7* 66 M 3°AVB 60 4.5 SB (HR = 48 bpm)ψ, CHB (pacemaker 
at age 42 yrs), 
II:8 nd F nd nd nd Clinically unaffected 
II:9* 64 F 180 65 4.4 HR = 49 bpm, HR = 58 bpm on re-
evaluation, clinically uncertain 
II:10 nd M nd nd nd Clinically unaffected 
II:11* 59 F 3°AVB 41 6.3 CHB (pacemaker at age 37 yrs), DCM, 
deceased at age 59 yrs 
II:12 nd M nd nd nd Clinically unaffected 
III:1* 40 M 160 64 4.4 LAD (30º axis), LAH, diagnosed age 36 
yrs 
III:2 38 M 3°AVB 38 6.2 SB (HR = 50 bpm), CHB (pacemaker 
at age 39 yrs), DCM, deceased at age 
43 yrs 
III:3 nd F nd nd nd Clinically unaffected  
III:4* 47 M 140 60 4.4 Clinically unaffected  
III:5* 43 M 140 60 4.4 Clinically unaffected  
III:6* 45 F 140 65 4.5 Clinically unaffected  
continued on overleaf 
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III:7* 39 F 3°AVB 52 5.1 SB (HR = 38 bpm)ψ, AF, CHB 
(pacemaker at age 33 yrs) 
III:8* 45 M 150 65 4.8 Clinically unaffected 
III:9* 46 M 3°AVB 42 5.7 CHB (pacemaker at age 41 yrs), DCM, 
deceased at age 46 yrs 
III:11* 36 M 200 nd nd SB (HR = 43 bpm) 
III:12 35 F  nd nd CHB (pacemaker  at age 35 yrs) 
III:15* 32 F 140 65 4.3 HR = 54 bpm, clinically uncertain 
III:16* 40 F 180 64 4.5 Slow R-wave progression; transition to 
dominant R-wave in V4, clinically 
uncertain 
III:18* 33 M 160 70 4.7 Clinically unaffected  
III:19* 31 M 200 63 4.9 Clinically unaffected  
III:20* 38 F 2° AVB or 
3°AVB 
61 5.5 1°AVB§, SB (HR = 43 bpm), 
Wenckebach/complete AVB 
III:21 nd M nd nd nd Clinically unaffected  
III:22* 41 M 200 64 4.4 Clinically unaffected  
III:23 16 M 3°AVB nd nd CHB (pacemaker at age 16 yrs), 
deceased at age 16 yrs 
III:24* 39 F 160 60 4.5 Clinically unaffected 
III:25* 43 F 3°AVB 40 5.8 CHB (pacemaker at age 29 yrs), DCM, 
deceased at age 43 yrs 
III:26 14 M nd nd nd Heart transplant, DCM, deceased at 
age 15 yrs  
IV:1* 23 F nd nd nd Chest pain, dyspnoea, syncope, clinically 
uncertain 
IV:2 nd F nd nd nd Clinically unaffected  
IV:3* 22 M 160 63 5.2 Clinically unaffected  
IV:4* 20 F 160 70 4.3 Clinically unaffected  
IV:5* 13 F nd nd nd Not examined, clinically uncertain 
IV:6* 13 F nd nd nd Not examined 
IV:7* 10 F nd nd nd Not examined 
# = age at diagnosis in years (yrs) or age when clinical history was obtained; ψ = heart rate prior to pacemaker 
implant; § = first-degree (°) atrioventricular block (AVB) preceded complete heart block (CHB) 
AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; cm = centimetres; DCM = dilated 
cardiomyopathy; EF = ejection fraction; F = female; HR = heart rate; LAH = left anterior hemiblock; LAD = left axis 
deviation; LVEDD = left ventricular end-diastolic diameter in centimetres; M = male; msec = milliseconds; nd = no 
data available or too young for clinical diagnosis; SB = sinus bradycardia.  
An asterisk indicates subjects who were genotyped in the present study (refer to Fig. 2.1).  
Affected individuals are shown in bold. 
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In an additional study, clinical examinations were performed in other branches of the core PFHBII-
affected family. These investigations did not identify features that suggested that the disorder 
segregated in the other families, although, in one branch, a male subject was identified who 
presented with HCM (see section 4.5). No other subjects were identified, in the other branches of 
the family that presented with HCM.  
 
Clinical designations for the linkage study 
Clinical data or clinical histories (Table 3.1) were obtained for 43 out of a total of 47 individuals in 
the PFHBII-affected kindred (Fig. 3.1); no clinical information was available for individuals II:13, 
III:10, III:13 and III:14 (Fig. 3.1). In the present study, 26 members of the PFHBII-affected family 
were genotyped for genetic linkage analysis (these subjects are indicated in Fig. 2.1 and Table 3.1). 
A conservative clinical classification system was applied when assigning a clinical status to the 26 
individuals (section 2.3), because false positive linkage results could be produced as a result of 
misclassifying subjects as clinically affected (Ott, 1999). Consequently, for this study, eight of the 
26 genotyped family members were designated clinically affected and 10 were designated clinically 
unaffected. The eight remaining subjects were assigned a clinically uncertain status, the reasons for 
these designations are provided below.  
 
Three individuals, under the age of 20 years, were not clinically evaluated, and thus were assigned 
a clinically uncertain status (refer to section 2.3) (Table 3.1) (Fig. 3.1). One subject (individual 
IV:1) consented to donate blood for genetic analysis but declined to undergo a clinical evaluation, 
despite reporting recurrent chest pain, dizziness and fainting spells. Because of an incomplete 
assessment, she was given a clinically uncertain status (Table 3.1) (Fig. 3.1).  
 
Four other family members were designated clinically uncertain based on their current and/or past 
clinical features. Generally, a heart rate of less than 60 bpm is considered an indication of SB 
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(Josephson et al., 1991), although the present study used more stringent diagnostic criteria and only 
subjects with a heart rate of less than 50 bpm were considered clinically affected. However, since 
progression from a slow heart rate to CHB has been demonstrated in the PFHBII-affected family 
(Fernandez et al., 2004), additional classification criteria for subjects with atypical clinical features 
were included (see section 2.3). It was noted that individual II:5 (Table 3.1) (Fig. 3.1) had 
previously been diagnosed with SB (Brink and Torrington, 1977), although, in a recent clinical 
assessment, the subject presented with a heart rate of 53 bpm. Unfortunately, the previous clinical 
record was not available and it was not possible to determine the historic base of this diagnosis. 
Therefore, this subject was tentatively assigned a clinically uncertain status. Another subject 
(individual II:9), presented with a slow heart rate of 49 bpm, although, on re-evaluation, had 
presented with a heart rate of 58 bpm. Because of the difference in the diagnosis, the subject was 
cautiously given a clinically uncertain status (Table 3.1) (Fig. 3.1), rather than being designated 
clinically affected. A third family member (individual III:15) was assigned a clinically uncertain 
status because she presented with a heart rate of 54 bpm (Table 3.1) (Fig. 3.1). The fourth subject 
assigned a clinically uncertain status (individual III:16) presented with a slow R-wave progression 
on an evaluation by ECG (Table 3.1) (Fig. 3.1). Section 4.6 provides a further discussion of the 
clinical designations of the subjects that were entered into the genetic study. 
 
3.2 Genetic analysis 
3.2.1 Genotype analysis at candidate loci 
Genotype analysis of members of the family in which PFHBII segregates 
A PCR-based assay was used to amplify alleles at each of the selected STR markers (Table 2.1) 
(section 2.8.7.1). Genotype scores were assigned, using the method described in section 2.8.7.3 
(Fig. 3.2), to each member of the PFHBII-affected family that was entered into the present linkage 
study (Fig. 3.1). The genotype data was used to calculate lod scores at the selected candidate loci.  
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Genotype analysis in a Caucasian South African Afrikaner panel 
The present study considered that the allele frequencies and STR marker heterozygosity values in 
the South African Afrikaner subpopulation may be different from the CEPH allele frequencies in 
Northern European reference families (refer to section 2.8.3). Genotype analyses were performed in 
a panel of 30 Caucasian Afrikaner individuals to determine the frequency of alleles at different STR 
markers (section 2.8.3). The allele frequencies at STR markers on chromosome 1q32.2-q32.3 are 
available at the US/MRC Centre for Molecular and Cellular Biology and the Department of 
Medical Biochemistry website (refer to section 2.8.5). The resultant allele frequencies (also used in 
the linkage study) were then used to calculate marker heterozygosity values in the Caucasian 
Afrikaner subpopulation (section 2.8.4).  
 
STR marker heterozygosity values at chromosome 1q32.2-q32.3 
The calculated heterozygosity values for the selected STR markers at chromosome 1q32.2-q32.3 
were above 0.60 (Table 3.2) (also available at the website, see section 2.8.5). The values in the 
Caucasian Afrikaner subpopulation were comparable to the CEPH and Marshfield Genetic Map 
Marker heterozygosity values, with the only heterozygosity value that differed observably was that 
of D1S70, which was 0.49 in the CEPH reference families, compared to 0.74 in the Afrikaner 
subpopulation (Table 3.2). 
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Fig. 3.1 
Clinical designations of members of the PFHBII-affected family, genotype assignments and haplotype 
construction with markers at chromosome 1q32.2-q32.3. 
a) A multigeneration pedigree showing the clinical designation of individuals from the family in which 
PFHBII segregates and haplotype data from a linked region on chromosome 1q32.2-q32.3. Marker order 
(centromeric to telomeric) is indicated on the top left. Filled symbols indicate clinically affected individuals; 
symbols with the letter N, clinically unaffected individual; symbols with a question mark, individuals with a 
clinically uncertain status and symbols with SB, a clinical history of sinus bradycardia. An asterisk indicates 
individuals used in linkage analyses. Parentheses indicate inferred genotype scores and question marks in 
parentheses indicate genotype scores with an indeterminate phase. Solid bars indicate the disease-
associated haplotype. Thin lines represent segments of haplotypes for which the genotypes could not be 
assigned unambiguously.  
b) An enlarged view of the disease-associated haplotype (2-4-6-3-8-4) for markers D1S3753, D1S205, 
D1S414, D1S2810, D1S2780 and D1S425, respectively, and, the recombination events (shown by the 
arrows) in individuals III:9 and III:25 (see section 3.3).  
 
 
 
1  D1S456  5 
6  D1S491  3 
6  D1S70   4 
2  D1S3753  2 
4  D1S205  4 
6  D1S414  6 
3  D1S2810  3 
8  D1S2780  8 
4  D1S425  4 
1  D1S505  4 
4  D1S217  2 
Centromeric 
 
 
 
 
 
 
 
 
 
 
 
 
Telomeric 
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Fig. 3.2 
Representative autoradiograph of a genotype analysis in a family in which PFHBII segregates. 
Radioisotope signals represent the repeat alleles at marker D19S412 on chromosome 19q13.3 (one of the 
excluded candidate loci). Alleles were assigned numerical values (indicated to the left of the 
autoradiograph), as described in section 2.8.7.3. Final genotype scores for each subject are indicated below 
the autoradiograph. Individual pedigree identifier numbers are indicated at the top of the autoradiograph 
 
Table 3.2 
Comparison of heterozygosity values for STR markers at chromosome 1q32.2-q32.3 
Genetic marker Afrikaner population CEPH data Marshfield marker data 
D1S456 0.77 0.75 0.72 
D1S491 0.72 0.75 0.76 
D1S70 0.74 0.49 0.62 
D1S3753 0.88 No data No data 
D1S205 0.74 0.89 0.80 
D1S414 0.77 0.82 0.77 
D1S2810 0.83 0.74 0.72 
D1S2780 0.69 0.67 0.70 
D1S425 0.82 0.73 0.81 
D1S505 0.86 0.82 0.75 
D1S217 0.68 0.61 0.68 
Heterozygosity score of less than 0.60 is underlined 
 
1 
 
 
2 
 
3 
4 
1/2    2/2         2/3      1/2        2/4     
III:1    III:4      III:5    III:6      III:7     
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3.2.2 Lod score calculation 
Pairwise lod score analysis 
Pairwise lod score calculations excluded all but one previously mapped candidate loci as cause of 
PFHBII, by generating lod scores of –2 or less (Table 3.3). Lod score calculations using genotype 
scores at the candidate locus on chromosome 1q32.2-q32.3 (Fig. 3.1) flanking the CMD1D locus 
generated a maximum two point lod score of 3.13 (theta [θ]=0.0) at marker D1S3753 (Table 3.4).  
 
Multipoint analysis 
Multipoint analysis generated a maximum lod score of 3.7 between the disease and markers 
D1S3753 and D1S414. The calculated multipoint lod scores were plotted against the genetic map 
distances between the STR markers at chromosome 1q32.2-q32.3 (Fig. 3.3). The resultant plot 
provides the 90% confidence limit that the PFHBII-causative gene is localised within an interval of 
about 2cM flanked by the genetic markers D1S205 and D1S505 (Fig. 3.3).  
 
Testing lod score stability 
Setting allele frequencies to equal or varying the penetrance (Hodge and Greenberg, 1992) did not 
significantly alter the maximum pairwise and multipoint lod scores and only resulted in changes 
after the second decimal point (data not shown). Because SB is common in the general population 
(Josephson et al., 1991), the lod scores were re-calculated by changing the clinical status of a 
subject with isolated SB (individual III:11) (Table 3.1) from a clinically affected to a clinically 
uncertain (or #possibly affected) status. This analysis generated a maximum pairwise lod score of 
2.83 with D1S3753 and a multipoint score of 3.4 between markers D1S3753 and D1S414 (Table 
3.5). 
 
# - classification used by the Cyrillic program  
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Table 3.3 
Pairwise lod score analysis indicating exclusion of previously mapped causative loci  
 
Locus 
 
0.0 
 
0.01 
Theta (θ) 
0.05 
 
0.1 
 
0.2 
Chromosome 1p1-1q21a 
D1S305 -16.39 -6.20 -2.98 -1.58 -0.39 
D1S2707 -4.47 -1.43 -0.30 0.1 0.39 
D1S176 -6.80 -1.43 -0.93 -0.25 0.19 
Chromosome 2q14-q22b 
D2S2224 -12.32 -6.67 -3.44 -1.98 -0.67 
D2S2339 -0.66 -0.58 -0.38 -0.22 -0.06 
D2S2215 -6.54 -2.09 -0.88 -0.42 -0.99 
D2S112 -6.03 -3.00 -0.83 -0.01 0.50 
Chromosome 3p22-p25c 
D3S1263 -3.94 -3.55 -2.32 -1.51 -0.71 
D3S2303 -7.89 -5.07 -2.34 -1.23 -0.34 
D3S1211 -10.58 -4.59 -2.89 -2.07 -1.17 
Chromosome 6q23d 
D6S262 -4.24 -0.92 -0.26 -0.03 0.1 
Chromosome 7q35-q36e      
D7S505 -3.71 -2.52 -1.06 -0.92 -0.92 
Chromosome 9q12-q13f 
D9S152 -6.30 -1.28 -0.66 -0.37 -0.13 
Chromosome 11p11g 
D11S1344 -7.26 -0.97 -0.25 -0.03 0.17 
Chromosome 14q12h 
MYH7int24 -3.64 -2.65 -1.62 -1.03 -0.43 
Chromosome 15q14i 
ACTC -4.77 -0.81 -0.12 -0.14 0.28 
Chromosome 15q22j 
D15S108 -2.21 -2.08 -1.64 -1.25 -0.72 
Chromosome 19q13.3k 
D19S412 -4.38 -2.81 -1.61 -1.01 -0.44 
D19S902 -12.64 -4.07 -2.11 -1.29 -0.56 
D19S596 -4.84 -1.13 -0.49 -0.26 -0.08 
D19S246 -7.53 -3.23 -1.89 -1.31 -0.72 
Disease-causative genes and clinical disorders (indicated in brackets below) that were excluded by linkage analysis 
were: a  = LMNA (CMD1A); b = unknown aetiology (CMD1H); c = SCN5A (CMD1E, PCCD and CCD); d = 
CMD1F; e = PRKAG2 (CMH4); f = unknown aetiology (CMD1B); g = MYBPC3 (CMH4); h = MYH7 (CMH1); i = 
ACTC (IDC); j = TPM1 (CMH3); k = unknown aetiology (PFHBI, ICCD) (refer to Fig. 1.2, 1.5 and 1.7). 
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Table 3.4 
Pairwise lod scores between PFHBII and markers on chromosome 1q32.2-q32.3 
 
Locus 
 
0.0 
 
0.01 
Theta 
0.05 
(θ) 
0.1 
 
0.2 
Zmax (θ) 
 
D1S456 -0.99  0.62 1.11 1.16 0.92 1.16 (0.1) 
D1S491 -1.55  0.84 1.38 1.48 1.33 1.48 (0.1) 
D1S70 -0.94  0.68 1.22 1.31 1.18 1.31 (0.1) 
D1S3753  3.13  3.08 2.88 2.62 2.06 3.13 (0.0) 
D1S205  0.38  0.37 0.31 0.25 0.14 0.38 (0.0) 
D1S414  2.51  2.47 2.29 2.06 1.57 2.51 (0.0) 
D1S2810  1.97  1.94 1.82 1.66 1.30 1.97 (0.0) 
D1S2780  1.95  1.91 1.78 1.61 1.25 1.95 (0.0) 
D1S425  0.12  0.12 0.10 0.08 0.05 0.12 (0.0) 
D1S505 -0.51  1.09 1.60 1.66 1.45 1.66 (0.1) 
D1S217 -1.52 -0.74 0.39 0.74 0.82 0.82 (0.2) 
Maximum lod score is underlined 
 
Table 3.5 
Pairwise lod scores generated by changing the phenotypic status of individual III:11 
 
Locus 
 
0.0 
 
0.01 
Theta 
0.05 
(θ) 
0.1 
 
0.2 
Zmax (θ) 
 
D1S456 -1.29  0.32 0.84 0.92 0.76 0.92 (0.1) 
D1S491 -1.85  0.55 1.10 1.22 1.12 1.22 (0.1) 
D1S70 -1.24  0.39 0.94 1.06 0.98 1.06 (0.1) 
D1S3753  2.83  2.79 2.61 2.37 1.86 2.83 (0.0) 
D1S205  0.30  0.29 0.24 0.19 0.09 0.30 (0.0) 
D1S414  2.43  2.39 2.22 2.00 1.53 2.43 (0.0) 
D1S2810  1.90  1.87 1.75 1.59 1.26 1.90 (0.0) 
D1S2780  1.87  1.84 1.71 1.55 1.21 1.87 (0.0) 
D1S425  0.11  0.11 0.09 0.07   0.04 0.11 (0.0) 
D1S505 -0.59  0.99 1.51 1.58 1.40 1.58 (0.1) 
D1S217 -1.68 -1.00 0.12 0.49 0.63   0.63 (0,2) 
Maximum lod score is underlined 
 
 
Fig. 3.3
Multipoint lod score curve at chromosome 1q32.2-q32.3.
Multipoint lod scores for the PFHBII locus versus markers used in linkage analysis. The recombination distance (θ) is plotted on the 
x-axis from an arbitrary origin, set at marker D1S3753. The 1-lod-down 90% support interval places the likely location of the 
PFHBII gene within a 2cM interval telomeric of D1S205 and centromeric of D1S505. 
x-axis: 1 unit = 0.5cM; y-axis: 1 unit = 0.5 lod score units
cen = centromeric; tel = telomeric
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3.3 Haplotype analysis at chromosome 1q32.2-q32.3 
The eight clinically affected individuals used in the linkage study carried a common inherited 
chromosomal haplotype of 2-4-6-3-8-4 for markers D1S3753, D1S205, D1S414, D1S2810, 
D1S2780 and D1S425, respectively (Fig. 3.1a and b). Recombination breakpoints, which were 
identified in individual III:9 and III:25, localised the PFHBII-associated gene to within a region 
spanning 3.9cM (2.85Mb) (physical map distances obtained from the Ensembl database) telomeric 
of D1S70 and centromeric of D1S505 (Fig. 3.1a and b). The haplotype data corresponded to the 1-
lod-down likelihood analysis (Fig. 3.3), further supporting the localisation of the PFHBII-causative 
gene. 
 
3.4 Construction of an integrated genetic, physical and transcript map 
PCR-based mapping of markers onto genomic clones 
The selected STR markers at chromosome 1q32.2-q32.3 (Table 2.1) were mapped onto the BAC, 
PAC and YAC clone-inserts using a PCR-based reaction that generated an amplification product 
(section 2.10.4) (Fig. 3.4). A PCR amplification product generated by an STR marker and genomic 
clone-insert DNA as a template indicated that the specific marker was physically mapped onto the 
insert of that genomic clone (Fig. 3.4). Thus, the PCR-based mapping data presented in this section 
(using marker D1S491) was incorporated onto a physical map of the PFHBII locus, as shown on 
Fig. 3.5. This iterative process was also used to map markers D1S70, D1S3753, D1S205, D1S414, 
D1S2810, D1S2780, D1S425 and D1S505 onto their respective genomic clones (see Fig. 3.5). 
Initially, the wet-bench mapping data for markers D1S70, D1S3753, D1S205 and D1S414 
corresponded to previous physical and transcript data that had been generated by Schutte et al., 
(2000). However, during the course of the study, the availability of chromosome 1 sequence data 
facilitated the use of bioinformatics-based mapping strategies (see sub-section below) in favour of 
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the PCR-based approach. Therefore, the present study incorporated both approaches in order to 
generate a validated and high-resolution map of the PFHBII locus. 
 
 
 
 
 
 
Fig. 3.4 
Representative agarose gel analysis of mapping an STR marker onto genomic clone-inserts.  
A 1.5% agarose gel analysis shows PCR amplification products generated using the STR marker D1S491 
and template DNA extracted from genomic clones. This PCR-based result is shown in Fig. 3.5. 
Lane 1 = DNA marker VI; Lane 2 = clone RP1-272L16 template DNA; Lane 3 = clone RP1-28O10 template 
DNA; Lane 4 = clone CTA-55I10 template DNA; Lane 5 = genomic template DNA (positive control); Lane 
6 = chromosome 19 BAC template DNA (negative control); Lane 7 = water blank 
 
Bioinformatics-based mapping of STR markers and gene sequences onto genomic clones 
Bioinformatics alignment algorithms at the Sanger Centre and NCBI website (section 2.11.1) were 
used to map electronic versions of STR markers and gene sequences (or transcripts) onto electronic 
versions of the selected genomic clones at chromosome 1q32.2-q32.3. The in silico STR mapping 
data was used as an adjunct to PCR-based mapping analyses, and, the combined data was used to 
generate a comprehensive integrated genetic, physical and transcript map of the PFHBII locus (Fig. 
3.5). The gene transcripts positioned onto the physical map of the PFHBII locus (Fig. 3.5) will be 
discussed in the section below. 
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Fig. 3.5
Integrated genetic, physical and transcript map of the PFHBII locus. 
The individual clones comprising the contig spanning the PFHBII locus are numbered: 1 = CTA-55I10; 2 = RP1- 272L16; 3 = RP1-28O10; 4 = RP3-434O14; 5 = 
CTA-447D17; 6 = CTA-321I20; 7 = RP4-782D21; 8 = CTA-11C7; 9 = RP5-879K22; 10 = YAC 937D4. Genetic markers were positioned onto clones using wet-
bench and in silico techniques. A solid bar represents the PFHBII critical interval flanked by D1S70 and D1S505. Vertical (dash) lines indicate the markers were 
mapped onto the genomic clone-insert by PCR-based mapping or bioinformatics analysis. The seven candidate genes indicated in blue were screened for the PFHBII-
causative mutation. The candidate genes indicated in red have been prioritised for future mutation screening. Intermarker physical map distances are shown in 
megabases (Mb)
CMD1D = dilated cardiomyopathy locus 1D; KCNH1 = potassium channel; KIAA0205 = putative acyltransferase; LAMB3 = laminin β3; NEK2 = never in mitosis A-
related kinase 2; NM_018254 = RCOR3 (REST co repressor); PPP2R5A = protein phosphatase 2A b56alpha; RAMP = retinoic acid regulated nuclear matrix 
associated protein; SLC30A1 = zinc transporter 1; SYT14 = synaptotgamin XIV; T3JAM =adapter protein that interacts with a cytoskeletal protein; VWS59 (MART2) 
= novel human gene.
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3.5 Candidate gene search at chromosome 1q32.2-q32.3 
3.5.1 Selecting candidate genes for mutation analysis 
Database searches (NCBI database builds 28 and 31) indicated that, by genome location, 27 genes 
map to within the PFHBII locus (Appendix G). Pathological mutations associated with three of the 
27 genes mapped to within the PFHBII locus have been implicated as cause of a skin disease 
(junctional epidermolysis bullosa [JEB]) (Pulkkinen et al., 1994), a disease associated with the 
formation of ovarian cysts (cortisone reductase deficiency [CRD]) (Draper et al., 2003) and two 
diseases associated with orofacial defects (VWS and politeal pterygium syndrome [PPS]) (Kondo 
et al., 2002) (Table 3.6). None of these described defects have been linked to electrophysiological 
or structural defects of the heart. Furthermore, heterozygous individuals carrying the causative 
mutation of the recessive condition, JEB (Pulkkinen et al., 1994) (Table 3.6), do not show any 
cardiac conduction abnormalities. Therefore, bioinformatics similarity analyses were used to 
prioritise plausible candidate genes, from the 24 other genes mapped to within the PFHBII locus, 
for mutation analysis based on alignment significance scores (refer to section 2.11.3). However, it 
has to be mentioned that laminin β3, which is encoded by LAMB3 and in which JEB-causative 
mutations have been described (Table 3.6), is an extracellular matrix structural protein linked to the 
sarcolemma (Pulkkinen et al., 1994). Previously, Norgett et al., (2000) and Tsubata et al., (2000) 
had demonstrated that defects in the sarcolemmal-linked proteins desmoplakin, δ-sarcoglycan and 
plakoglobin could cause DCM. Thus, based on this evidence, it was opted to rank LAMB3 as a 
possible PFHBII candidate gene (see paragraph hereafter), even though described defects in the 
gene has not been associated with any form of cardiac abnormality (see Table 3.6). 
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Table 3.6 
Diseases caused by defects in genes mapped to within the PFHBII locus  
Gene OMIM Disease  Phenotypic description Reference 
LAMB3  
(laminin β3) 
150310 Junctional 
epidermolysis 
bullosa (JEB) 
Skin blisters within the dermal-
epidermal basement membrane 
Pulkkinen et 
al., (1994);  
HSD11B1 
(hydroxysteroid 11- 
beta dehydrogenase) 
600713 Cortisone reductase 
deficiency (CRD) 
Hirsutism (increased female 
body hair), obesity, infertility 
and hyperandogenism 
Draper et al., 
(2003) 
IRF6  
(interferon regulatory 
factor 6) 
119300, 
119500 
VWS, popliteal 
pterygium 
syndrome (PPS) 
Lip pits with cleft lip or palate 
(VWS); cleft lip or palate, 
genital abnormalities and 
webbing of skin (PPS) 
Kondo et al., 
(2002) 
 
Based on the selection criteria described in section 2.11, the seven candidate genes selected for 
mutation screening (in order of prioritisation) were a gene encoding an K+ channel (KCNH1) 
(accession number AJ001366) (Occhiodoro et al., 1998), a protein phosphatase (PPP2R5A) 
(accession number L42373) (McCright and Virshup, 1995), an adapter protein that interacts with a 
cytoskeletal protein (T3JAM) (accession number AL049667) (Dadgostar et al., 2003), an 
extracellular matrix protein laminin β3 (LAMB3) (accession number D37766) (Gerecke et al., 
1994), a retinoic acid-regulated nuclear matrix associated protein (RAMP) (accession number 
AF195765) (Cheung et al., 2001), a putative acyltransferase (KIAA0205) (accession numbers 
D86960) (Nagase et al., 1996) and a novel human gene encoding an acyltransferase-like protein 
(*VWS59 or MART2) (accession number NM_018194) (B.C Schutte, personal communication) 
(Fig. 3.5). A summary of the selected candidate genes, the most significant bioinformatics 
similarity alignment results and the reasoning for selecting the genes are provided in Table 3.6.  
 
* - the gene name was provided by Dr. B Schutte (University of Iowa) in October 2000. The provisional 
name for VWS59 is indexed as melanoma antigen recognized by T cells 2 (MART2) in the NCBI database. 
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Table 3.7 
Candidate genes selected for mutation screening 
Candidate gene Gene/protein signature 
similarity 
E-value  
(max) 
Comparative disease or 
pathophysiological association  
KCNH1 K+ and Na+ channels 0.0 K+ and Na+ channels are associated 
with arrhythmias and conduction 
disorders (Curran et al., 1995; Wang 
et al., 1995; Chen et al., 1998; Schott 
et al., 1999; Tan et al., 2001) 
PPP2R5A Protein phosphatases 1.8e-275 Mouse model studies indicate that 
mutations in a phosphatase 
(calcineurin), are associated with 
hypertrophy (Molkentin et al., 1998) 
T3JAM Adapter protein that 
interacts with myosin class 
II heavy chain (a 
cytoskeletal protein)  
6.5e-116 Cytoskeletal proteins (e.g. desmin and 
cardiac muscle LIM protein) are 
associated with DCM and HCM (Li et 
al., 1999; Knöll et al., 2002; Geier et 
al., 2003; sections 1.3.2, 1.3.3 and 
1.3.6). A mutation in an adapter 
protein, ankyrin 2, is associated with 
LQTS type 4 (LQT4) (Mohler et al., 
2003) 
VWS59 
(MART2) 
KIAA1173 (acyltransferase-
like protein) 
3.7e-77 Acyltransferases (e.g. tafazzin) are 
associated with BTHS and DCM 
(Bione et al., 1996) 
LAMB3 LAMA2 (laminin α-2) (an 
extracellular matrix 
protein) 
4e-39 Extracellular matrix proteins (e.g. 
merosin) are associated with juvenile 
DCM and muscular dystrophy 
(Spyrou et al., 1998) 
RAMP GTPase-protein containing 
a WD40 repeat 
2e-32 WD40 domains act as 
adaptor/regulatory modules in signal 
transduction or are involved in pre-
mRNA processing and cytoskeleton 
assembly; altered cytoskeletal 
architecture has been implicated in 
DCM (section 1.3.3.1.2) 
KIAA0205 G4.5 (tafazzin) 
(acyltransferase) 
2e-13 Acyltransferases (e.g. tafazzin) are 
associated with BTHS and DCM 
(Bione et al., 1996) 
Candidate genes are listed in descending order of priority, starting with the gene with the most significant E-value. 
BTHS = Barth syndrome; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; Na+ = sodium; K+ 
= potassium; LAMB3 = laminin β3; LQTS = long QT syndrome; KCNH1 = K+ channel; KIAA0205 = a putative 
acyltransferase; PPP2R5A = protein phosphatase; RAMP = a retinoic acid-regulated nuclear matrix associated 
protein; T3JAM = an adapter enzyme that interacts with a cytoskeletal protein; VWS59 = a novel human gene 
encoding an acyltransferase-like protein 
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3.6 Mutation screening of seven prioritised candidate genes 
3.6.1 PCR-SSCP analysis and characterisation of sequence variants  
Mutation analyses of KIAA0205, PPP2R5A, RAMP and T3JAM did not identify any PCR-SSCP gel 
electrophoresis variant patterns (Fig. 3.6). Variant PCR-SSCP electrophoretic mobility patterns 
were identified in three selected candidate genes, namely, KCNH1, VWS59 (MART2) and LAMB3 
(Table 3.7). For each of the three genes, the variant patterns were observed in affected and 
unaffected members of the PFHBII family (see section 2.12.2 for individuals used in the PCR-
SSCP analysis), as well as in subjects from a Caucasian Afrikaner control panel (discussed further 
in section below). Sequence characterisation of individual samples representative of each of the 
different electrophoretic mobility patterns identified three separate nucleotide substitutions. These 
sequence substitutions were either identified in an exon, but did not alter an amino acid residue (see 
the example hereafter), or were located away from the splice consensus sequences of an intron 
(Table 3.7). Additional direct automated sequence analyses (see section 2.12.5.3) identified a 
thymine (T) to cytosine (C) (T>C) substitution in the 3’-untranslated region (UTR) of KCNH1 and 
a single nucleotide substitution in exon 11 of RAMP, the latter resulted in a substitution of a 
threonine with lysine amino acid residue (Table 3.7). Neither of these sequence variations was 
detected by PCR-SSCP analysis. The implications of these results as a reflection of the relative 
sensitivity of the PCR-SSCP and sequence analyses will be discussed at greater length in section 
4.8.3.1. 
 
The sequence variations identified in KCNH1 and VWS59 were submitted to the NCBI SNP 
database, and, subsequently, were all described by other investigators in other populations (Table 
3.7). The nucleotide substitutions identified in the present study in LAMB3 and RAMP had, at the 
time, already been identified in other population groups in Japan and North America (Table 3.7). 
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Representative examples of the process of identifying the sequence variants in KCNH1 and RAMP 
are provided below. 
 
   KIAA0205          PPP2R5A 
 
  
 
Fig. 3.6 
Representative PCR-SSCP gel electrophoresis analysis of genes in which no mobility variations were 
identified. 
No variant electrophoretic mobility patterns were identified in KIAA0205, PPP2R5A, RAMP and T3JAM. 
A representative of these PCR-SSCP analyses is provided in the figures above, which show analyses of 
exons 5 and 6 of KIAA0205 and exons 8 and 9 of PPP2R5A.  
II:7, III:1 and III:9 = clinically affected subjects; III:4 and III:8 =  clinically unaffected subjects (see Fig. 
3.1) 
II:7     III:1    III:9    III:4    III:8            II:7     III:1    III:9   III:4    III:8 II:7   III:1  III:9  III:4   III:8    II:7    III:1   III:9   III:4  III:8 
exon 5            exon 6 exon 8     exon 9
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Mutation analysis of KCNH1 
Gel electrophoresis analysis by PCR-SSCP indicated two different electrophoretic patterns in exon 
11a of KCNH1 (Fig. 3.7a). One variant pattern (designated C/C) (Fig. 3.7a) segregated in two 
clinically affected subjects (individuals II:7 and III:9) and a two clinically unaffected subjects 
(individuals III:4 and III:6) (refer to subjects used, section 2.12.2); the other pattern (designated 
T/T) (Fig. 3.7a) was observed in a clinically unaffected and a clinically affected subject 
(individuals III:1 and III:8, respectively) (see Table 3.1). The same PCR-SSCP mobility variant 
patterns in exon 11a were identified in members of the Caucasian Afrikaner subpopulation (Fig. 
3.7b).  
 
Sequence analysis of an individual sample with the C/C pattern identified a T>C transition at 
nucleotide position 2225 (Fig. 3.8a and b) (Table 3.7). This sequence variant had previously been 
identified in a North American population of unknown ethnicity (submitted by Lee714008, NCBI 
SNP accession number ss1537837). Translation of the nucleotide sequence of a subject with the 
T>C transition indicated that the variation did not change an aspartic acid residue at the amino acid 
codon position 712, that is, it was a synonymous substitution. The PCR-SSCP analyses of 30 
Caucasian subjects showed that frequency of the T- and C-alleles in the Afrikaner subpopulation 
were 0.900 and 0.100, respectively. No data is currently available that indicates the frequency of 
the T- and C-alleles in the population described by Lee714008 (Table 3.7).  
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a)     b) 
 
              
 
 
 
 
Fig. 3.7 
PCR-SSCP analysis of exon 11a of KCNH1.  
a) A 10% mildly denaturing polyacrylamide gel showing the electrophoretic variant patterns in exon 11a of 
KCNH1, which segregated in members of the PFHBII-affected family.  
b) A representative PCR-SSCP analysis of the segregation of the different electrophoretic mobility patterns 
in a Caucasian Afrikaner panel.  
Based on sequence analyses (see text), the different electrophoretic patterns were designated C/C and T/T 
(indicated below the PCR-SSCP image) to facilitate scoring the different alleles that segregated in the 
Caucasian Afrikaner control panel.  
C = cytosine; T = thymine 
 
  
II:7         III:8 
     C/C  T/T  C/C   T/T     T/T     T/T    T/T     T/T    C/C    C/C     T/T   T/T   T/T      T/T   T/T    T/T 
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a)      nt 2225 (T>C) 
        ↓ 
 
 
 
 
b) BLAST analysis 
Ind III:1   :   gattgtgttccggaagatcagcgacgtgaaacgtgaagaggaagaacgcatgaaacgaaa 79 
                   | | | | | | | | | | | | | | | | | | | | | |*| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq:      gattgtgttccggaagatcagcgatgtgaaacgtgaagaggaagaacgcatgaaacgaaa 1778 
 
Ind III:1:      gaatgaggcccccctgatcttgcccccggaccaccctgtccggcgcctcttccagagatt 139 
                   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq        gaatgaggcccccctgatcttgcccccggaccaccctgtccggcgcctcttccagagatt 1838 
                                                                        
Ind III:1:      ccgacagcagaaagaggccaggctggcagctgagagagggggccgggacctggatgacct 199 
                   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq       ccgacagcagaaagaggccaggctggcagctgagagagggggccgggacctggatgacct 1898 
                                                                         
Ind III:1       agatgtggagaagggcaatgtccttacagagcatgcctccgccaaccacagcctcgtgaa 259 
                   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq       agatgtggagaagggcaatgtccttacagagcatgcctccgccaaccacagcctcgtgaa 1958 
 
Ind III:          ggccagcgtggtcaccgtgcgtgaga 265 
                    | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq        ggccagcgtggtcaccgtgcgtgaga 1984                         
 
Fig. 3.8 
Sequence analysis of exon 11a of KCNH1.  
a) Sequence analysis of individual III:1 indicated a T>C transition at nucleotide position 2225.  
b) The BLAST alignment of the nucleotide sequence of individual III:1 against the KCNH1 coding sequence 
obtained from the NCBI database (accession number AF078741) indicating the nucleotide mismatch (*). 
Nucleotide alignment co-ordinates do not correspond to the nucleotide position at which the sequence 
variation was identified. 
Db seq = database sequence; Ind = individual identifier, nt = nucleotide 
 
 
 T 
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Assessment of mutation screening sensitivity and the identification of sequence variants 
To test the sensitivity of the PCR-SSCP mutation-screening regimen used in the present study, 29 
exons were screened by direct automated sequence analysis (see section 2.12.5.3). The following 
sub-sections provide a synopsis of two exons in which sequence variations were identified.  
 
KCNH1 
Using primer set 11d of KCNH1 (Appendix F), sequence analysis of members of the PFHBII-
affected family identified a cytosine to adenine (A) (C>A) transversion at nucleotide position 2963 
(Fig. 3.9a and b) (Table 3.7). The sequence variation was identified in two clinically unaffected 
subjects (individual III:4 and III:6) (Table 3.1) and, subsequently, was submitted to the NCBI SNP 
database (Brincor, accession number ss4383560) (submitted on 20/02/2002). Later, a study by 
another group in a Japanese population identified the same sequence variant (IMS-JST147545, 
accession number ss4976734) (date of submission on 12/08/2002), and, in that population, the 
frequency of the C- and the A-alleles was 0.384 and 0.616, respectively. The frequency of the C>A 
nucleotide substitution was not calculated in the Afrikaner panel because it was not detected by 
PCR-SSCP analysis. Additionally, allele specific restriction enzyme analysis (Maeda et al., 1989) 
was not performed because the sequence variation did not alter a restriction enzyme site. However, 
such variants could be detected by other methods, such as primer extension analyses (Makridakis 
and Reichardt, 2001), for example. 
 
RAMP 
Direct sequence analyses of exon 11b of RAMP identified an A>C transversion at nucleotide 
position 34260 (Fig. 3.10a and b), which segregated exclusively in two clinically affected members 
of the PFHBII-affected family (individuals II:7 and III:20, father and daughter) (Fig. 3.1). The 
sequence variation was not identified upon sequence analyses of the other clinically affected 
members of the PFHBII-affected family or in five subjects from the Caucasian Afrikaner panel. A 
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subsequent analysis of the NCBI SNP database indicated that the A>C sequence variation had been 
identified in three North American populations (Table 3.7).  
 
 
a) 
      nt 2963 (C>A)     
                 ↓ 
 
 
 
b) BLAST analysis        
Ind III:8       gccacagtcctggaggtgaggcacgagctgaaggaggacatcaaggccttaaacgccaaa 65 
                   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq        gccacagtcctggaggtgaggcacgagctgaaggaggacatcaaggccttaaacgccaaa 2918 
 
Ind III:8       atgaccaatattgagaaacagctctctgagatactcaggatattaacttccagaagatcc 125 
                   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq       atgaccaatattgagaaacagctctctgagatactcaggatattaacttccagaagatcc 2978 
 
Ind III:8       tctcagtctcctcaggagttgtttgaaatatcgaggccacagtccccagaatcagagaga 185 
                   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq        tctcagtctcctcaggagttgtttgaaatatcgaggccacagtccccagaatcagagaga 3038 
 
Ind III:8        gacatttttggagccagctgagaggtctatttaaaaaaaaagtcagagacagatacctac 245 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |*| 
Db seq        gacatttttggagccagctgagaggtctatttaaaaaaaaagtcagagacagatacctacc 3098 
 
Ind III:8       aacc 249 
                   | | | | 
Db seq       aacc 3102 
 
Fig. 3.9 
Sequence analysis of the 3’ UTR of KCNH1.  
a) Direct sequence analysis (individual III:8) identified a C>A transversion at nucleotide position 2963. 
b) The BLAST alignment of the nucleotide sequence of individual III:8 against the KCNH1 coding sequence 
indicating the nucleotide mismatch (*). Nucleotide alignment co-ordinates do not correspond to the 
nucleotide position at which the sequence variation was identified. 
Db seq = database sequence; Ind = individual identifier, nt = nucleotide 
 
 C 
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Alignment analysis of the RAMP variant 
The NCBI SNP database indicated that the nucleotide alteration at position 34260 in RAMP 
resulted in a Thr694Lys amino acid substitution (Table 3.7). In order to assess whether the amino 
acid substitution possibly had a pathological consequence (from “Guidelines for deciding whether a 
DNA sequence change is pathogenic”, Strachan and Read, 1999), the L2DTL (RAMP) protein 
sequence derived from translating the nucleotide sequence of individual II:7 (see section 2.12.5.4) 
was compared to the human and mouse L2DTL sequences obtained from the NCBI database 
(accession numbers NP_057532 and AK054412). This alignment analysis showed a species 
conserved threonine residue at human codon position 694 (mouse equivalent codon position 693) 
(Fig. 3.11). Although further analyses were not pursued, this finding was interesting as it is possible 
that the sequence variation could play a modifying role in the pathogenesis of PFHBII (also see 
section 4.7).   
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a)          nt 34260 (A>C) 
      ↓ 
 
 
b) BLAST analysis 
 
II:7                ttgctggtaaccaggaagaccttagtaaggactctctaggtcctaccaaatcaagcaaaa 180 
                     | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq          ttgctggtaaccaggaagaccttagtaaggactctctaggtcctaccaaatcaagcaaaa 35229 
 
II:7                ttgaaggagctggtaccagtatctcagagcctccgtctcctatcagtccgtatgcttcag 240 
                     | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq          ttgaaggagctggtaccagtatctcagagcctccgtctcctatcagtccgtatgcttcag 35289 
 
II:7               aaagctgtggaacgctacctcttcctttgagaccttgtggagaagggtctgaaatggtag 300 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq        aaagctgtggaacgctacctcttcctttgagaccttgtggagaagggtctgaaatggtag 35349 
                                                                          
II:7               gcaaagagaatagttccccagagaataaaaactggttgttggccatggcagccaaacgga 360 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq        gcaaagagaatagttccccagagaataaaaactggttgttggccatggcagccaaacgga 35409 
 
II:7               aggctgagaatccatctccacgaagtccgtcatcccagacacccaattccaggagacaga 420 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Db seq        aggctgagaatccatctccacgaagtccgtcatcccagacacccaattccaggagacaga 35469                                                        
 
II:7               gcggaaagacattgccaagcccggtaagtcagcagtggtgggaagatacatttc 474 
                    | | | | | | | | | |*| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db seq         gcggaaagaaattgccaagcccggtaagtcagcagtggtgggaagatacatttc 35523       
 
Fig. 3.10 
Sequencing analysis of exon 11b of RAMP.  
A novel sequence variation was identified in exon 11b of RAMP. a) Sequence analysis of individual II:7 
identified an A>C transversion at nucleotide position 34260. b) The BLAST alignment of the nucleotide 
sequence of individual II:7 against the RAMP coding sequence (NCBI accession number AF195765) shows 
the nucleotide mismatch (indicated by an asterisk). 
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Fig. 3.11 
Protein sequence alignment analysis of L2DTL. 
ClustalW analysis of the alignment of the protein sequence of individual II:7 against the human and mouse 
L2DTL sequences, which were obtained from the NCBI database (accession numbers NP_057532 and 
AK054412). The position of the threonine-694 to lysine amino acid substitution identified upon sequence 
analyses of individual II:7 is indicated by the arrow.  
Db seq = database sequence; Ind = individual identifier, nt = nucleotide; MusL2DTL = mouse RAMP 
protein sequence; RAMPind7 = translated protein sequence for individual II:7; RAMPdb = human RAMP 
protein sequence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.8  
Summary of the sequence variations identified in the present study 
Candidate 
Gene 
Nucleotide 
change and 
position 
Amino acid 
residue change 
Allele frequency in the 
Afrikaner subpopulation  
NCBI SNP accession 
number and date of 
submission 
Other NCBI SNP entries for the 
same sequence variant and date of 
submission  
Allele frequency in other 
populations 
KCNH1 T>C 
nt 2225 
Asp712Asp T = 0.9; C = 0.1 Not submitted Lee714008 ss1537837; 13/09/2000 No data available 
KCNH1 C>A 
nt 2963 
3’ UTR Not determined Brincor ss483560 
20/02/2002 
IMS-JST147545 ss4976734; 
12/08/2002 
C = 0.384; A = 0.616 
VWS59 G>C 
nt 31624 
Leu178Leu G= 0.714 C = 0.286 
 
Brincor ss2978390 
07/03/2001 
YUSUKE|IMS-JST041633 
ss3231548; 05/09/2001 
BCM_SSAHASNP ss9851849; 
27/06/2003 
CSHL-HAPMAP|CSHL-HuFF-
200402 ss19845568; 21/02/2004  
No data available  
LAMB3 A>C 
nt 2591 
Intronic A = 0.525; C = 0.475 Not submitted YUSUKE|IMS-JST004433 
ss2991738; 24/05/2001 
A = 0.702; C = 0.298 
RAMP A>C 
nt 34260 
Thr694Lys Not determined Not submitted BCM_SSAHASNP ss9829563; 
27/06/2003 
WI_SSAHASNP ss11361027; 
03/07/2003  
SSAHASNP|WGSA-200403 
ss20430185; 18/03/2004 
No data available 
A = adenine; Asp = aspartic acid; C = cytosine; G = guanine; Leu = leucine; Lys = lysine;  nt = nucleotide position; T = thymine; Thr = threonine; UTR = untranslated region 
 
 
 
 116
CHAPTER 4 
Discussion 
Index             Page 
4.1 The clinical profile of PFHBII revisited        117 
4.2 Possible influences on disease presentation       119 
4.3 Mapping the PFHBII-causative locus        122 
4.4 Implications of mapping the PFHBII locus       125 
4.5 Genealogical studies and the origins of PFHBII       126 
4.6 Haplotype analysis at the PFHBII locus: diagnostic implications     129 
4.7 Rationale for selecting candidate genes for mutation analyses     130 
4.8 Study limitations           134 
 4.8.1 Linkage analysis         134 
 4.8.2 Bioinformatics analysis and sequence status at chromosome 1q32.2-q32.3  134 
 4.8.3 Limitations of laboratory techniques       136 
  4.8.3.1 PCR-SSCP analysis        136 
  4.8.3.2 Study design: screening coding and intron-exon junctions    137 
4.9 Changing paradigms: implications for selecting candidate genes in future mutation  
      screening            138 
4.10 Conclusion           141 
 
 117
Discussion 
In theory there is no difference between theory and practice, but in practice there is. 
- Anonymous 
 
4.1 The clinical profile of PFHBII revisited  
A detailed clinical specification of a disorder is a prerequisite for accurate mapping analyses, as 
incomplete or incorrect clinical diagnoses may increase the chance of false linkage associations 
(Ott, 1999). Therefore, the present linkage study provided impetus to perform follow up 
examinations and reassess the PFHBII-affected family described by Brink and Torrington (1977). 
Three important findings that resulted from this extensive clinical investigation are discussed 
below. 
 
Redefining the clinical classification of PFHBII 
Since the original study by Brink and Torrington in 1977, PFHBII has been classified as a pure 
cardiac conduction disease, although, in 1986, A. Brink speculated that the disorder might be 
caused by an underlying “cardiomyopathy” (Van der Merwe et al., 1986). Consequently, the present 
study provides the first evidence that a cardiomyopathy is indeed a feature of the disorder, by 
demonstrating a familial occurrence of DCM and progression to congestive heart failure in the 
PFHBII-affected family (Fernandez et al., 2004). In so doing, the present study redefines the 
clinical classification of PFHBII, 27 years after its first description.  
 
Familial SB and early detection 
The clinical study also demonstrated that individuals with isolated SB could show progression to 
CHB or DCM (Fernandez et al., 2004). Although isolated SB may be considered “normal” in the 
general population (Josephson et al., 1991), a study by Sarachek and Leonard (1972) demonstrated 
a familial occurrence of this feature in a number of North American families with cardiac 
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conduction disease. Thus, the recognition of a familial occurrence of isolated SB in the PFHBII-
affected family could facilitate the early identification of clinically affected subjects before they 
show progression to heart failure. The prognostic implication of early detection is important 
because members of the PFHBII-affected family have demonstrated progression from conduction 
defects to end-stage heart failure in as little as five years (Fernandez et al., 2004). By detecting the 
disease at an early stage, clinicians could possibly slow progression to heart failure by 
recommending the use of angiotensin converting enzyme (ACE) inhibitors, which, by lowering the 
pressure inside blood vessels, reduce the effort needed by the heart to pump blood through the body 
(Takano et al., 2003).  
 
An AV conduction system defect 
The third conclusion drawn from the clinical investigation was that the conduction defect in 
PFHBII occurs in the proximity of the AV node or Bundle of His (forming the AV conduction 
system) (refer to Fig. 1.6), and not in the ventricular conduction system (section 3.1) (Fernandez et 
al., 2004). This finding is particularly significant in a South African context, because, for many 
years, it has been suggested that PFHBI (a ventricular conduction system disease) (see section 
1.4.3.1) and PFHBII may be clinical extremes of the same disease (P. Brink, personal 
communication). This misconception had also resulted in the mis-diagnosis of subjects with 
PFHBII as having PFHBI (P. Brink, personal communication).  
 
Consequently, by publishing a clinical profile of PFHBII, it is envisaged that, at least in South 
Africa, other individuals or families with the disorder will be identified. However, this may not be a 
straightforward task, given that some individuals in the PFHBII-affected family have shown 
progression from conduction abnormalities to DCM, while others only presented with conduction 
defects, and one subject (individual III:26) (Table 3.1), developed DCM without preceding 
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conduction defects. This suggests that other factors can influence the phenotypic expression of 
PFHBII. The section below provides two possible reasons for the differences in the phenotype. 
 
4.2 Possible influences on disease presentation 
Geographical isolation and lifestyle  
Brink and Torrington (1977) indicated that the ancestors of the family described in the present study 
had settled in a geographically isolated region in the Eastern Cape Province of South Africa (this 
district was integrated into the Southern Cape Province of South Africa in 1994). A number of 
subjects from the PFHBII-affected family still reside in this geographically isolated region, whereas 
historically, other families had relocated to present-day urban centers (A. Goosen, personal 
communication) (Fig. 4.1).  
 
Members of the PFHBI-affected family that live in the isolated district have a rural lifestyle and are 
primarily, subsistence woodcutters (lumberjacks) (P. Brink, personal communication) - an 
occupation requiring a fair amount of physical activity. It is interesting that past and present clinical 
data or family histories have, to date, not identified DCM in any subjects from the rural Southern 
Cape Province community (data not shown). On the other hand, all the subjects that have been 
identified with DCM (individuals II:12, III:2, III:9, III:25 and III:26) (Table 3.1) are from urban 
centres in South Africa (Fig. 4.1). It could be argued that the availability of better medical facilities 
in the urban centres could account for the different diagnoses. However, all the subjects described 
in the present study, even those that live in the remote rural districts mentioned above, had been 
clinically assessed in a nearby city where there are proper ECG and echocardiographic facilities.  
 
For all clinical examinations performed in the present study, subjects were interviewed to ascertain 
the influence of external influences such as exercise and alcohol consumption, the latter factor can 
 120
significantly contribute to the development of cardiomyopathy (see section 1.1) (Braunwald, 1980). 
It was established that the lifestyle of the rural and urban PFHBII-affected family members was 
similar, although the subjects that are woodcutters are physically more active. Thus, it is this 
writer’s opinion that a physically active lifestyle may offset the progression to DCM, possibly 
because of the compensatory hypertrophic response that is normally associated with sustained 
physical exercise (Aniansson et al., 1992). This data could form the basis of an interesting future 
study, although, it is possible that different rural and urban dietary habits may also be a factor in the 
phenotypic expression of PFHBII (Dracup et al., 1994). If environmental factors do play a role in 
the disease presentation, the study may lead to the suggestion of lifestyle changes that could 
improve disease-management or prognosis. 
 
To deviate slightly from the topic, the lives of woodcutters from the same region in which a large 
percentage of subjects from the PFHBII-affected family currently reside have been portrayed in the 
novel “Kringe in die bos” (“Circles in a forest”) by the Dalene Matthee (Penguin Books). This 
narrative should provide interesting insights into the lifestyle of the family described in the present 
study.   
 
Genetic modifying factors 
The above hypothesis suggests external factors may contribute to variations in disease expression. 
However, there is an equal possibility that the differences may be due to genetic factors, or, 
probably, a combination of both. Although the precise causes are not yet known, it has been 
suggested that variability in phenotypic expression in subjects with HCM caused by the same 
mutation, might be caused by genetic modifying factors (Moolman-Smook et al., 2003). Thus, it is 
possible that modifying factors may also cause the differences in disease-progression in the 
PFHBII-affected family. A current investigation is being undertaken at the US/MRC Centre for 
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Molecular and Cellular Biology to identify possible genetic modifying factors that may play a role 
in the phenotypic variability in HCM and DCM (Y. Yako, personal communication), and members 
of the PFHBII-affected family have been entered into this important study. 
 
 
 
Image provided by Prof. V Corfield (US/MRC Centre for Molecular and Cellular Biology, Cape Town, RSA). 
Fig. 4.1 
The distribution of members of the South African PFHBII-affected family. 
The green pins indicate subjects or clusters of individuals from the PFHBII-affected family and red pins 
indicate PFHBI-affected families (see text). A circle shows the isolated district in the Southern Cape 
Province of South Africa where most of the PFHBII-affected family members presently live. Arrows indicate 
the cities where PFHBII-affected family members with DCM have been identified. 
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4.3 Mapping the PFHBII-causative locus 
Candidate loci linkage analyses 
The literature review in Chapter 1 of this dissertation describes the clinical features and common 
underlying molecular aetiologies for different clinical entities, namely DCM, HCM and cardiac 
conduction disorders. To refresh the reader’s memory and to serve as a point of reference for the 
discussion that follows, two examples will be recalled.  
 
Clinically, DCM and HCM share many common clinical features, although morphological and 
physiological differences between familial DCM and HCM led to their classification as two 
separate clinical entities (Goodwin, 1970; Braunwald, 1980). Furthermore, subsequent molecular 
genetic analyses have resulted in the identification of common aetiologies between DCM and 
HCM, for example, mutations in cardiac actin and troponin T have been shown to cause both DCM 
(Olson et al., 1998; Kamisago et al., 2000; Li et al., 2001; Hanson et al., 2002) and HCM 
(Thierfelder et al., 1994; Moolman et al., 1997; Mogensen et al., 1999; Olson et al., 2000) (also 
refer to sections 1.3.2 and 1.3.6). Interestingly, Kamisago et al., (2000) and Hanson et al., (2002) 
identified the same deletion mutation (ΔLys210) in cardiac troponin T, although the families 
described by Kamisago and colleagues had isolated DCM, whereas the two unrelated families 
described by the Hanson group presented with DCM and conduction defects. This data might 
demonstrate the influence of genetic modifying factors on phenotypic expression of this 
cardiomyopathy (see previous section).  
 
Genetic analyses have additionally identified mutations in a cardiac Na+ channel that may cause the 
isolated cardiac conduction diseases, PCCD (Schott et al., 1999) and CCD (Tan et al., 2001), or the 
arrhythmic disturbances, LQT3 (Wang et al., 1995) and IVF (Chen et al., 1998) (also refer to 
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section 1.4.4.1). This finding is unique because conduction diseases and arrhythmias are 
phenotypically diverse, as the one condition is associated with a slowing or a block of the heart rate, 
while the other is associated with an increased or irregular heart rhythm (section 1.4.4.1). 
 
Consequently, the present study proposed that PFHBII might share a common molecular aetiology 
with a previously described cardiomyopathy or cardiac conduction disease, which, thereby, 
provided the rationale for embarking on a candidate loci linkage study. The premise was that a 
genome-wide study would be undertaken if no linkage were found to a previously described 
disease-causative locus. 
 
Linkage to a locus on chromosome 1q32.2-q32.3 
Following a candidate locus linkage study, it was fortuitous that initial data suggested the PFHBII-
causative gene was mapped to the CMD1D (TNNT2) locus on chromosome 1q32 (Thierfelder et al., 
1994; Durand et al., 1995; Kamisago et al., 2000; Li et al., 2001; Hanson et al., 2002), because 
preliminary lod scores of 1.16 and 1.66 were generated with markers D1S456 and D1S505, 
respectively (Table 3.4). However, subsequent fine mapping and haplotype analysis identified 
recombination events in two clinically affected subjects (Fig. 3.1a and b), placing the PFHBII-
causative locus distal to TNNT2 (Fig. 3.5).  
 
At the time of the linkage study and fine mapping analysis, the database entries of genetic markers 
spanning the PFHBII locus were prone to positional rearrangements (Chromosome 1 Workshop 6 
group discussion, Iowa, USA – September 2000). Therefore, it was deemed necessary to construct 
an integrated map of the PFHBII locus, in order to assess the correct specification of genetic map 
data and to update it regularly during the course of this study (section 3.4) (also refer to Le Hellard 
et al., 2001 and Nievergelt et al., 2004). This analysis showed that all the selected genetic markers 
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at chromosome 1q32.2-q32.3 (Table 2.1) were reconciled onto a physical map of the region (Fig. 
3.5). In so doing, the haplotype analysis in the present study was authenticated, thereby 
unequivocally excluding TNNT2 from being the PFHBII-causative gene. 
 
Testing lod score stability at chromosome 1q32.2-q32.3 
For linkage analysis, the correct clinical designation of subjects is important because assigning a 
clinically affected status to individuals who are, in reality, clinically unaffected may result in false-
positive linkage associations (Ott, 1999). As SB may be common in the general population 
(Josephson et al., 1991), and because of concerns of basing a clinical diagnosis on only one ECG 
examination, the lod scores at chromosome 1q32.2-q32.3 were re-calculated by changing the 
clinical status of individual III:11 (Table 3.1) to a clinically uncertain status (see section 3.2.2). 
These analyses generated a maximum pairwise lod score of 2.83 and a multipoint score of 3.4 with 
markers D1S3753 and D1S414.  
 
Thus, re-assessment of the lod scores produced a maximum pairwise value that was below the 
significance level for linkage, although the maximum multipoint lod score remained above +3. The 
low pairwise scores generated in this study were most likely the result of the limited pedigree size 
or uninformative marker alleles (Ott, 1999); an example of the latter is indicated by individual II:12, 
who is homozygous for alleles at the markers D1S414, D1S2810, D1S2780, D1S425 (Fig. 3.1). 
However, a multipoint analysis provides a stronger indication of linkage when pedigree size or 
uninformative markers cause a reduction in statistical power (Lathrop and Lalouel, 1984; Ott, 
1999). Consequently, the additional tests that were performed statistically support linkage of 
PFHBII to the locus to chromosome 1q32.2-q32.3. 
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Simulated lod score analysis using an alternative phenotypic classification model 
To test the robustness of the maximum lod score, various parameters were changed in order to 
“reduce” the score, thereby assessing whether it remained above or fell below the significance level 
of +3. It has to be noted that the strict (conservative) clinical classification model applied in the 
present study. This model was applied to avoid clinical misclassification of subjects and, in so 
doing, reducing the chances of generating false positive linkage. Unfortunately, the maximum 
obtainable lod score that would be generated by this model was also reduced.  
 
To determine the “maximum” possible lod score that could be generated with the available data, a 
second (less conservative) phenotypic classification model was used in the pairwise and multipoint 
lod score analysis. If a less strict but accepted definition of SB was used, namely, a heart rate of less 
than 60 bpm (Josephson et al., 1991), then three additional subjects (individuals II:5, II:9 and III:15) 
(Table 3.1) (Fig. 3.1) could be assigned a clinically affected status, in that way increasing the 
maximum obtainable lod score (Ott, 1999). In order to assess the influence of identifying additional 
clinically affected subjects on the lod score calculations, the clinical status of individuals III:16 and 
IV:1, who present with “unusual” clinical features and carry the disease-associated haplotype 
(Table 3.1) (Fig. 3.1), was changed from clinically uncertain to clinically affected. This analysis 
generated a maximum pairwise lod score of 4.55 and a maximum multipoint score of 4.9 (data not 
shown). Consequently, this data indicates that the further identification of clinically affected 
subjects should strengthen the linkage data presented in this study. 
  
4.4 Implications of mapping the PFHBII locus 
 
Publication of mapping of the PFHBII locus (Fernandez et al., manuscript submitted) may lead to other 
investigators who have identified families with DCM and conduction defects, isolated DCM, isolated 
cardiac conduction abnormalities or HCM-associated disorders, to perform linkage analyses at this 
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locus. These analyses could map an analogous disorder to the locus described in the present study, 
which may help to refine the PFHBII locus. The French group that had mapped an analogous cardiac 
conduction disorder to the same interval on chromosome 19q13.3, to which the PFBHI-causative gene 
is mapped, used this approach to refine the ICCD locus (Z.Arieff, personal communication) (see 
section 1.4.3.1). 
 
Additionally, the present linkage study is particularly relevant to South African families, because it 
demonstrates the exclusion of the PFHBI-causative locus (Brink et al., 1995; de Meeeus et al., 1995) as 
cause of PFHBII. Historically, PFHBI and PFHBII have both been shown to segregate in different 
South African Caucasian Afrikaner families (Brink and Torrington, 1977) that, coincidentally, lived in 
the same geographical regions (Fig. 4.1). Previously, it was assumed that PFHBI and PFHBII were 
extremes of the same disease, and, therefore, had the same underlying molecular aetiology (P. Brink, 
personal communication). However, by showing that PFHBII is an AV conduction defect and by 
mapping the PFHBII locus, the present study has demonstrated that PFHBI and PFHBII are not only 
clinically distinct (see section 4.1), but also, that these clinical entities are caused by a defect in 
different genes.  
 
4.5 Genealogical studies and the origins of PFHBII 
Brink and Torrington (1977) speculated that the branch of the PFHBII-family, which they had 
investigated, descended from one of the four sons of a Dutch immigrant that arrived in South Africa 
in 1713, although in the article, they did not speculate about the genetic origin of the disorder. 
Later, Torrington (1979) traced additional branches of the PFHBII-affected family by following the 
family surname of individuals described by Brink and Torrington (1977). This data appeared to 
support the notion that there might be more South African families with the PFHBII. However, a 
limitation of that study was the use of a family history of “any heart condition” as a criterion to 
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trace “affected“ subjects.  
 
New genealogical data suggesting a recent genetic origin of PFHBII 
The present study obtained genealogical data from the kindred in which PFHBII segregates by 
assessing the information that Torrington had collected in 1979. Additionally, all first- and second-
degree relatives and progeny of subjects that had not been described by Brink and Torrington 
(1977) or Torrington (1979) were interviewed telephonically or in person. Although archived 
records dating back to the 1700’s were obtained, family records derived from the “Familie Bybel” 
(Family Bible), which is a valuable source of genealogical information, particularly among the 
South African Afrikaner subpopulation (Hayden et al., 1980), provided accurate information on the 
personal histories of ancestral subjects from the PFHBII-affected family. This extensive 
investigation demonstrated that PFHBII could only be traced in five generations of the family 
described in the present study and not in other branches of the extended kindred (Fig. 4.2). This 
data might suggest that the PFHBII-causative mutation arose de novo in individual I:1 (Table 3.1) 
(Fig. 3.1) (also, the individual indicated by an arrow in Fig. 4.2). 
  
An additional finding resulting from the extensive genealogical and clinical investigation 
The extensive genealogical and clinical investigation identified a 55-year-old male subject that 
presented with HCM (see section 3.1). Although the subject was related to members of the PFHBII-
affected family, he was shown to be in a branch of the family in which the disorder does not 
segregate (Fig. 4.2) (P. Brink, personal communication). Initially, it was thought that the subject 
might have a familial form of HCM, given the prevalence of this condition in South Africa (J. 
Moolman-Smook, personal communication). However, subsequent examinations of the subject’s 
siblings and progeny did not identify other individuals with HCM (Fig. 4.2). Therefore, it is 
unlikely that the subject has familial HCM, although this finding does not preclude the future 
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identification of HCM in this branch of family. It has to be viewed that any data derived from this 
study may contribute to other studies on cardiac diseases in South Africa, or even, in other 
countries. For this reason, the subject reported in this sub-section has given his consent to be 
entered into a comprehensive study to determine the underlying causes of HCM in South Africa (J. 
Moolman-Smook, personal communication).     
 
Fig. 4.2 
Tracing the origins of PFHBII by extensive pedigree analysis. 
The PFHBII-affected family described in the present study, and previously by Brink and Torrington (1977) is 
shown on the lefts half of the pedigree. Genealogical studies did not trace the segregation of PFHBII beyond 
five generations (indicated by roman numerals) in this kindred. The arrow indicates the subject previously 
designated individual I:1 in Table 3.1 and Fig. 3.1, who is presumed to have introduced the PFHBII-
causative defect into the family described in this study.  
Solid symbols = PFHBII-affected subjects; * = subject presented with HCM. 
*
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4.6 Haplotype analysis at the PFHBII locus: diagnostic implications  
Haplotype analysis identified individuals with the disease-associated haplotype who presently do 
not manifest clinical signs of PFHBII (individuals II:5, II:9, III;15, III:16, III;19, III:22, IV:1, IV:3 
and IV:5) (Fig. 3.1), although, for most of these subjects, “unusual” cardiac features were noted. 
Individual II:5 had previously been diagnosed with SB (Brink and Torrington, 1977), while a 
previous assessment of individual II:9 had identified a slow heart of 49 bpm. However, both these 
subjects had had follow up clinical examinations that indicated heart rate values of 53 bpm and 58 
bpm (Table 3.1). Therefore, for the linkage analysis performed in the present study, these subjects 
were assigned a clinically uncertain status (Table 3.1). From the clinical aspect of their future 
management, however, further follow-up clinical examinations have been recommended for these 
subjects, because Alboni et al. (2001) suggested that a slow heart rate may be an indicator of 
forthcoming heart failure in individuals older than 70 years. Another haplotype carrier (individual 
III:15) had a heart rate of 54 bpm (Table 3.1). Additional examinations should be performed to 
determine whether the subject’s slow heart rate was physiological (possibly exercise-induced) or, 
the result of the disorder. Additionally, clinical assessment of individual IV:3 did not identify any 
atypical features, while his sister, individual IV:5, was not examined because she is younger than 20 
years of age (see section 2.3).  
 
In addition ECG examinations indicated that individuals III:19 and III:22 (Table 3.1) (Fig. 3.1) 
were at the borderline of a diagnosis of first-degree AV block (P-R intervals of 200 milliseconds) 
(Table 3.1), although the significance of this observation, if any, has yet to be established. 
Characteristics that suggested early-clinical markers of PFHBII were identified in individuals III:16 
and IV:1 (Table 3.1) (Fig. 3.1). Individual III:16 displayed a slow R-wave progression, which may 
be associated with DCM (Fatkin and Graham, 2002), whilst individual IV:1, who had been 
interviewed in 1997, reported severe chest pain, dyspnoea and syncopal episodes. However, the 
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possible progression of this individual’s symptoms have not been evaluated clinically although, 
contact has recently been re-established and the subject has reported a similar clinical picture. It has 
been recommended that continuous clinical evaluations be performed on members of the PFHBII-
affected family (P. Brink, personal communication), thereby not only allowing early detection of 
the disease, but also, to provide a sense of reassurance for concerned members of the family.  
 
4.7 Rationale for selecting candidate genes for mutation analyses 
Mutations in ion channels and ion channel modulators have primarily been implicated in the 
pathogenesis of isolated cardiac conduction disorders and arrhythmias, while mutations in genes 
encoding cytoskeletal, sarcomeric, nuclear envelope, intracellular Ca2+-regulating and energy 
homeostasis proteins have been identified as causes of cardiomyopathies (Schott et al., 1999; 
Schönberger and Seidman 2001; Seidman and Seidman 2001; Tan et al., 2001; Fatkin and Graham, 
2002; Ashrafian et al., 2003; Towbin, 2003; Watkins, 2003). Equipped with this background, the 
following sections will provide the rationale for selecting each of the candidate genes that were 
screened in the present study. 
 
LAMB3 
Mutations in the gene encoding extracellular matrix protein laminin-α2 chain of merosin (LAMA2) 
have been shown to cause early-onset DCM with muscular dystrophy in children (Spyrou et al., 
1998) (Table 3.1). In addition, Bies et al., (1992) demonstrated that extracellular matrix proteins are 
expressed in cardiac conduction tissue. Thus, LAMB3 was a candidate gene for PFHBII because it 
encodes the cardiac expressed extracellular matrix protein laminin β3. However, no disease-
causative mutation was found in LAMB3, although a synonymous polymorphism, which did not 
segregate with the disorder, was identified (Table 3.7). 
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T3JAM 
Dadgostar et al., (2003) recently demonstrated that T3JAM encodes a TRAF3-interacting Jun N-
terminal kinase-activating modulator protein that interacts with cytoskeletal proteins of the myosin 
class II heavy chain family (Table 3.6). In Chapter 1, sections 1.3.2, 1.3.3 and 1.3.6, the effect of 
alterations in cytoskeletal protein function and its role in the pathogenesis of DCM and HCM has 
been demonstrated. Another reason for selecting T3JAM for mutation screening is because it may 
also serve as an adaptor molecule that modulates the localisation of TRAF3-interacting Jun N-
terminal kinase (Dadgostar et al., 2003). This finding is significant because recently Mohler et al., 
(2003) described a LQTS type 4-causative mutation in ankyrin-B, a membrane adaptor protein that 
positions the subunits of ion channels, themselves implicated as cause of LQTS (see section 1.4.4 
and 1.4.5), to specific domains in the sarcolemma and endoplasmic reticulum. Therefore, the 
TRAF3-interacting Jun N-terminal kinase-activating modulator was screened, although these 
analyses did not identify the PFHBII-causing mutation. 
 
VWS59 
Transcript data derived from EST analyses suggests VWS59 is highly expressed in heart tissue  
(Unigene accession number Hs.58650). Moreover, bioinformatics-based similarity analyses 
indicated that the protein expressed by VWS59 might have a role similar to acyltransferases (Table 
3.6). Mutations described in the tafazzin protein, a member of the acyltransferase family of 
proteins, have been shown to cause the DCM-associated condition known as BTHS (Bione et al., 
1996). No disease-causative mutation was identified in VWS59, although a polymorphism was 
identified that segregated in the PFHBII-affected family and was present in an unaffected Caucasian 
Afrikaner panel (Table 3.7). 
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KCNH1 
Ion channel activity and intracellular ion homeostasis have been shown to be crucial for the 
functioning of the cardiac conduction and contractile apparatus (refer to section 1.3.3.2, 1.3.6.2.2 
and 1.4.4). Furthermore, voltage-gated K+ channels have functions that include regulating 
neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte 
transport and smooth muscle contraction (Occhiodoro et al., 1998). Therefore, a human-ether-a-go-
go related K+ channel gene, KCNH1, which is related to KCNH2, the gene in which mutations have 
been described that cause LQT2 (Curran et al., 1995), was deemed a strong PFHBII-candidate gene. 
The disease-associated mutation was not identified upon screening of KCNH1, although two 
polymorphisms were identified that segregated in the PFHBII-affected family and were present in 
an unaffected Caucasian Afrikaner panel (Table 3.7). 
  
KIAA0205 
Mutations in the G4.5 gene encoding tafazzin have been identified as cause of X-linked recessive 
BTHS, which may be associated with DCM (Bione et al., 1996). KIAA0205 was considered a 
plausible PFHBII-candidate gene because it is predicted to encode a putative acyltransferase similar 
to tafazzin (Table 3.6). However, the PFHBII-causative mutation was not detected in KIAA0205.  
 
RAMP  
The nuclear matrix-associated gene, RAMP, encodes the L2DTL protein, a G-protein containing a 
WD40 repeat sequence (Cheung et al., 2001). In eukaryotic proteins, WD40 domains can function 
as adaptor/regulatory modules in signal transduction pathways, or are involved in pre-mRNA 
processing and cytoskeleton assembly (Garcia-Higuera et al., 1996). Additionally, a mutation has 
been identified in a WD40 repeat in the peroxin-seven gene (PEX7), which causes Refsum disease 
(MIM 266500), a condition characterised by progressive adult retinitis pigmentosa, peripheral 
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neuropathy, cerebellar ataxia, sensorineural deafness, skeletal dysplasia and cardiac arrhythmias 
(Braverman et al., 2002). Therefore, RAMP was screened for the PFHBII-causative mutation. The 
PFHBII-causative mutation was not identified, but a non-synonymous polymorphism, which caused 
a substitution of a species-conserved threonine amino acid residue, was identified in only two of the 
eight PFHBII-affected subjects (section 3.6.1) (Table 3.7). The sequence variation was not 
identified in the Afrikaner population, although it has to be noted that only five subjects from the 
control panel were subjected to direct sequence analysis (see section 3.6.1). It is possible that this 
polymorphism may have a modifying role in the pathogenesis of PFHBII in these subjects. 
Clinically, the two subjects with the sequence variation in RAMP (individuals II:7 and III:20) (Fig. 
3.1) showed progression to CHB necessitating a pacemaker implantation (Table 3.1). This clinical 
presentation does not appear to be different from the rest of the clinically affected members of the 
family, although it has to be noted that individual III:20 progressed from first-degree AV block to 
CHB within two years (data not shown). Unfortunately, time constraints did not permit further 
investigation, although this data could be used in an investigation to identify potential genetic 
modifying factors in cardiomyopathies (see section 4.2). 
 
PPP2R5A  
Serine/threonine protein phosphatases have regulatory roles that include growth factor signaling and 
cell transformation (McCright and Virshup, 1995). Previously, by altering the delta 5 subunit of 
protein phosphatase 2A, Brewis and colleagues (2000) produced transgenic mice that presented 
with DCM. Additionally, the Ca2+-dependent protein phosphatase, calcineurin, has been shown to 
induce foetal cardiac gene expression with resultant cardiac hypertrophy in mice (Molkentin et al., 
1998). Thus, PPP2R5A was considered a good PFHBII candidate gene. However, the disease-
associated mutation was not identified upon analysis of this gene. 
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4.8 Study limitations 
4.8.1 Linkage analysis 
Chance linkage associations 
The present study has provided evidence that supports mapping the PFHBII-causative gene to a 
locus on chromosome 1q32.2-q32.3. As a candidate, rather than a whole-genome, linkage study was 
undertaken, the possibility that a locus that was not analysed could produce significant lod scores to 
suggest the causative gene lies elsewhere cannot be excluded. Generally, chance linkage 
associations are probable in one in twenty loci screened (Morton, 1955). However, the present 
investigation excluded a number of DCM, HCM and cardiac conduction-causative loci (Table 3.3). 
Thus, it can be presumed that for PFHBII chance associations are likely to be much less than 5%, 
because sequential exclusion analyses decrease the genomic interval that has to be assessed in order 
to map a disease to its causative locus (Morton, 1955; Ott, 1999). Furthermore, barring a whole-
genome linkage analysis, the present investigation has performed numerous tests to assess the 
robustness of the lod score analyses at chromosome 1q32.2-q32.3 (section 3.2.2). Although a 
maximum lod score of +3 is used to establish linkage, it is widely viewed that a score of greater 
than +3.3 provides a more significant indication that a disease is linked to a locus (Ott, 1999). In the 
present study, the lowest simulated multipoint lod score generated was +3.4 (section 3.2.2) when 
applying a very cautious (conservative) assessment. 
  
4.8.2 Bioinformatics analysis and sequence status at chromosome 1q32.2-q32.3 
Gene annotation and prediction  
Data obtained from the NCBI database builds 28 and 31 (freeze dates 24 December 2001 and 5 
November 2002) were used to delineate candidate genes at the PFHBII locus. At the time, a total of 
27 genes (known and computer predicted) were assigned to the PFHBII locus (Appendix G), of 
which seven genes were prioritised for mutation analysis. Furthermore, the sequence at the PFHBII 
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locus, between markers D1S205 and D1S505, was in the draft phase (see section 1.5.2.1) when 
selecting the seven candidate genes for mutation screening. Recent analyses of the Ensembl 
database in December 2003 indicated that one computer-predicted gene (ENSG00000173964) 
(Appendix G) had been removed from the interval between D1S70 and D1S505 on chromosome 
1q32.2-q32.3. Thus, 26 genes map to within the interval of 2.85Mb, which gives an average gene 
density of one gene per 110kb of genomic sequence. This figure is about the same as the overall 
gene density of chromosome 1, which is approximately one gene per 116kb (see section 1.5.3.2), 
though significantly lower than that of chromosome 19, which has a density of one gene per 26kb 
of genomic sequence (Grimwood et al., 2004).   
 
Exon prediction 
Due to sequencing errors, or incomplete sequence data, it has been shown that computer algorithms 
used to annotate genes may miss, or incorrectly predict, the exon-intron boundaries of genes (Burge 
and Karlin, 1997; Felsenfeld et al., 1999; Bork, 2000; Katsanis et al., 2001; Stein, 2001). This holds 
true for the seven candidate genes that were screened in the present study, even a well-characterised 
gene such as PPP2R5A (McCright and Virshup, 1995), for which the genomic organisation had been 
defined about a decade ago. Moreover, as sequence quality improves, additional exons could be 
identified within these genes. A recent database search indicated that four of the seven genes screened 
in the present study have had additional exons or alternative transcripts assigned after the 5 November 
2002 freeze date (Table 4.1). Thus, it is possible that the PFHBII-causative mutation may reside within 
a newly identified exon or an alternative transcript. Future mutation analysis will therefore focus on 
screening the newly identified exons and alternative transcripts in the genes that were investigated in 
the present study, thereby permitting the exclusion of a PFHBII-causative mutation within the coding 
regions of these genes.  
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Table 4.1 
Comparison of database entries showing changes to exon numbers of the candidate genes screened at the 
PFHBII locus  
NCBI build 31     NCBI build 33 
Gene   5 November 2002    14 April 2003    
LAMB3   23 exons     23 exons 
T3JAM   17 exons     17 exons 
VWS59   8 exons + 1 alternative transcript   12 exons + 1 alternative transcript 
KCNH1  11 exons     11 exons 
KIAA0205  7 exons      8 exons 
RAMP   12 exons + 1 alternative transcript  15 exons + 1 alternative transcript 
PPP2R5A  11 exons     13 exons    
 
4.8.3 Limitations of laboratory techniques 
4.8.3.1 PCR-SSCP analysis 
Mutation analysis by PCR-SSCP gel electrophoresis was previously optimised in our laboratory to 
increase detection sensitivity to approximately 95-100% (W. de Lange, PhD thesis). However, this 
meant that, theoretically, up to 5% of sequence variations could have been missed during mutation 
screening. In the present study, 92 exons, or a total of 101 “amplification products”, if one 
considers that more than one set of primers were used to amplify across large exons, were screened 
by PCR-SSCP analyses (refer to Appendix E). In order to assess the possibility of missing the 
PFHBII-causative mutation, the sensitivity of the PCR-SSCP screening analyses was tested, as 
described in section 2.12.5.3. Consequently, 29 exons were screened by direct sequence analysis, of 
which two demonstrated a sequence variation that was not detected by PCR-SSCP gel 
electrophoresis analysis (refer to section 3.6.1). For this study, the sensitivity of the PCR-SCCP 
analyses was approximately 93% (2 out of 29 exons), which is consistent with the sensitivity level 
determined by W de Lange (PhD thesis), and more than the 70% and 85% sensitivity level 
demonstrated by Sheffield et al., (1993) and Larsen et al., (2001), respectively. However, it has to 
be noted that an amplified product with a known sequence variant (a positive control) was not 
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loaded onto any of the PCR-SSCP gels. Therefore, the mutation screening protocol did not provide 
a measure to assess whether there was variability in the gel-detection sensitivity over time. 
Consequently, in future, it may be justified to perform automated sequence analyses of the 
prioritised candidate genes screened in the present study, since this method is more sensitive and 
there is a lesser likelihood that the strategy will show detection variability (Kaczorowski and 
Szybalski, 1996). 
 
4.8.3.2 Study design: screening coding and intron-exon junctions  
Mutations that cause autosomal dominant cardiac conduction disease or cardiomyopathies have, by 
and large, been identified in the exons of genes (Marian and Roberts, 2003). Additionally, splice 
junctions are usually analysed during screening protocols because mutations that can alter exon 
splicing, and thus result in truncated protein products or non-functional proteins, have been 
identified as cause of conditions such as HCM (in MyBPC3 and TNNT2) (Watkins et al., 1995; 
Watkins et al., 1996) or cardiac conduction disease (in SCN5A) (Schott et al., 1999) (refer to 
sections 1.3.6.2.1 and 1.4.5). In general, intronic sequences are not screened for mutations as they 
are long and, therefore, not suitable for PCR-SSCP analysis (Orita et al., 1989). Moreover, a larger 
number of sequence variations occur within introns (Louie et al., 2003), but, more importantly, even 
if a variant is identified in an intron, it is difficult to determine the significance thereof because the 
functional role of intronic sequences has yet to be clearly defined (Mattick, 1994). These limitations 
also apply to analyses of promoter regions, although, functional significance can be assigned to 
variations identified in canonical motifs such as transcription factor-, enhancer- and repressor-
binding sites (Frith et al., 2004).  
 
Because of the considerations mentioned above, the present study analysed exons and the splice 
junctions of each of the seven selected candidate genes. However, Towbin et al., (1993) and 
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Muntoni et al., (1993) demonstrated associations between a deletion mutation in the promoter 
sequence of dystrophin and XLCM. Furthermore, promoter mutations in genes encoding 
cardiotrophin 1 (Erdmann et al., 2000), phospholamban (Minamisawa et al., 2003) and serum 
response factor (Zhang et al., 2003) have been identified as cause of human and mouse cardiac 
conduction or cardiomyopathy-associated disorders. Consequently, the candidate genes screened in 
this study cannot conclusively be excluded as cause of PFHBII because the regulatory regions were 
not screened by PCR-SSCP analysis.  
 
Because a deletion mutation in the promoter region of dystrophin has been reported to cause XLCM 
by Muntoni et al., (1993), it is suggested that restriction enzyme- and Southern blot analyses 
(Sambrook et al., 1989; Armour et al., 2002) be used in future screening of the candidate genes that 
were assessed in the present investigation. This analysis might not only identify large deletions, but 
also other chromosomal rearrangements such as inversions or duplications, or, it could fortuitously 
result in the identification of a point mutation that changes a restriction enzyme site used in the 
analysis.  
 
4.9 Changing paradigms: implications for selecting candidate genes in future mutation 
screening 
Initially, the available literature had demonstrated that mutations in cytoskeletal, sarcomeric, ion 
channel and ion channel modulating proteins (sections 1.3.3.1.3, 1.3.3.1.3, 1.3.6.2.1 and 1.4.5.1) 
were primarily implicated in the pathogenesis of cardiomyopathies and cardiac conduction 
disorders. The more recent identification of common disease mechanisms illustrating the role of 
Ca2+ handling and energy homeostasis in the pathogenesis of DCM and HCM (refer to sections 
1.3.3 and 1.3.6) suggested that there could be additional molecular causes of cardiomyopathies 
(Watkins, 2003). Consequently, genes associated with Ca2+ or energy pathways, which map to the 
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PFHBII locus, warrant future investigation. Immediately prior to the submission of this dissertation, 
using bioinformatics tools, all the genes that map within the PFHBII locus, barring the seven 
screened in the present study, were re-assessed to include criteria for involvement in Ca2+ or energy 
homeostasis, for example Ca2+ or ATP-binding sites. A few of the plausible candidate genes that 
complied with these criteria are discussed below.   
 
Synaptotgamin XIV (SYT14) 
SYT14 (Ensembl accession number AK091517) encodes a protein composed of conserved C2 
domains, which are also components of protein kinase C isozymes, phospholipases and 
synaptotamins (Davletov and Sudhof, 1993). The C2 domain of protein kinase C and 
phospholipases are thought to be involved in Ca2+-dependent phospholipid binding (Davletov and 
Sudhof, 1993). Additionally, model animal studies have shown an association between beta-
adrenergic receptors, the phospholipase/protein kinase C pathway and left ventricular remodeling 
(Dorn, 2002), while a C2 domain-containing protein, namely, phosphoinositide 3-kinase gamma 
(PI3Kgamma), has recently been shown to trigger hypertrophy, fibrosis and cardiac dysfunction in 
response to beta-adrenergic stimulation (Oudit et al., 2003).  
 
REST co-repressor (NM_018254)  
NM_018254 (Ensembl accession number BC031608) encodes the REST co-repressor protein 
(RCO3), which consists of ELM2 domains, myb (beta leucine zipper) domains and an ATP/GTP 
binding motif (Nagase et al., 1996). The ELM2 and myb domains of RC03 are involved in protein-
protein interactions and DNA-binding, respectively, while ATP binds to the ATP/GTP motif of the 
protein. The recent identification of cardiomyopathy-associated mutations in proteins involved in 
cellular energy homeostasis (Blair et al., 2001) has given credibility to screening genes encoding 
proteins with affinities for high-energy substrates such as ATP. In addition, database analyses 
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indicated that RCO3 is homologous to the KIAA1343 protein, which, in turn, has a weak similarity 
to rabbit myosin light chain kinase 2 (accession number P07313). Furthermore, Takio et al., (1985) 
demonstrated that rabbit myosin light chain kinase 2 regulates cardiac and skeletal muscle 
contraction, thus making NM_018254 an attractive PFHBII candidate gene. 
 
Never in mitosis A-related kinase 2 (NEK2) 
NEK2 (Ensembl accession number U11050) encodes a serine/threonine protein kinase which is 
involved in cell cycle control and ATP-binding (Schultz et al., 1994). A binding affinity for the 
energy substrate ATP, and thus its potential involvement in cellular metabolism and energy 
homeostasis, makes NEK2 a good candidate for PFHBII. Furthermore, database analysis indicates 
that NEK2 protein domains have similarity to phosphorylase B kinase (personal observation), 
which catalyses the phosphorylation of serine substrates in cardiac troponin I, in which a mutation 
has been described that causes autosomal recessive DCM (Murphy et al., 2004).  
 
Zinc transporter 1 (SLC30A1) 
SLC30A1 (Ensembl accession number AF323590) encodes zinc ion transporter 1 (ZNT-1). 
Generally, it has been viewed that mutations in Na+ and K+ ion channels cause cardiac conduction 
disorders (CCD and PCCD) (Schott et al., 1999; Tan et al, 2001) and arrhythmic disturbances (BrS, 
IVF and LQTS) (Abbott et al., 1999; Chen et al., 1998; Curran et al., 1995; Splawski et al., 1997; 
Tyson et al., 1997; Wang et al., 1995 and 1996). However, transgenic mice with an altered zinc 
transporter 5 gene (znt5) have been shown to develop AV block, SB, osteopenia and sudden cardiac 
death (Inoue et al., 2002). 
 
Preferably, all genes that map to within the PFHBII locus should be screened for the disease-
causative mutation. However, such a task would be too expensive to perform in our laboratory. 
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Consequently, following further screening of the candidate genes already analysed in the present 
study, the future screening of the plausible candidate genes mentioned above, will receive priority. 
 
4.10 Conclusion  
For 27 years, PFHBII has been described as a cardiac conduction disorder that segregated in a 
Caucasian South African Afrikaner family. However, the present study has demonstrated that 
PFHBII is, in fact, a DCM-associated disorder complicated or preceded by cardiac conduction 
defects. This finding has been published and will undoubtedly influence the diagnoses of other 
individuals with PFHBII, as well as on the treatment and management of the disease, particularly in 
a South African setting, but maybe in other countries as well (Fernandez et al., 2004).  
 
Additionally, the present study describes extensive genetic analyses that have resulted in mapping 
the PFHBII-causative gene to within a 3.9cM region on chromosome 1q32.2-q32.3 (Fernandez et 
al., manuscript submitted). The disease-associated mutation was not identified in an analysis of 
seven strong candidate genes and continuous and future mutation screening will be pursued. It is 
possible that mapping of the PFHBII-causative locus may allow other investigators to show linkage 
of an analogous disorder to the chromosomal region described in this study, which may help further 
refine the locus and thereby contribute to identifying the disease-causative gene. Because PFHBII is 
an adult-onset disorder that shows progression of clinical features, it is possible that individuals 
who are currently diagnosed as clinically unaffected, could, in future, present with symptoms of the 
disorder. Follow-up examinations have been recommended as these measures might allow the 
timely detection of the disease before it progresses to congestive heart failure, a stage associated 
with a poor prognosis. If detected early, subjects may be prescribed appropriate drug therapies that 
could prevent or slow the progression of the disorder.  
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To conclude, by identifying a novel disease-causative locus, it is proposed that the future 
identification of the underlying molecular aetiology of PFHBII might add weight to support existing 
hypotheses, or, alternatively, could result in the elucidation of a novel pathobiology for 
cardiomyopathies complicated by conduction defects. As a consequence, this data might provide 
new insights into an understanding of the complex mechanisms that result in heart failure, which in 
turn, might aid in the development of new therapeutic targets. 
 
A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing. 
George Bernard Shaw 
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APPENDIX A 
 
EBV-medium 
EBV-containing supernatant was harvested from a culture of lymphoblastoid marmoset cell line B95-8, 
which secretes and is permanently infected with EBV-virus. The supernatant was centrifuged at 
1200rpm in a bench-top centrifuge and then filtered through a 0.45μm membrane (Millipore, USA) to 
remove all viable cells. The medium was stored at 4oC for up to 6 months. 
 
Stock solutions 
Na-EDTA (1L stock solution) 
NaCl (Merck)     18.75ml of 4M solution 
EDTA (Biorad)    250ml of 100mM solution 
Mix well to total volume 
 
10% SDS (1 litre stock solution) 
SDS (Sigma)     100g 
make up to 1 litre with dH2O 
 
Tris-Cl (1L stock solution) 
Tris (Merck)     121.14g 
Make up to 1L with dH2O 
pH to 8.0 with HCl 
 
5M NaCl (1 litre stock solution) 
NaCl       292.2g 
Make up to 1 litre with ddH2O 
 
4M NaOH (1 litre stock solution) 
NaOH (Merck)    160g 
Make up to 1 litre with ddH2O 
 
20xSSC (1litre stock solution) 
NaCl (Merck)     250.6g  
NaCitrate (Merck)    176.4g  
pH to 7.0, autoclave  
 
DNA extraction from blood 
Chloroform/octonol 
Chloroform (Merck)    24vol. 
Octonol (Merck)    1vol. 
 
Phenol/chloroform 
Phenol (Sigma)    25vol. (1xTE saturated) 
Chloroform (Sigma)    24vol. 
8-hydroxyquinoline (Merck)   
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Na-EDTA/SDS 
Na-EDTA (stock)    450μl 
10% SDS (Sigma)    50μl 
 
Na-acetate (3M) 
Na-acetate.3H2O (Merck)   40.81g 
dH2O      50ml 
Adjust to pH 5.2 with glacial acetic acid (Merck) and make up to 100ml final volume with dH2O 
 
Phosphate buffered saline 
NaCl (Merck)     1mM 
KCl (Merck)     2.68mM 
Na2HPO4 (Merck)    141.96mM 
KH2HPO4 (Merck)    141.96mM 
 
Cell lysis buffer 
Sucrose (Saarchem)    0.32mM 
Triton X-100 (Sigma)    1% 
MgCl2 (Merck, BDH)    5mM 
Tris-HCl pH 7.6 (Merck)   25mM 
Adjust to pH 8.0. Store at 4oC. 
 
RPMI-medium 
RPMI (Separations)    10.4g 
Fetal calf serum (Centrolab)   15% 
Pen/ Strep (Boehringer Mannheim)  1% 
pH to 7.5, make up to 100ml and store at 4oC. 
 
Gel electrophoresis 
10xTBE (per 1000ml) 
Tris (Merck)     108g 
Boric acid (Merck)    55g 
EDTA (Biorad)    9.3g 
Mix well and make up to 1000ml with dH2O. 
 
1xTBE (per 1000ml) 
10xTBE stock     100ml 
Add 900ml H2O to a final volume of 1000ml 
 
1xTE 
Tris-HCl pH 8.0 (Merck)   10mM 
EDTA (Biorad)    1mM 
 
10% Ammonium persulphate (AMPS) 
AMPS (Merck)    10g 
Add H2O fill to 100ml 
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CA loading dye 
Formamide (Sigma)    95% 
Bromophenol blue (Merck)   0.02% 
Xylene cyanol (Biorad)   0.02% 
 
Polyacrylamide 6% denaturing (genotyping/sequencing) gel (60ml) 
Urea      26.64g 
10xTBE     6ml 
H2O      26.6 
40% Acrylamide/37.5:1 Bis (Promega) 7.7ml 
10% AMPS (Merck)    500μl 
TEMED (Promega)    50μl 
 
Methodolgy 
Glass plates with dimensions of 30x40x0.5cm were prepared by silanising the surface of the notched 
plate with Wynns C-Thru (Wynns (Pty) Ltd, South Africa). Two 0.5mm plastic spacers were placed on 
the longitudinal edges of one plate and overlayed by the other plate. The edges of the plates were 
sealed in a U-shaped sealing boot (Laboratory Specialist Services). The 6% denaturing gel solution 
was poured between the plates with the smooth side of a shark-toothed comb placed in 5-8mm at the 
notched end of the solution. The gel was allowed to polymerise through the reaction of the AMPS and 
TEMED for at least 2 hours. Upon removal of the sealing boot and comb the gel was cleaned 
thoroughly to remove any remaining urea that could affect the gel running conditions. The toothed-end 
of the comb was carefully placed into the gel until it created separate wells. The completed setup was 
attached to a vertical gel electrophoresis apparatus by bulldog clamps and connected to ~3000V 
powerpack (James Duncan, South Africa) and pre-run in 0.5xTBE buffer at 1800V for 15-30 minutes 
before the samples were loaded in each well. The gel electrophoresis proceeded at 1800V for 2-4 
hours, depending on the size of the amplified fragments, before being removed and lifted onto 3MM 
Whatmann paper (Merck) and dried on a gel-dryer (Drygel Slabgel Sr model se1160, Scientific 
Associates, RSA) for 1 hour. Dried gels were then placed in an autoradiography cassette, overlayed 
with X-ray (3MM, South Africa) and exposed depending on the radioactive signal efficiency.  
 
Developer solution 
Solution A (Polycon)    1.98L 
Solution 2 (Polycon) 18.1ml (do not pour directly into container) 
make up to 9.9L with dH2O. 
 
Stop solution (6% acetic acid) 
Acetic acid (Merck)    540ml 
Make up to 9L with dH2O. 
 
Fixer solution 
PERFIX     1.8L 
Hardner-S     225ml 
Make up to 9L with dH2O. 
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BAC and PAC DNA extraction  
Luria Broth   
Bacto tryptone (Difco)   2.5g 
Yeast extract (Difco)    1.25g 
NaCl (Merck)     2.5g 
Make up to 250ml with dH2O 
pH to 7.2 
Autoclave and let cool down to 55°C 
Chloramphenicol (12.5mg/ml stock)  250µl (final concentration ~12.5µl/ml) 
 
LB agar (LA) plates 
Bacto tryptone (Difco)   2.5g 
Yeast extract (Difco)    1.25g 
NaCl (Merck)     2.5g 
Make up to 250ml with dH2O 
pH to 7.2 
Bacto agar (Difco)    3.75g 
Autoclave and let cool down to 55°C 
Chloramphenicol (12.5mg/ml stock)  250µl (final concentration ~12.5µl/ml) 
Pour plates in an extractor hood and allow solidify 
Store in the dark at 4°C 
 
BAC and PAC mini-prep solutions 
Solution I 
Glucose (Merck)    0.9g (50mM) 
Tris-HCl (1M stock)    2.5ml (25mM) 
EDTA (Biorad)    2ml (10mM) 
Make up to 100ml with dH2O 
Autoclave and store at 4°C 
 
Solution II (made fresh daily) 
NaOH (stock)     0.4ml 
10% SDS (stock)    1ml 
Make up to 10ml with dH2O 
 
Solution III 
Potassium acetate (Merck)   29.4g (5M) 
dH2O      ±30ml 
pH to 4.8 with glacial acetic acid 
Make up to 100ml with dH2O 
 
YAC DNA extraction 
YPD medium  
Yeast extract     10g 
Peptone     20g 
Make up to 1 litre with dH2O, pH to 5.8 
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YPD agar 
Yeast extract     10g 
Peptone     20g 
Make up to 1 litre with dH2O, pH to 5.8 
Bacto agar     20g 
40% Glucose (Merck)    50ml 
 
2-Mercaptoethanol 
0.5M EDTA     40ml 
2-Mercaptoethanol (12M stock)  3.8ml 
Add 456.2ml dH2O 
 
SCE 
2M Sorbitol     50ml 
1M Sodium citrate    10ml 
0.25M EDTA     0.24ml 
Make up to 100ml with dH2O 
Filter sterilise 
 
Polyacrylamide 12% gel (10ml) 
dH2O      6ml 
1xTBE (stock)     1ml 
40% acrylamide/37.5:1 Bis (Promega) 3ml 
10% AMPS (Merck)    100µl 
TEMED (Promega)    30µl 
 
Mutation analysis 
SSCP loading dye 
Formamide (Sigma)    95% 
Bromophenol blue (Merck)   0.02% 
Xylene cyanol (Biorad)   0.02% 
NaOH (Merck)    10mM 
EDTA (Biorad)    20mM 
 
Solution B 
AgNO3 (Merck)    1g 
Make up to 1litre with H2O 
 
Solution C 
NaOH (Merck)    15g 
NaBHO3 (Sigma)    0.1g 
Formaldehyde (Merck)   4ml 
Make up to 1litre with H2O and constant stirring 
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10 % SSCP + 5% gycerol (160ml) 
40% Acrylamide/37.5:1 Bis   40.5ml 
10xTBE     8ml 
Glycerol (BDH)    8ml 
H2O      84ml 
Urea (Merck)     24g 
10% AMPS (Merck)    1600μl 
TEMED (Promega)    160μl 
 
8% SSCP + 5% glycerol (160ml) 
40% Acrylamide/37.5:1 Bis   32.4ml 
10xTBE     8ml 
Glycerol (BDH)    8ml 
H2O      91.8 
Urea (Merck)     24g 
10% AMPS (Merck)    1600μl 
TEMED (Promega)    160μl 
 
Methodology 
Glass plates with dimensions of 30x40x0.5cm were prepared as before, except that a sheet of 
GelbondTM  (FMC Bioproducts, Rockland, Maine, USA) was adhered to the non-silanised glass plate 
using 70% ethanol, with the hydrophobic side facing upward. Two 1mm plastic spacers were placed at 
either longitudinal end of the plate and overlayed with the other plate. The plates were sealed as before 
and the appropriate gel solution poured in between. A flat-edged 46 well comb was placed into the gel, 
which was then allowed to polymerise for 2 hours. The comb was removed and the wells cleaned to 
remove excess urea. The gel was placed in a gel apparatus and electrophoresis proceeded at a constant 
power of 70W for 10 minutes at 4°C. Samples were loaded into each well and electrophoresis 
proceeded at constant power of 25W at 4°C for 16 hours. The gel was removed and silver in solution B 
for 20min with constant shaking then washed with distilled water and stained with solution C for 20 
minutes with shaking. The gel was air-dried for at least 1 hour before analysing. 
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APPENDIX B 
 
Ensembl annotation database: http://www.ensembl.org 
The screen-shot shows the ensembl database catalogue of genetic markers and known/predicted genes that rae 
mapped to the PFHBII locus on chromosome 1q32.2-q32.3. 
 
 
University of California Santa Cruz (UCSC) database: http://genome.ucsc.edu 
The UCSC database index of genetic markers, ESTS, known/predicted genes (and their genomic organisation) 
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for the chromosomal interval between D1S491 and D1S205 on chromosome 1q32.2. 
 
 
 
National Centre for Biotechnology Information (NCBI) database: http://www.ncbi.nlm.nih.gov 
The NCBI database catalogues of the genomic clones (or genomic contigs), the chromosomal order of genes 
(centromeric to telomeric) and links to databases containing human/mouse genomic sequence for the specific 
gene. The chromosomal interval shown is between D1S491 and D1S205. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151
 
 
APPENDIX C 
 
Unigene database: http://www.ncbi.nlm.nih.gov/Unigene.  
The output shows the alignment percentages and tissue distribution profiles using the entry sequence of T3JAM 
(accession number AL049667). 
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STACK™ 
BLASTN 2.2.1 [Jul-12-2001] 
Reference: 
Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer,  
Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997),  
"Gapped BLAST and PSI-BLAST: a new generation of protein database search 
programs",  Nucleic Acids Res. 25:3389-3402. 
 
Query=  
         (1826 letters) 
 
Database: /var/blast/heart3_0.fasta 
           33,206 sequences; 10,152,790 total letters 
 
Searching..................................................done 
                                                                     Score     E 
Sequences producing significant alignments:                    (bits)  Value 
 
I708567 PROJECT:heart ; LENGTH:490bp ; DIRECTION:0 ; CLONE:IMAG...   963  0.0 
Z32860 PROJECT:heart ; LENGTH:362bp ; DIRECTION:0 ; CLONE:HEA03N...   101  5e-21 
A032194 PROJECT:heart ; LENGTH:538bp ; DIRECTION:0 ; CLONE:IMAG...    36  0.22 
cl4135ct4465cn5825 PROJECT:heart ; COVERAGE:0.99; CRAWID: 1; TOT...    36  0.22 
cl4135ct4463cn5823 PROJECT:heart ; COVERAGE:1.0; CRAWID: 1; TOTA...    36  0.22 
A249418 PROJECT:heart ; LENGTH:178bp ; DIRECTION:0 ; CLONE: n/a...    34  0.88 
C16976 PROJECT:heart ; LENGTH:204bp ; DIRECTION:0 ; CLONE:GEN-53...    34  0.88 
cl4435ct4775cn6167 PROJECT:heart ; COVERAGE:0.99; CRAWID: 1; TOT...    34  0.88 
cl3224ct3521cn4743 PROJECT:heart ; COVERAGE:0.99; CRAWID: 1; TOT...    34  0.88 
R47404 PROJECT:heart ; LENGTH:395bp ; DIRECTION:0 ; CLONE:f291-r...    32  3.5 
N56050 PROJECT:heart ; LENGTH:397bp ; DIRECTION:0 ; CLONE:J6391 ...    32  3.5 
A215854 PROJECT:heart ; LENGTH:245bp ; DIRECTION:0 ; CLONE: n/a...    32  3.5 
 
>AI708567 PROJECT:heart ; LENGTH:490bp ; DIRECTION:0 ; 
            CLONE:IMAGE:2353662 LEN: 490 b.p. FILE gbest24.seq 
            3-PRIME DEFN: as98e04.x1 Barstead aorta HPLRB6 Homo 
            sapiens cDNA clone IMAGE:2353662 3', mRNA sequence. ; 
            CLONELIB:Barstead aorta HPLRB6 ; TISSUE:[] 
          Length = 490 
 
 Score =  963 bits (486), Expect = 0.0 
 Identities = 489/490 (99%) 
 Strand = Plus / Minus 
 
                                                                         
Query: 1324 cgtgtggagtccaaagtccttccctaacgaagtggagcctgagggtacagggaaggagaa 1383 
                      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Sbjct: 490    cgtgtggagtccaaagtccttccctaacgaagtggagcctgagggtacagggaaggagaa 431 
 
                                                                         
Query: 1384 agactgggatctcagagaccagctgcaaaagaagactttgcagctccaggccaaggaaaa 1443 
                     | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Sbjct: 430    agactgggatctcagagaccagctgcaaaagaagactttgcagctccaggccaaggaaaa 371 
 
STACK database: http:// http://www.sanbi.ac.za/Dbases.html 
The output shows the alignment percentages and tissue distribution profiles using the entry sequence of T3JAM 
(accession number AL049667). 
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APPENDIX D 
 
BLASTN 2.2.5 [Nov-16-2002]  
Reference: 
Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer,  
Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997),  
"Gapped BLAST and PSI-BLAST: a new generation of protein database search 
programs",  Nucleic Acids Res. 25:3389-3402. 
 
RID: 1049723957-03455-25496 
 
Query=  
         (6253 letters) 
 
 
Database: All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, 
GSS, or phase 0, 1 or 2 HTGS sequences)  
           1,726,556 sequences; 8,074,398,388 total letters 
 
  
If you have any problems or questions with the results of this search  
please refer to the BLAST FAQs 
 
Taxonomy reports 
 
Distribution of 324 Blast Hits on the Query Sequence 
Mouse-over to show  defline and scores. Click to show  alignments  
 
 
 
                                                                                                           Score    E 
Sequences producing significant alignments:                                    (bits) Value 
 
gi|7661995|ref|NM_014873.1|  Homo sapiens KIAA0205 gene prod...  6901   0.0    
gi|1503993|dbj|D86960.1|  Human mRNA for KIAA0205 gene, comp...  6901   0.0    
gi|15668074|gb|AC096637.1|  Homo sapiens chromosome 1 clone ...  6877   0.0    
gi|22902214|gb|BC034621.1|  Homo sapiens, similar to KIAA020...  2452   0.0    
gi|19352306|gb|AC084736.5|  Homo sapiens chromosome 8, clone...  1400   0.0    
gi|10048003|gb|AC008066.4|  Homo sapiens BAC clone RP11-293D...  1400   0.0    
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gi|23593471|ref|XM_129651.2|  Mus musculus hypothetical prot...  1326   0.0    
gi|26986566|ref|NM_172266.1|  Mus musculus hypothetical prot...  1326   0.0    
gi|15489110|gb|BC013667.1|  Mus musculus, Similar to KIAA020...  1326   0.0    
gi|19353716|gb|BC024750.1|  Mus musculus, clone IMAGE:536249...   950   0.0    
 
Alignments 
 
 
>gi|7661995|ref|NM_014873.1|   Homo sapiens KIAA0205 gene product (KIAA0205), mRNA 
          Length = 6253 
 
 Score = 6901 bits (3481), Expect = 0.0 
 Identities = 3619/3688 (98%) 
 Strand = Plus / Plus 
 
                                                                         
Query: 2558 agacaggtcttactctgtcacccaggctgtagtgcagtggcataatctcagctcactgca 2617 
                     | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Sbjct: 2558  agacaggtcttactctgtcacccaggctgtagtgcagtggcataatctcagctcactgca 2617 
 
                                                                         
Query: 2618 gtctctgcctcccgggttcgagcgattctcctgcctcagcctcccgagtagctgggacta 2677 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Sbjct: 2618 gtctctgcctcccgggttcgagcgattctcctgcctcagcctcccgagtagctgggacta 2677 
 
                                                                         
Query: 2678 caggcacccaccatcatgcttggctaatttttgtatttttagtagagatggggtttcacc 2737 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Sbjct: 2678 caggcacccaccatcatgcttggctaatttttgtatttttagtagagatggggtttcacc 2737 
 
                                                                         
Query: 2738 atgttggccaggctggcctcgaactcctgacctcaggtgatctgcccacctcggcttcct 2797 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Sbjct: 2738 atgttggccaggctggcctcgaactcctgacctcaggtgatctgcccacctcggcttcct 2797 
 
                                                                         
Query: 2798 aaagtgctgggattgcaggcgtgagccaccacgcccggcctccagttgcttttgaagagg 2857 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 
Sbjct: 2798 aaagtgctgggattgcaggcgtgagccaccacgcccggcctccagttgcttttgaagagg 2857 
 
                                                                         
Query: 2858 gtaaagtcaagtttctatttctagaaaacattttttagaaatttgttgcgatgtttgtac 2917 
                    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Sbjct: 2858 gtaaagtcaagtttctatttctagaaaacattttttagaaatttgttgcgatgtttgtac 2917 
 
                                                                         
BLAST database: http://www.ncbi.nlm.nih.gov/Blast 
The output for KIAA0205 (accession numbers D86960) is shown. The biological/structural similarity scores and 
alignment sequence is provided. A hyperlinked graphic output of the alignment is provided at the top of the web 
page. Hyperlinks to other annotation and protein databases are also provided. 
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BLAT database: http://genome.ucsc.edu/BLAT 
The output for KIAA0205 (accession numbers D86960) is shown. The biological/structural similarity is 
indicated in a graphic format. Similarity scores can be obtained through clicking on the hyperlinks. 
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Pfam database: http://www.sanger.ac.uk/Software/Pfam 
The output for KIAA0205 (accession numbers D86960) is shown. The biological/structural similarity score and 
alignment is provided as text. Hyperlinks to other annotation and protein databases are also provided. 
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Blocks database: http://www.blocks.fhcrc.org/blocks_search.html 
The output for KIAA0205 (accession numbers D86960) is shown. The biological/structural similarity score and 
alignment is provided as text. Hyperlinks to other annotation and protein databases are also provided. 
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Prosite: http://www.expasy.org/prosite 
The output for KIAA0205 (accession numbers D86960) is shown. The biological/structural similarity alignment 
is provided as text. Hyperlinks to other annotation and protein databases are also provided. 
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APPENDIX E 
 
Allele frequencies in the Afrikaner control panel 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
D1S456 .26 0 .038 0 .24 .019 .3 .13      
D1S491 0 .1 .125 .4 .275 0 .125       
D1S70 .05 .1 .35 .25 .05 .2        
D1S3753 .03 .1 .17 .07 .07 .17 .17 .03 .07 .07 0 .07  
D1S205 .08 .04 .08 .4 .08 .02 .29       
D1S414 .0185 .0185 .056 .259 .093 .037 .185 .074 .204 .056    
D1S2810 0 0 0 .028 .056 .056 .222 .222 .167 .167 .083   
D1S2780 .003 0 0 .13 0 .4 .07 .36      
D1S425 .021 .104 .146 .188 .104 .313 .063 .021      
D1S505 .095 .024 .190 .167 .071 .214 .024 .048 .095 .071    
D1S217 .019 .352 .019 .111 .167 .074 .259       
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 160 
APPENDIX F 
 
Oligonucleotide primers, annealing temperatures and amplification product sizes of candidate genes screened in the present study 
GENE 
Exon 
Sense oligonucleotide 
5’ → 3’ 
Antisense oligonucleotide 
5’ → 3’ 
Annealing 
temperature 
(°C) 
Product 
size 
(bp) 
KCNH1 
1 CGAGGCCAGTTTCCTGCTG GCGGCGAGAGGTTCTGCAAT 54 229 
2 GAATCTCAACTAATGTGTTGCCTCATG CCATAATAGATTGTTCACCAGAACAACTC 55 250 
3 CATATGCTTGTAGAATAATGAATACTTCT TTCAAACACATAAAGGTATGGTTCAGAATG 51 212 
4 CAAATGAGAATGCAAATTACTGACCAAC AAGGCATAAATGTATTTGTACAAGTCAG 51 214 
5 GTGCACCTTTGGGATGTGGTT CTAAAAGTGAGGCTCAAGATGAGC 51 214 
6a GACTGGTTAGATACTTGCAATTAAATCC CAATGTCCACCAAAAAGATAACATCC 53 243 
6b CAGAATAATGTGGCCTGGCTGGTT CAGCAAAACCAATCTTCCCTGG 53 262 
7a CCAGCTAACAGAAGAGATGGCC GACACCAAGACAATCCGCAACAACA 53 287 
7b GCCAATGTCCATCGCTAGTTGG  AGTAGTATCTTTGGTTCTTTGGCCCT 53 298 
8 CAAAAGACAAATGGTTTCCCTGAGCTC GGCTCAGGGACCACTAACTTG 53 297 
9 GCTAAGCCAACCCCAGATACT CTGAAGGATGTGGGCTGAAGGC 53 358 
10 AGTGTACAGAGACTGTTCTTTGTGGA CCTCTCCTGGCCAACACTTTC 52 292 
11a GTCATGTGGACATATGTGGTAGG TACCCCATCCCTGAGCAGAC 52 311 
11b CTTCAGCTCGTGCCTCACCT GAGGACTGGAACAAGGTGTCC 55 261 
11c CGCTTTTGTCCTCTCGGGAAGT CATGCCTCCGCCAACCACAG 55 282 
11d TCTCACGCACGGTGACCAC ATGTGGCTAACACGCCATGTCATT 52 309 
PPP2R5A     
1 GGAGCTGCCAAGCGTCAG CTGCGCTCGCTGCTGGGG 51 246 
2 TTCTGAGTAGGTTATTTCTAAGTTTT CATAAATCTGAGGAACATAATTCTAG 47 276 
3 AAATATAAAAACTGCCAATACGTAATTATG TCAATTACACATACAACAACGAACGT 47 187 
4 GAATATATGAGAATCTAAGACAAAAGAG CATCATCTTAGCCTTTATTTGACTTTC 47 164 
5 GGAAAAGCAATATACAATAAATGA ATTTTTTAAAAGTAATTTCTCAGGTTTC 47 202 
6 TACTTAATTCTTAAAAAGAACAAAAAAACC GTTTGATTTTGATTACATCTTGTCTTTA 47 138 
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7 ATAATATTCATTTCATCTGAAATGTTTCTG TACTTAACCCTTCCCCTGCC 47 182 
8 GCTATTAATGCAGACCAAAAACATGAA CTCACTAATATTTATAAACTGTCCCTTA 47 135 
9 CAGCTATGGAAAATACGCTGGGATTAAC CAGCCCAAAGAAGCATGGTTTATAGC 51 203 
10 CATTTGTATGGTTTCTATATTAGTTTCAC CTAGTGTAAAGTAAAGGCTTCACTG 51 328 
11 CTTTCCTATTTTAGTTTTGACATTTCTCTA CTGTAATAGGTTTCAAGTATGAGTTAG 51 272 
T3JAM     
1 GACGGTACCAAGAAGGGACG GTTGGAGTTCCCAAACCTGGAC 55 209 
2 GCCTGGCTCCCTGGAAACTT CTCCAATACTGTTGGGGCTGAG 55 208 
3a CCCCTTCTCCTCCCTCTTGG GTGGTCACATTGGGACGGCA 55 230 
3b AGCGCAGGCAAGAGATCCGTG CTGGCACAAGACAAGGGTTCC 55 250 
4 CTCCAGGCAGTGGTTTTCAGC CAGGCCCTGTGGAGTGAG 55 223 
5 CCTCACTTCCTCCCTGTAAGTTC GAGGAATGGATGGGATGTGAGAG 55 151 
6 CTGCCTCCTGACTTGATTCTTTGG CCAGAATGTCAGAGCTTAATACTTTCTG 55 145 
7 CAGGGTTTCAGGGGACTTACAGA GTAAGATTAACCTGGAGGATCGG 55 155 
8 CTTACCCTCTTGCACTTTGTGCC GAACACATAGAAGCCCAAGCTTTGT 53 179 
9 CTCTTTGCAGACTAGATTTTGCCCC TCATTTAATTCTAGATTCCTGAGATGGAAG 53 156 
10 GCTCAGGATTTGGCACACAGAAG AGCTGCCTGGAGTCCCCAG 55 247 
11 GAGCCAGCTGCACAACTCC CATACCCTGTCTTCCCTCCC 53 227 
12 CACTGACCTCCTTCTATATTGGCC GCTGCCATGCACTCAAGGC 53 213 
13 GTACTGAGTTCATTAAGTCTTGGGTTC GCCAGGACCCCAGGAAAAC 53 177 
14 GTAGTAAATATGCTAGCATAGACAAGTTCC GCCTCTAGGCAGGTAAGAGAAG 55 166 
15 CTCACTGTCACCAAGAATCTGGC GCTATTTCGCAAATGAGCCCTCAC 55 214 
16 TGTCCTAGACAGAAGTGACAGTGA GAAGGAATCGTCCCATCATCCAG 53 214 
17 CCACTTTCTTCTGTCTCCCTGTC GTTAATGTAATACACCATTCAGGAATAAAC 53 336 
VWS59 
Transcript 1 
    
1 CATGTTCATGGCTTAAAGTTTTG AGGAGGTCTGAAAAGCTTGG 57 199 
2 AGCCAGCCCAGTTTTGTTTA CTGGATCGACTCCAAATACAA 57 209 
3 CCCTCTGATAAACTATTTTGTCCTATT TACCTTTCTTGCCAGCAGTG 57 147 
4 ACCATTTGCAGCACAGACC CCCAATGGTAACAGGAAAACA 57 232 
5 GGCCACTCAAAGGTTGTTCT ATCCCCAGCGGGCTCTAC 57 272 
6 TTTAGATGCAGCAGCAGGAG ATCCCACTGTTGGTGATTCC 57 236 
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7 GACTGGTCTGTTTGCCTTTCA TGCCTGACCAACTTTAGCAA 57 207 
8 ATCTTTTATTGATATGCTTGTCTATGTCTC AACCATAGTGTTAGCAATGTTTTCTTGACA 52 220 
VWS59  
Transcript 2 
    
1 TTCAGCTCTTCAGCCAGCCC GCTGAATCTGATACCTGGATCGAC 55 234 
2 GTGTTCTGACTCAGACGTGTACTG GCTTGGACTCTTTCTTCACAAGAAGC 55 242 
LAMB3     
1 CACAGGCAGGTGGGCATTGT CGGCCCGCACCAGGCAGG 50 314 
1’ ACGGCTGCCAGATTCCTGAG GCCACTGAGGTGCTTATCAAATGTG 55 352 
2 CTCTAGGGGTTTGCACTGTTGTACC CTGCCATATAACAGGGCCTGGA 55 156 
3 GGACTCCTCCATCACACATCCC GTGGACAAATGGCAGCTCACAC 55 222 
4 CAGGACCCCACCTCTGAGTTTCT GAGGCTGTACAGTTTGAGTTCCCGT 55 200 
5 AGTGGACAGTCTCTGGATGACAGTT CCCCTCTCCTATCCACTGCCAC 55 175 
6 CAGTGCCTCCCCTCTGCACA CCCCAGGGCTACTTTTAGGATTC 55 264 
7 CGGGGCACACTATTTGTCTCTTC CCCCACCCATAGCTCCATGGAC 55 161 
8 CTCCAACTCTTCCCTCCTTGCTG TCCCCTTCCCACCCTAGGCT 55 256 
9 GGTGCCCTTCTTTGTTGATTACTCC AGGGGCCAGCACTCGACC 55 225 
10 GGTGTGGGTCAGATGTCAGCC GGAGATGGGGAGTAACAGACAAATG 55 278 
11 GAACTCTACTTTTCTTGTCCTA CACCCCACNTCATNCTGG 52 239 
12 GTGTGTCCTCTGGGGGTGAGTT CACTGAGGGGGCCCCCCG 52 296 
13 TGTGAGGCAGGGTCCAC CCCCAGAGCCTCAGCGT 55 190 
14 ACCCCTGTCTCTGACTGTC CACAGGCTGGCGGTGGCA 55 268 
14’ TATGATGCGGACCTCCGGGA TCCAGCATAATTCTTGCAAATG 55 260 
15 CCTCCTATATTTTAGTGTAAGC CCACGGCAGTCCCATGC 55 246 
16 CCTGCTCCTCCTCCATCTCCATT CAAGCTGGGTGTGGGCTCCA 55 314 
17 GTTATTGAGGGGCTTGGGTAGCCT TCCTCCTACCTGTGCCCCAC 55 286 
18 CCTTACCCCTTCTGACCTAGAGT GCAGGACTGGAACAGCAGCC 55 223 
19 GGTTAGTGGGCTCCTACAGTCAA GGGCAGAGAGAAGTTCAGGGCC 52 283 
20 TCACTGTTCACTCATTCTCTCTCTCC GCCCAAATTTTCCTGTTTATGCCC 52 249 
21 GATCCACTATAAAGGCCAGATCTC CACTGGCCGTACATCATTGAGCTAA 50 261 
22 GCATGATGACAATGACACTGAGAC AGCCTTCATGAATGCCCAATAGTCC 50 243 
23 GAGTCTTGGGGAGTCTCACCATC GATGAGTGGGGCAACGGGC 50 228 
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RAMP     
1 GTGTTGTGAGAGGCGCAAGC GAGGTGGCGTGTGTTTCGGG 55 210 
2 GACAGAGCAAGACTCCGTCTGA ATAATAATATACTTGAGGATGTGTAAAGTT 50 245 
3 ACAGCTTTCCAGGCATTTAAAGTTATATTA TCCCTTATCAGTATTTACCCAGATC 50 200 
4 GGTAAATACTGATAAGGGAGTGCTTTAT CTGCAAAGAAGGTTAAGGAGATGAAA 50 203 
5 ATGTGTCATTGACTGGTTTTGTTAACCT ATTAAGTACAGGGTAATCCCAAATCTC 50 177 
6 GTTATATTCAGCATGTAAGAATCCTGAAAC CTATCCTACAGATAAGATCTGCACAC 50 219 
7 AGATTATGATGCCCAAGATAGAATCTTC CTCATAAAAAAGATCTCGTCGGAAG 50 168 
8 CCACTAGAAATAACAAGAGCCAAG CTTCAGTCTAACACTTGTGGGTG 50 201 
9 GGGAAATCTAATATTGCTTTGCTGAC ACCTGTGATCTACATTTTAAACCAACT 50 186 
10 GATTGAAATTTCTTAATTCCCTTCTTGG CTAGTCAAACCATAAAAAACTTGGAAAG 50 221 
11a CTTCTGATCTTCATGATCCTCTCC CCAGACAGCTTGAGTCTAGCC 50 451 
11b AGGCTTGCTCTGAGTCTAGAAATAG GAAATGTATCTTCCCACCACTGC 50 503 
12 CAGTTGAACTTCAAGGAAATCTCTG GACCAAAGCTCAGTAACTCACT 50 180 
RAMP 
Transcript 2 
    
1 TGCTGAAATGTGATGCTGTATTGGAATTC GAAATAGATCATTTCTGTCCAAGCCTTG 55 227 
KIAA0205     
1 CACCCCAGAAAGACAGGACG CTTATGCATTAAAGAAAAGTGTTCTC 50 307 
2 CTTTAAAATGACAGCTTTGAAACTTTTTTG GATGTCTATCTACTGCCTTCAG 50 190 
3 TCTTCTATCCAATATTATTTCTTGCTTTTA CTGCGGGGAAAAAGTGCTCA 50 164 
4a GGATATACCTGTACTTATTACGTG AGTAACATTTGTAAGAAATGGCAAG 50 220 
4b GAGAAACAAGTCAGGCATTTGC CCAACAAGGTAAAAAATGCTAAAAAC 50 187 
5 TTGCTGCAGATAATATAAAAGTTGATTTAA GTTGGATATATACTGAGTACTAATATAG 50 222 
6 CTAAATAGTTTTTGTTCTTTTCTTCTAACC GCTATAATTTAGCAACTATTTAAAGGTT 50 182 
7 ACAGTAAAACAAACTAATATTTCTATCTTG GACCTTGACAAGTCCACG 50 215 
bp = base pairs; KIAA0205 = putative acyltransferase; KCNH1 = ether-a-go-go related potassium channel; LAMB3 = laminin b3; PPP2R5A = protein 
phosphatase 2A b56alpha; RAMP = retinoic acid regulated nuclear matrix associated protein; T3JAM = adapter protein that interacts with a cytoskeletal 
protein; VWS59 = novel gene 
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APPENDIX G 
 
Genes annotated to within the PFHBII locus between D1S70 and D1S505 (obtained 
from the Ensembl database, November 2002) 
 
Ensembl Gene ID and gene description 
*ENSG00000008141.1,LAMININ BETA-3 CHAIN PRECURSOR (LAMININ 5 BETA 3) 
(LAMININ B1K CHAIN) (KALININ B1 CHAIN). [Source:SWISSPROT;Acc:Q13751] 
ENSG00000123689.1,PUTATIVE LYMPHOCYTE G0/G1 SWITCH PROTEIN 2. 
[Source:SWISSPROT;Acc:P27469] 
ENSG00000117594.1,CORTICOSTEROID 11-BETA-DEHYDROGENASE, ISOZYME 1 (EC 
1.1.1.146) (11-DH) (11-BETA-HYDROXYSTEROID DEHYDROGENASE 1) (11-BETA-
HSD1). [Source:SWISSPROT;Acc:P28845] 
*ENSG00000009790.1,B 3 1 DJ434O14 
ENSG00000162757.1,AMBIGUOUS 
ENSG00000117595.1,INTERFERON REGULATORY FACTOR 6 (IRF-6). 
[Source:SWISSPROT;Acc:O14896] 
HYPOTHETICAL 84 KD PROTEIN FROM SGA1-KTR7. [Source:RefSeq;Acc:NM_014388] 
ENSG00000117597.1,NOVEL PUTATIVE PROTEIN SIMILAR TO YIL091C YEAST  
ENSG00000143464.1,AMBIGUOUS 
ENSG00000173964.1,LINE 1 REVERSE TRANSCRIPTASE HOMOLOG 
ENSG00000143469.1,SYNAPTOTAGMIN 
ENSG00000082497.1,UNKNOWN 
*ENSG00000054392.1,SIMILAR TO MELANOMA ANTIGEN RECOGNIZED BY T CELLS 2 
ENSG00000152015.1,IG CHAIN V REGION 
ENSG00000177394.1,TRANSFORMATION-RELATED PROTEIN (FRAGMENT). 
[Source:SPTREMBL;Acc:Q15662] 
*ENSG00000143473.1,POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY H 
MEMBER 1 (ETHER-A-GO-GO POTASSIUM CHANNEL 1) (HEAG1) (H-EAG). 
[Source:SWISSPROT;Acc:O95259] 
ENSG00000174660.1,40S RIBOSOMAL S25 
ENSG00000174658.1,PX19 
ENSG00000117625.1,AMBIGUOUS 
ENSG00000082512.1,TNF RECEPTOR-ASSOCIATED FACTOR 5. 
[Source:RefSeq;Acc:NM_004619] 
ENSG00000153363.1,UNKNOWN 
ENSG00000179809.1,ARP2/3 COMPLEX 21 KDA SUBUNIT P21 ARC 
ENSG00000174649.1,UNKNOWN 
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ENSG00000170385.1,ZINC TRANSPORTER 1 (ZNT-1). 
[Source:SWISSPROT;Acc:Q9Y6M5] 
ENSG00000117650.1,SERINE/THREONINE-PROTEIN KINASE NEK2 (EC 2.7.1.37) (NIMA-
RELATED PROTEIN KINASE 2) (NIMA-LIKE PROTEIN KINASE 1) (HSPK 21). 
[Source:SWISSPROT;Acc:P51955] 
*ENSG00000123684.1,AMBIGUOUS 
*ENSG00000143476.1,L2DTL PROTEIN. [Source:RefSeq;Acc:NM_016448] 
ENSG00000162767.1,60S RIBOSOMAL PROTEIN L21. [Source:SWISSPROT;Acc:P46778] 
*ENSG00000066027.1,SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 56 KDA 
REGULATORY SUBUNIT, ALPHA ISOFORM (PP2A, B SUBUNIT, B' ALPHA ISOFORM) 
(PP2A, B SUBUNIT, B56 ALPHA ISOFORM) (PP2A, B SUBUNIT, PR61 ALPHA ISOFORM) 
(PP2A, B SUBUNIT, R5 ALPHA ISOFORM). [Source:SWISSPROT;Acc:Q15172] 
ENSG00000065600.1,AMBIGUOUS 
ENSG00000117691.1,SECRETED PROTEIN OF UNKNOWN FUNCTION. 
[Source:RefSeq;Acc:NM_013349] 
 
The annotated genes (known and predicted) are indicated in bold to allow easier 
identification 
* = genes that were screened for the PFHBII-causative mutation in the present  
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Summary
An evaluation of a 38-year-old Caucasian woman, who 
was referred to Tygerberg Hospital (Western Cape 
Province, RSA) with Wenckebach second-degree or 
possibly complete atrioventricular (AV) block that had 
progressed from first-degree AV block, identified a fam-
ily history of the cardiac conduction system disorder 
progressive familial heart block type II (PFHBII). This 
prompted a retrospective clinical review of the subjects 
described in the original study, as well as additional 
family members who had not been examined in the 
original study.1 Progression of clinical features was 
observed, but more importantly, PFHBII was clinically 
redefined as an AV nodal disorder, which may progress 
to dilated cardiomyopathy (DCM). 
Cardiovasc J South Afr 2004; 15: 129–132.  www.cvjsa.co.za
In January 2003, a 38-year-old Caucasian woman with 
Wenckebach second-degree or possibly complete atrioven-
tricular (AV) block and a heart rate of 43 beats per minute 
(bpm) (Fig. 1) (Table I, individual IV:20) was admitted to 
the Cardiology Unit of Tygerberg Hospital (Western Cape 
Province). The subject had been examined previously (P.A. 
Brink, May 2000) and diagnosed with first-degree AV block 
with a P–R interval of 240 milliseconds (Fig. 2). Genealogy 
studies indicated that the subject was the daughter of the 
index case of the previously described South African family 
with progressive familial heart block type II (PFHBII).1
In 1977, Brink and Torrington characterised PFHBII as 
an inherited autosomal dominant cardiac conduction system 
disorder, which segregated in a South African Caucasian 
Afrikaner family from the Eastern Cape Province.1 The ECG 
features of PFHBII were at that time defined by isolated 
sinus bradycardia (SB), isolated left posterior hemiblock 
(LPHB) or complete heart block (CHB) with narrow QRS 
complexes. In this report, we describe a retrospective study 
of the family members examined by Brink and Torrington in 
1977. Clinical data are also presented of additional subjects 
from the same family who were not examined in the original 
study. The results of the study reiterated the progressive 
nature of the disorder and prompted a redefinition of the 
clinical profile of PFHBII.
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Fig. 1. Twelve-lead ECG strip for individual IV:20, 
taken in January 2003, showing a slow, irregular 
sinus rhythm with no consistent ventricular 
response. The AV nodal delay could represent a 
Wenckebach phenomenon or alternately, complete 
AV dissociation. The subject subsequently had a 
pacemaker implanted. 
Fig. 2. Twelve-lead ECG strip for individual IV:20, 
showing first-degree AV block (P–R interval = 240 
milliseconds). The ECG was taken in May 2000.
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Methods
Ethical approval
The present study formed part of a project approved by the 
Ethics Committee of the Faculty of Health Sciences at the 
University of Stellenbosch. 
Genealogy and extent of the disease
The South African Caucasian Afrikaner family presented in 
this study was previously described.1 Extensive genealogy 
studies were performed to determine the segregation of 
PFHBII in other branches of the family.
Patient panel
Twelve-lead ECG and two-dimensional echocardiographic 
follow-up examinations were acquired (1977 to present) 
from Tygerberg Hospital or from the personal physicians of 
subjects described in the original PFHBII study.1 Clinical 
data were also obtained for the children (born after 1977) of 
these subjects, as well as other available members who were 
not examined in the original study.1 Where the records were 
unavailable, if possible, clinical histories were obtained 
from the subjects themselves or close relatives. Clinical 
histories of deceased individuals were also included in the 
study.
Electrocardiographic and echocardiographic 
criteria
The ECG diagnostic criteria for PFHBII were previously 
established.1 In addition, the study included minimum 
criteria for an echocardiographic diagnosis of dilated 
cardiomyopathy (DCM), defined by an ejection fraction of 
less than 45% and a left ventricular end-diastolic diameter 
of greater than 5.6 cm in the absence of hypertension 
and valvular heart disease or a history consistent with 
ischaemic heart disease. All measurements were made 
according to the American Society of Echocardiography 
guidelines.2
Results
Genealogy and extent of the disease
The study by Brink and Torrington in 1977 obtained 
information on 140 members of a South African family, of 
which 24 members of one family branch were examined 
by ECG. We performed extensive family studies question-
ing living first-, second- and third-degree relatives of indi-
vidual II:2 (Fig. 3) (not including his progeny). Wherever 
possible, ECGs were performed, and occasionally echo-
cardiographic assessment. We did not detect disease with 
features of PFHBII, although one third-degree relative had 
hypertrophic cardiomyopathy. Additionally, we questioned 
relatives of individual II:3 (Fig. 3) and did not identify 
evidence of the disease in her lineage. We concluded that 
individual II:2 was the true carrier of PFHBII (Fig. 3), as 
his children reported him to have had a heart block. We do 
not therefore have evidence of segregation of the disease 
in ancestors or siblings and their progeny of II:2 and II:3, 
limiting known disease to the current pedigree (Fig. 3). 
TABLE I. EVALUATION OF FOLLOW-UP CLINICAL DATA OF THE PFHBII FAMILY MEMBERS 
CLINICALLY ASSESSED IN THE ORIGINAL STUDY
Indidual  aAge (y) ECG  EF LVEDD Comment
III:6 68 normal 76 4.8 unaffected
III:8 42 3° AVB 60 4.5 bSB = 48 bpm, CHB (PM 42 y); present age = 69 y
III:10 64 normal 65 4.4 unaffected 
III:12 37 3° AVB 41 6.3 CHB (PM 37 y), DCM, +59 y 
IV:9 41 3° AVB 42 5.7 CHB (PM 41 y), DCM, +46 y 
IV:11 35 3° AVB nd nd CHB (PM 35 y); present age = 36 y 
IV:14 32 normal 65 4.3 unaffected
cIV:16 40 normal 64 4.5  slow R-wave progression; transition to dominant R-wave in V4 – 
otherwise unaffected
IV:18 33 normal 70 4.7 unaffected
IV:19 31 normal 63 4.9 unaffected
IV:20 38 2° or 3° AVB 61 5.5  1° AVB (P–R interval = 240 m/s, May 2000); SB = 43 bpm, 
Wenckebach/complete AVB (PM 38 y), January 2003; present 
age = 38 y 
IV:21 41 normal 64 4.4 unaffected
IV:24 39 normal 60 4.5 unaffected
IV:25 29 3° AVB 40 5.8 CHB (PM 29 y), DCM, +43 y
IV:26 15 nd nd nd heart transplant, DCM, +15 y 
Not shown in the table are individuals II:3, III:7, III:9, III:11; IV:12, IV:13, IV:15, IV:17 and IV:22, who were designated 
clinically unaffected based on family history or a family physician’s medical report. No further data could be obtained for 
these individuals.
aAge at examination in years (y); bHeart rate prior to pacemaker (PM) implant; cIndividuals with atypical accompanying features; 
+Age at death
1° = first-degree; 2° = second-degree; 3° = third-degree; AVB = atrioventricular block; bpm = beats per minute; CHB = complete 
heart block; DCM = dilated cardiomyopathy; EF = ejection fraction; LVEDD = left ventricular end diastolic diameter; m/s = 
milliseconds; nd = no data available; (PM y) = PM age at implant; SB = sinus bradycardia 
Clinically affected individuals are indicated in bold
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Clinical data
Twenty-four subjects were assessed in the original study,1 
of whom six were designated clinically affected, and three 
were identified with SB. Follow-up clinical data or family 
histories were obtained for the 24 subjects described in 
the original study1 (Table I). Our data indicated that two 
of the three subjects previously identified with SB1 (Fig. 
3, individuals IV:9 and IV:20) subsequently developed AV 
block and had pacemakers implanted (Table I). Furthermore, 
three subjects (Fig. 3, individuals III:12, IV:9 and IV:25) 
showed progression to DCM (Table I). A fourth subject 
(Fig. 3, individual IV:26), who had previously shown no 
conduction abnormalities,1 required a heart transplant as a 
result of juvenile-onset DCM (Table I). Our follow-up data 
also differed from the previous diagnoses of three family 
members. These subjects (Fig. 3, individuals IV:16, IV:19 
and IV:24), who had previously been designated clinically 
affected, presently did not meet our strict diagnostic criteria, 
although individual IV:16 did present atypical associated 
features on examination (Table I). 
In addition, we obtained clinical or family information 
for 15 subjects who were not clinically examined in the 
original study or who were born after 1977 (Fig. 3). Eight 
of the 15 subjects were assigned a clinically affected status 
(Table II). Seven of the eight clinically affected individuals 
developed conduction defects that ranged from atrial fibril-
lation and CHB to left anterior hemiblock (LAH) (Table 
II). The eighth affected subject (Table II, individual IV:2) 
showed progression from AV block to DCM. An additional 
family member (Table II, individual V:1) presented with 
atypical features that included severe chest pain with 
frequent dyspnoea and syncopal episodes. However, the 
subject has declined to be examined and her clinical status 
remains uncertain.
Discussion
Evaluation of clinical and family data spanning 26 years 
confirmed the progression of features in PFHBII. More 
importantly, the study highlighted the progression to DCM, 
which was not apparent in the original study. The follow-up 
study showed that SB preceding CHB occurred frequently 
in the family, although it must be noted that SB is fairly 
common in the general population, particularly among 
athletes.3 However, upon questioning, most of the affected 
family members indicated that they had fairly sedentary 
lifestyles and SB was absent in unaffected subjects with 
similar living patterns. Therefore, in this family, a slow 
heart rate of less than 50 bpm is considered familial and a 
diagnostic criterion of PFHBII. 
Generally, individuals with first-degree AV block are 
asymptomatic and diagnosis thereof is usually incidental. 
The present study also aimed to identify clinical or physical 
characteristics occurring in the family that could be indica-
tive of underlying disease. Two subjects with potentially 
early clinical markers for PFHBII were identified. The 
first subject (individual IV:16), who was examined in the 
original study and re-evaluated by us in 2000, was, unlike 
the previous study, assigned a clinically unaffected status. 
Our evaluation did indicate a slow R-wave progression, 
where the transition to a dominant R-wave occurs in V4. 
A slow R-wave progression is often associated with DCM,4 
although lead placement could also play a role in the ECG 
assessment. However, we speculate that in this family, the 
atypical feature could be an early indication of impending 
Fig. 3. A family tree showing all kindred of an individual with PFHBII. Squares represent males and 
circles represent females. An asterisk indicates the individuals examined in the original study. The 
clinical assessments of subjects whose present diagnoses differ from the original study1 are shown 
below the respective symbols (af, subject previously diagnosed as affected; sb, subject previously with 
sinus bradycardia; unaf, subject previously unaffected).
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cardiac abnormalities. The second subject (individual V:1) 
had reported severe chest pains, shortness of breath and 
fainting episodes. Recent correspondence with individual 
V:1 indicated a persistence of features, despite treatment with 
Atenolol (P.A. Brink, personal communication). Interestingly, 
there is a history of sudden death at a relatively young age 
in the subject’s family, with both her grandfather and father 
(Table II, individuals III:1 and IV:2) having died aged 41 
and 43 years, respectively.  
The importance of this retrospective study is exemplified 
by our redefinition of the clinical profile of PFHBII. Barring 
the one individual with LAH (individual IV:1), we propose 
that the absence of ventricular conduction delay makes 
it highly likely that the conduction block occurs close to 
the origins of the Bundle of His. This suggests that PFHBII 
is not a disease of the ventricular conduction system. 
Drawing on observations from ECG data, we have amended 
the diagnostic criteria and characterise PFHBII as an 
AV nodal disorder with clinical onset between the fourth 
and sixth decade. In addition, four family members were 
identified who progressed from conduction block to DCM 
(Tables I and II, individuals III:12, IV:2, IV:9 and IV:25). 
For these subjects, the progression from complete AV block 
to congestive heart failure (CHF) ranged from five years 
(individuals IV:2 and IV:9) to 22 and 14 years (individual 
III:12 and IV:25), respectively. Furthermore, a fifth subject 
(Table I, individual IV:26) with no prior conduction defects 
developed DCM in early adolescence. Consequently, these 
data indicate that in this family, on average, death as a result 
of CHF occurred before the sixth decade. Unfortunately, 
the available data did not permit assessing whether the 
prognosis for individuals who only developed conduction 
defects was better than for those subjects with DCM. 
We cannot explain why particular individuals advanced 
from AV block to DCM, while others only developed 
conduction defects, but this pattern of clinical features was 
consistent with other described disorders.5,6 Consequently, 
we performed a genetic linkage study and excluded the 
lamin A/C5 and CMD1H6 loci as cause of PFHBII (data 
not shown). 
Conclusions
The data presented emphasise the importance of establish-
ing a family history when making patient diagnoses. The 
progressive nature of the disorder was reiterated, but more 
importantly, a familial DCM component was demonstrated 
in PFHBII. Consequently, the study provides a more com-
prehensive clinical profile of PFHBII, which may assist 
clinicians to identify other South African families or indi-
viduals with this potentially life-threatening disorder.
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TABLE II. EVALUATION OF CLINICAL DATA OF PFHBII FAMILY MEMBERS WHO WERE NOT 
CLINICALLY ASSESSED IN THE ORIGINAL STUDY
Indidual  aAge (y) ECG  EF LVEDD Comment
II:2 61 nd nd nd HB (type unknown), +61 y 
III:1 40 nd nd nd HR < 50 bpm, CHB (PM 41 y), +41 y 
III:3 45 nd nd  nd CHB (PM 45 y), failed PM, +45 y 
IV:1 36 LAD 64 4.4 LAD (–30º axis), LAH; present age = 41 y
IV:2 38 3° AVB 38 6.2 bSB = 50 bpm, AF, CHB (PM 39 y), DCM, +43 y
IV:4 49 normal 60 4.4 unaffected 
IV:5 45 normal 60 4.4 unaffected
IV:6 47 normal 65 4.5 unaffected 
IV:7 33 3° AVB 52 5.1  1° AVB (P–R interval = 220 m/s, March 1990),  cSB = 38 bpm, 
AF, CHB (PM 33 y, October 1996); present age = 38 y
IV:8 45 normal 65 4.8 unaffected 
IV:10 36 SB nd nd SB = 43 bpm; present age = 39 y
IV:23 16 3° AVB nd nd CHB (PM 16y), +16 y
cV:1 23 nd nd nd chest pain, dyspnoea, syncope 
V:3 22 160 63 5.2 unaffected
V:4 20 160 70 4.3 unaffected
aAge at examination in years (y); bHeart rate prior to pacemaker (PM) implant; cIndividuals with atypical accompanying features; 
+Age at death
1° = first-degree; 3° = third-degree; AF = atrial fibrillation; AVB = atrioventricular block; bpm = beats per minute; CHB = complete 
heart block; DCM = dilated cardiomyopathy; LVEDD = left ventricular end diastolic diameter; HB = heart block; HR = heart rate; 
LAH = left anterior hemiblock; LAD = left axis deviation; EF = ejection fraction; m/s = milliseconds; nd = no data available; 
(PM y) = PM age at implant; SB = sinus bradycardia
Clinically affected individuals are indicated in bold
